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Abbreviations		2DE	=	two-dimensional	echocardiography	2D-STE	=	two-dimensional	speckle	tracking	3DE	=	three-dimensional	echocardiography	ALK1	=	activin	receptor-like	kinase-1		BMPR2	=	bone	morphogenetic	protein	type	II	receptor	CCB	=	calcium	channel	blockers	CHD	=	congenital	heart	disease	CMR	=	cardiac	magnetic	resonance	COPD	=	chronic	obstructive	pulmonary	disease	CT	=	computed	tomography	CTD	=	connective	tissue	disease	CTEPH	=	chronic	thromboembolic	pulmonary	hypertension	DLCO	=	lung	diffusion	capacity	for	carbon	monoxide		DPG	=	diastolic	pressure	gradient	FC	=	functional	class	IVS	=	interventricular	septum	LongEF	=	longitudinal	ejection	fraction	LS	=	longitudinal	strain	LV	=	left	ventricle/ventricular	miRNA	=	microRNA	mPAP	=	mean	pulmonary	artery	pressure	PAECs	=	pulmonary	artery	endothelial	cells	PAH	=	pulmonary	arterial	hypertension	PAP	=	pulmonary	artery	pressure
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PASMs	=	pulmonary	artery	smooth	muscle	cells	PAWP	=	pulmonary	artery	wedge	pressure	PCH	=	pulmonary	capillary	haemangiomatosis	PEA	=	pulmonary	endoarterectomy	PH	=	pulmonary	hypertension	PVOD	=	pulmonary	veno-occlusive	disease	PVR	=	pulmonary	vascular	resistance	RadEF	=	radial	ejection	fraction	RHC	=	right	heart	catheterization	RV	=	right	ventricle/ventricular	RVEF	=	right	ventricualr	ejection	fraction	RVF	=	right	ventricular	failure	RVFW	=	right	ventricular	free	wall	RVFWLS	=	right	ventricular	free	wall	longitudinal	strain	RVGLS	=	right	ventricular	global	longitudinal	strain	SSc	=	systemic	sclerosis	TD	=	transversal	displacement	TR	=	tricuspid	regurgitation								
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Riassunto	
	
Presupposti:	il	ventricolo	destro	(VDx)	è	una	cavità	cardiaca	di	forma	complessa	la	cui	 funzione	 di	 pompa	 in	 condizioni	 di	 normalità	 sembra	 essere	 determinata	prevalentemente	 dall’accorciamento	 longitudinale.	 Tale	 affermazione	 deriva	 da	 studi	anatomici	 che	 hanno	 mostrato	 come	 nella	 parete	 ventricolare	 destra,	 lo	 strato	 di	 fibre	miocardiche	 longitudinali	 sia	 il	 più	 rappresentato.	 L’ecocardiografia	 convenzionale	dimostra	 numerosi	 limiti	 nello	 studio	 delle	 dimensioni	 e	 della	 funzione	 del	 VDx,	 legati	principalmente	 alla	 complessità	 della	 sua	 forma	 e	 meccanica.	 Tuttavia,	 la	 funzione	ventricolare	 destra	 ha	 dimostrato	 essere	 un	 importante	 fattore	 prognostico	 in	 alcune	condizioni	 patologiche,	 tra	 cui	 l’ipertensione	 polmonare	 (PH).	 E’	 tuttora	 sconosciuta	 la	sequenza	di	eventi	che	conducono	alla	disfunzione	di	pompa	globale	del	VDx	nei	soggetti	affetti	da	PH.	Due	metodiche	ecocardiografiche	di	recente	introduzione,	lo	speckle-tracking	bidimensionale	 e	 l’ecocardiografia	 tridimensionale,	 permettono	 una	 più	 accurata	valutazione	 delle	 dimensioni	 e	 funzione	 della	 cavità	 ventricolare	 destra.	 In	 particolare,	consentono	di	valutare	i	volumi	e	la	forma	del	VDx,	 la	funzione	di	pompa	globale	e	la	sua	meccanica	miocardica,	in	termini	di	deformazione	longitudinale	e	trasversale.	
Scopo	 dello	 studio:	 valutare	 la	 meccanica	 del	 ventricolo	 destro	 in	 condizioni	 di	normalità	 ed	 in	 presenza	di	 PH,	 definendo	 le	 alterazioni	meccaniche	 che	 determinano	 la	progressiva	 disfunzione	 di	 pompa	 globale	 del	 VDx	 che	 caratterizza	 la	 storia	 clinica	 dei	pazienti	affetti	da	PH.	
Materiali	 e	 metodi:	 sono	 stati	 arruolati	 270	 soggetti	 sani,	 75	 pazienti	 affetti	 da	sclerosi	sistemica	(in	quanto	popolazione	ad	alto	rischio	di	sviluppare	PH)	senza	PH	e	59	pazienti	affetti	da	PH	(esclusa	PH	tipo	2).	In	quest’ultimo	gruppo	alcuni	soggetti	sono	stati	sottoposti	 a	 più	 di	 un	 esame	 ecocardiografico,	 a	 distanza	 di	 tempo,	 per	 un	 totale	 di	 81	
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ecocardiogrammi.	 Dalla	 popolazione	 di	 soggetti	 sani	 è	 stato	 scelto	 un	 campione	 di	 57	soggetti	 sovrapponibile	 per	 età	 e	 sesso	 alle	 due	 popolazioni	 patologiche.	 Tutti	 i	 pazienti	sono	 stati	 sottoposti	 ad	 almeno	 un	 ecocardiogramma	 completo,	 comprensivo	 di	acquisizioni	 tridimensionali	 del	 VDx.	 Mediante	 un	 software	 dedicato	 da	 un’immagine	bidimensionale	 dedicata	 per	 il	 VDx	 è	 stata	 eseguita	 l’analisi	 speckle	 tracking	 che	 ha	permesso	 di	 valutare	 lo	 strain	 longitudinale	 e	 la	 deformazione	 trasversale	 della	 parete	libera	e	del	setto	interventricolare.	Il	data	set	tridimensionale	è	stato	analizzato	mediante	un	 software	dedicato	 che	ha	permesso	di	misurare	 i	 volumi	 e	 la	 frazione	di	 eiezione	del	VDx.	 Il	 beutel	 tridimensionale	 così	 ottenuto	 è	 stato	 successivamente	 analizzato	 con	 un	software	 ad	hoc	 che	ha	permesso	di	 stimare	 separatamente	 il	 contributo	 longitudinale	 e	radiale	alla	genesi	della	frazione	di	eiezione	del	VDx.	
Risultati:	 dall’analisi	 del	 gruppo	 di	 soggetti	 sani	 sono	 stati	 ottenuti	 i	 valori	 di	normalità	di	volume	telediastolico	e	telesistolico,	frazione	di	eiezione,	strain	longitudinale	e	displacement	trasversale	del	VDx.	Dall’analisi	del	beutel	tridimensionale	del	VDx	è	emerso	che	la	deformazione	longitudinale	e	radiale	contribuiscono	in	eguale	misura	alla	funzione	di	pompa	globale	del	VDx.	 I	 soggetti	affetti	da	sclerosi	 sistemica	hanno	dimostrato	valori	leggermente	 superiori	 di	 pressione	 sistolica	 in	 arteria	 polmonare	 e	 resistenze	 vascolari	polmonari	 totali	 rispetto	 ai	 soggetti	 sani,	 seppure	 senza	 raggiungere	 i	 criteri	 patologici.	Invece,	 i	 valori	 di	 dimensione	 e	 funzione	del	VDx	 sono	 risultati	 sovrapponbili	 rispetto	 ai	controlli	 sani.	 I	 pazienti	 affetti	 da	 PH	 hanno	 dimostrato	 volumi	 del	 VDx	 sensibilmente	superiori	con	una	ridotta	frazione	di	eiezione.	Le	componenti	longitudinale	e	radiale	della	frazione	di	eiezione	sono	risultate	entrambe	ridotte,	ma	in	particolare	il	contributo	relativo	radiale	 ha	 dimostrato	 essere	 quello	 maggiormente	 alterato.	 Per	 quanto	 riguarda	 la	meccanica	 miocardica,	 lo	 strain	 longitudinale	 della	 parete	 libera	 e	 del	 setto	interventricolare	 è	 risultato	 ridotto	 ed	 anche	 la	 deformazione	 trasversale	 globale	 è	
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risultata	 alterata.	 In	 particolare	 nei	 soggetti	 con	 PH,	 soprattutto	 la	 meccanica	 del	 setto	interventricolare	ha	dimostrato	di	essere	alterata,	con	una	minore	entotà	di	spostamento	sistolico	dello	stesso	verso	il	centro	della	cavità	ventricolare	sinistra.	Dividendo	i	pazienti	con	PH	in	due	gruppi	(con	frazione	di	eiezione	conservata	e	frazione	di	eiezione	ridotta),	è	stato	possibile	dimostrare	che	 tutti	 i	parametri	di	 funzione	e	deformazione	del	VDx	sono	maggiormente	alterati	nel	secondo	gruppo.	Tuttavia,	mentre	il	contributo	longitudinale	alla	frazione	 di	 eiezione	 è	 risultato	 preservato,	 il	 contributo	 radiale	 ha	 dimostrato	 di	 essere	significativamente	ridotto.	
Conclusioni:	 in	 condizioni	 di	 normalità	 la	 funzione	 ventricolare	 destra	 sembra	essere	determinata	in	egual	misura	dalla	deformazione	longitudinale	e	radiale.	In	presenza	di	ipertensione	polmonare,	il	progressivo	deterioramento	della	funzione	di	pompa	del	VDx	è	veicolata	prevalentemente	da	una	riduzione	del	contributo	radiale.								
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Summary	
	
Background:	the	right	ventricle	(RV)	is	a	complex	shaped	cardiac	chamber,	whose	pump	 function	 is	mainly	driven	by	 a	 longitudinal	 deformation,	 as	 showed	by	 anatomical	studies.	 Conventional	 echocardiography	 showed	 several	 limitations	 in	 the	 analysis	 of	RV	size	 and	 function.	 RV	 systolic	 dysfunction	 is	 an	 important	 prognostic	 factor	 in	 several	pathological	 condition,	 among	 which	 pulmonary	 hypertension	 (PH).	 However,	 the	progression	 of	 RV	 mechanical	 changes	 that	 lead	 to	 the	 RV	 pump	 function	 impairment	remains	 to	be	 clarified.	The	new	echocardiographic	 techniques,	 two	dimensional-speckle	tracking	 (2D-STE)	 and	 three-dimensional	 echocardiography	 (3DE),	 allow	 to	 investigate	volumes,	ejection	fraction	and	myocardial	mechanics	of	the	RV.	Moreover,	we	developed	a	custom-made	 software	 package	 that	 applied	 to	 the	 3DE	 beutel	 of	 the	 RV	 allows	 to	discriminate	between	the	relative	contribution	of	the	longitudinal	and	radial	displacement	to	the	global	RV	pump	function.	
Purpose:	to	value	the	mechanics	of	RV	in	healthy	condition,	in	presence	of	systemic	sclerosis	(SSc),	a	condition	predisposing	to	PH,	and	in	presence	of	PH.	
Methods:	 we	 enrollled	 270	 healthy	 subjects,	 75	 patients	 affected	 by	 SSc	 (a	pathological	 condition	 at	 high	 risk	 of	 PH),	 without	 PH,	 and	 59	 patients	 affected	 by	 PH	(excluded	PH	type	2).	Some	of	PH	patients	underwent	to	more	than	one	echocardiograms,	for	a	total	of	81	exams.	57	age-	and	gender-matched	healthy	volunteers	have	been	selected.	All	subjects	underwent	a	complete	echocardiogram,	including	dedicated	3DE	acquisition	of	the	RV.	A	dedicated	 software	has	been	applied	on	apical	2D	 image	of	 the	RV	 in	order	 to	measure	 the	 longitudinal	 strain	 (LS)	 and	 the	 transversal	 displacement	 (TD)	 of	 both	 the	free-wall	(RVFW)	and	the	interventricular	septum	(IVS).	3DE	data	sets	of	the	RV	have	been	analyzed	 by	 RV	 function	 2.0	 (TomTec)	 in	 order	 to	 obtain	 volumes	 and	 ejection	 fraction	
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(RVEF).	 Then	 PH	 have	 been	 divided	 according	 to	 RV-EF:	 preserved	 (≥45%)	 or	 impaired	(<45%).	Finally,	the	3DE	RV	beutels	were	analyzed	by	our	custom	made	software	package	obtaining	 the	 longitudinal	 EF	 (LongEF)	 and	 radial	 EF	 (RadEF)	 and	 their	 relative	contribution	to	RVEF	by	calculating	the	ratios	LongEF/RVEF	and	RadEF/RVEF.		
Results:	 the	 analysis	 of	 the	 healthy	 volunteers	 provided	 reference	 values	 of	 RV	volumes,	ejection	fraction,	LS	and	TD.	The	3DE	RV	beutel	analysis	showed	that	in	healthy	subjects	the	relative	contribution	of	longitudinal	and	radial	motion	is	equal.	In	SSc	patients	no	significant	differences	about	RV	size	and	function	have	been	demonstrated.	PH	patients	showed	significantly		larger	3DE	RV	end-diastolic	and	end-systolic	volumes	(106±39	ml	vs	67	 ±14	ml	 and	 65±33	 vs	 28±7	ml,	 respectively;	 p<0.0001),	 lower	 3D	RVEF	 (41±11%	vs	58±4%;	p<0.0001),	lower	LS	values	and	impaired	TD	values	than	controls.	Similarly,	both	LongEF	 and	 RadEF	 were	 lower	 (18±7%	 vs	 27±4%	 and	 15±7%	 vs	 27±5%,	 respectively;	p<0.0001)	 in	PH	patients.	However,	 only	 the	RadEF/RVEF	appeared	 impaired	 (36±11	vs	47±6,	 p<0.0001),	whereas	LongEF/RVEF	 (47±9	vs	47±6,	 p=NS)	was	 similar	 between	pts	and	 controls.	 Looking	 at	 the	 subgroup	 of	 patients	 with	 reduced	 RVEF,	 RV	 pump	dysfunction	was	mainly	 driven	 by	 progressive	 reduction	 of	 the	 radial	 component	 of	 RV	wall	displacement.	
Conclusions:	in	healthy	condition,	the	radial	component	of	RV	wall	displacement	is	as	 important	 as	 the	 longitudinal	 one	 to	 determine	 global	 RV	 pump	 function.	 In	 patients	with	 PH,	 the	 impairment	 of	 RV	 pump	 function	 seems	 to	 be	 mainly	 driven	 by	 the	progressive	reduction	of	RV	radial	displacement.					
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Introduction	
	Pulmonary	hypertension	(PH)	is	a	pathological	process	involging	pulmonary	circulation.	It	may	 appear	 in	 multiple	 clinical	 conditions,	 in	 which	 its	 development	 is	 associated	 with	increased	morbidity	 and	mortality.	 The	 natural	 hystory	 of	 this	 pathological	 condition	 is	characterized	by	the	appearance	of	progressive	right	ventricular	(RV)	dysfunction,	with	RV	failure	being	the	main	cause	of	patients’	mortality.	Then,	accurate	evaluation	of	RV	fuction	appears	 to	 be	 critical	 in	 PH	 patients	 follow-up.	 Accordingly,	 echocardiography	 plays	 a	major	 role	 during	 initial	 assessment	 and	 follow-up	 of	 patients	 with	 PH.	 However,	conventional	 two-dimensional	 (2DE)	 and	 Doppler	 echocardiography	 has	 several	limitations	to	evaluate	the	RV,	which	are	mainly	related	to	its	complex	three-dimensional	geometry	and	peculiar	function.		The	 development	 of	 novel	 echocardiographic	 techniques,	 such	 as	 three-dimensional	echocardiography	 (3DE)	 and	 two-dimensional	 speckle-tracking	 echocardiography	 (2D-STE)	has	provided	new	ways	to	obtain	a	more	accurate	and	reproducible	assessment	of	the	RV	morphology	and	function	by	echocardiography.												
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Pulmonary	Hypertension	
	
Definition	PH	 is	 diagnosed	 when	 mean	 pulmonary	 artery	 pressure	 (mPAP)	 measured	invasively	 by	 right	 heart	 catheterization	 (RHC)	 at	 rest	 is	 higher	 than	 25	 mmHg	 [1].	Insufficient	 data	 are	 available	 about	 the	 normal	 behaviour	 of	 mPAP	 and	 pulmonary	vascular	resistance	(PVR)	during	exercise.	Moreover,	no	diagnostic	 threshold	of	exercise-induced	changes	in	mPAP	has	been	identified	because	of	the	lack	of	prognostic	data.	Then,	according	 to	 the	current	guidelines,	 the	entity	of	 “PH	on	exercise”	has	not	been	accepted	[2].		 	
Classification	To	be	properly	managed,	patients	with	PH	should	be	classified	using	hemodynamic	and	clinical	parameters.	The	 first	 distinction	 to	 be	 made	 is	 between	 pre-capillary	 and	 post-capillary	 PH	(Table	 1),	 a	 haemodynamic	 classification.	 Pre-capillary	 PH	 is	 defined	 by	 the	 presence	 of	low	pulmonary	artery	wedge	pressure	(PAWP;	≤	15	mmHg).	It	includes	pulmonary	arterial	hypertension	(PAH),	PH	due	to	lung	diseases/ipoxia,	chronic	thromboembolic	PH	(CTEPH)	and	PH	due	 to	multifactorial	 and	unclear	mechanisms.	 Finally,	 PAH	 is	 a	pre-capillary	PH	(with	PAWP	≤	15	mmHg	and	PVR	>	3	WU)	in	the	absence	of	other	causes	of	pre-capillary	PH.	Conversely,	post-capillary	PH	 is	defined	by	values	of	PAWP	higher	 than	15	mmHg,	 It	includes	PH	due	to	left	heart	diseases	or	multifactorial	and	unclear	mechanisms.	The	latter	entity	can	be	divided	in	isolated	or	combined	post-capillary	PH.	Differentiation	is	based	on	the	 values	 of	 the	 diastolic	 pressure	 gradient	 (DPG;	 lower	 or	 higher	 than	 7	 mmHg),	 a	
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haemodynamic	 parameter	 defined	 as	 the	 difference	 between	 diastolic	 PAP	 and	 PAWP	(Table	1).				Table	1.	Haemodynamic	definitions	of	pulmonary	hypertension	
Definition	 Characteristics	
PH	 mPAP	≥	25	mmHg	
					Pre-capillary	PH	 mPAP	≥	25	mmHg	PAWP	≤	15	mmHg						Post-capillary	PH														Isolated	post-capillary	PH													Combined	post-capillary	PH	
mPAP	≥	25	mmHg	PAWP	>	15	mmHg		DPG	<	7	mmHg	and/or	PVR	≤	3	WU		DPG	≥	7	mmGf	and/or	PVR	>	3	WU	DPG=diastolic	 pressure	 gradient;	 mPAP=mean	 pulmonary	 artery	 pressure;	 PH=pulmonary	 hypertension;	PVR=pulmonary	 vascular	 resistance.	 From:	 Galiè	 N.	 et	 al	 2015	 ESC/ERS	 Guidelines	 for	 the	 diagnosis	 and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].		 		
The	 clinical	 classification	 divides	 PH	 into	 five	 groups	 (Table	 2)	 [3].	 It	 is	 based	 on	pathophysiological,	clinical,	and	therapeutic	considerations.	
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Table	2.	Clinical	classification	of	pulmonary	hypertension	1.	Pulmonary	arterial	hypertension								1.1	Idiopathic							1.2	Heritable	(BMPR2	mutation;	other	mutations)							1.3	Drugs	and	toxins	induced							1.4	Associated	with:																		1.4.1	Connective	tissue	disease																		1.4.2	HIV	infection																		1.4.3	Portal	hypertension																		1.4.4	Congenital	heart	disease																		1.4.5	Schistosomiasis		1’.	Pulmonary	veno-occlusive	disease	and/or	pulmonary	capillary		haemangiomatosis		1’’.	Persistent	pulmonary	hypertension	of	the	newborn	2.	Pulmonary	hypertension	due	to	left	heart	disease									2.1	Left	ventricular	systolic	dysfunction									2.2	Left	ventricular	diastolic	dysfunction									2.3	Valvular	disease									2.4	Congenital/acquired	left	heart	inflow/outflow	tract	obstruction	and																											congenital	cardiomyopathies								2.5	Other	3.	Pulmonary	hypertension	due	to	lung	diseases	and/or	hypoxia										3.1	Chronic	obstructive	pulmonary	disease											3.2	Interstitial	lung	disease											3.3	Other	pulmonary	diseases	with	mixed	restrictive	and	obstructive	pattern											3.4	Sleep-disordered	breathing											3.5	Alveolar	hypoventilation	disorders											3.6	Chronic	exposure	to	high	altitude											3.7	Developmental	lung	diseases		4.	Chronic	thromboembolic	pulmonary	hypertension	and	other	pulmonary	artery	obstructions										4.1	Chronic	thromboembolic	pulmonary	hypertension											4.2	Other	pulmonary	artery	obstructions	5.	Pulmonary	hypertension	with	unclear	and/or	multifactorial	mechanisms											5.1Haematological	disorders											5.2	Systemic	disorders											5.3	Metabolic	disorders											5.4	Others	From:	Galiè	N.	et	al	2015	ESC/ERS	Guidelines	for	the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].			
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The	first	edition	of	the	clinical	classification	dates	back	to	1973	[4].	It	simply	divided	PH	in	primary	and	secondary,	according	to	the	presence/absence	of	identifiable	causes.	In	1998	in	Evian	 (France)	during	 the	Second	World	Symposium	on	Pulmonary	Hypertension,	 the	first	classification	was	replaced	by	the	first	version	of	the	current	classification.	The	aim	of	the	“Evian	classification”	was	to	distinguish	categories	sharing	similar	pathophysiological	mechanisms,	 clinical	 presentation	 and	 treatment	 strategies.	 A	 first	 update	 of	 the	 “Evian	classification”	 was	 performed	 in	 2003	 in	 Venice	 [3].	 At	 that	 time	 the	 introduction	 of	 a	genetic	 classification	 was	 proposed,	 because	 of	 the	 recognition	 of	 bone	 morphogenetic	protein	type	II	receptor	(BMPR2)	gene	mutations	as	the	possible	cause	of	a	sizable	number	of	 familial	and	sporadic	case	of	PAH,	but	not	only.	However,	 it	remained	only	a	proposal,	because	the	evidences	about	the	role	of	genes	in	various	forms	of	PH	were	still	at	an	early	stage	 [3].	 The	 term	 “primary”	 and	 “secondary”	 PH	were	 abandoned	 due	 to	 the	 evidence	that	 the	 idiopathic	 form	of	PH	share	similar	pathological	 findings	with	other	 forms	of	PH	secondary	 to	 drug/toxins,	 connective	 tissue	 disease	 or	HIV	 infection.	 Then,	 the	 terms	 of	“pulmonary	arterial	hypertension”	and	“idiopathic	arterial	hypertension”	were	introduced.	Pulmonary	 veno-occlusive	 disease	 (PVOD)	 and	 pulmonary	 capillary	 haemangiomatosis	(PCH)	 were	 reclassified	 and	 included	 in	 the	 PAH	 group,	 because	 they	 have	 similar	pathological	 and	 clinical	 features.	 Particularly	 they	 share:	 the	 possibility	 of	 pulmonary	edema	 occurrence	 during	 epoprostenol	 therapy	 [5,6];	 similar	 pathological	 conditions	associated	 with	 PAH,	 such	 as	 scleroderma	 disease	 [7]	 or	 HIV	 infection	 [8,9];	 and	 likely	familial	occurrence	in	both	PVOD	[10]	and	PCH	[11],	as	well	as	in	PAH.	In	2008,	during	the	fourth	 World	 Symposium	 on	 PH	 held	 in	 Dana	 Point	 (California),	 the	 “Evian-Venice	classification”	was	maintained,	with	modifications	of	 some	specific	points	 [12].	The	 term	“familial”	 PAH	 was	 replaced	 by	 “heritable”,	 for	 the	 evidence	 of	 specific	 gene	 mutations	identified	not	only	in	familial	but	in	sporadic	cases	too	[13,14].	A	clinical	and	anatomical-
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pathophysiological	version	of	the	classification	of	PAH	related	to	congenital	heart	disease	[15]	 was	 also	 introduced.	 The	 group	 of	 “associated	 PAH”	 was	 updated,	 with	 the	introduction	of	 schistosomiasis	as	an	associated	condition,	because	of	 the	demonstration	that	schistosomiasis	has	similar	specific	clinical	and	pathological	features	[16].	PVOD	and	PCH	were	reclassified	as	group	1’,	because	they	share	some	features	with	 idiopathic	PAH	but	also	demonstrate	some	differences.		Finally,	in	2015	the	current	version	of	the	clinical	guidelines	 on	 PH	 [2]	 was	 published.	 In	 this	 document	 some	 other	 modifications	 of	 the	clinical	classification	have	been	made.	Pre-capillary	PH	associated	with	chronic	haemolytic	anaemia	 has	 been	 moved	 from	 group	 1	 to	 5,	 because	 it	 appears	 significantly	 different	regard	to	pathological	and	haemodynamic	characteristics,	as	well	as	to	response	to	specific	therapies.	 	 The	 group	 1’	 has	 been	 expanded	 with	 the	 inclusion	 of	 idiopathic,	 heritable,	drug/toxin/radiation-induced	 and	 associated	 forms	 of	 PVOD/PCH.	 Persistent	 PH	 of	 the	newborn	 has	 been	 subcategorized	 alone	 as	 group	 1’’,	 because	 it	 demonstrated	 to	 be	 a	heterogeneous	 group	 of	 conditions	 [17-19].	 Finally,	 some	 paediatric	 heart	 diseases	 have	been	included	in	group	2.		
	
Epidemiology	Literature	reports	about	the	incidence	of	PH	are	limited.	About	80%	of	patients	with	PH	 live	 in	 the	developing	world,	where	heart	 disease	 and	 lung	disease	have	become	 the	most	 frequent	 causes	 of	 pulmonary	 hypertension	 [20].	 Particularly,	 in	 industrialised	countries,	pulmonary	hypertension	affects	mainly	elderly	people	whereas	 the	majority	of	young	people	with	PH	are	diagnosed	in	the	developing	world.	
An	overview	of	the	global	distribution	of	the	most	prevalent	forms	of	PH	is	shown	in	Figure	1.	
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	Figure	 1.	 	 Estimated	 global	 distribution	 of	 the	 most	 prevalent	 form	 of	 pulmonary	hypertension.	From:	Hoeper	MM	et	al.	Lancet	Respir	Med	2016;4:306-22	[20].		
Figure	2	provides	and	overview	of	 the	global	distribution	of	 the	most	prevalent	 forms	of	PAH.	
 Figure	2.	 	Estimated	global	distribution	of	 the	most	prevalent	 form	of	pulmonary	arterial	hypertension.	From:	Hoeper	MM	et	al.	Lancet	Respir	Med	2016;4:306-22	[20].	
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The	 data	 presented	 in	 Figure	 1	 and	 2	 should	 be	 presented	with	 caution	 as	most	 of	 the	underlying	 evidence	has	been	derived	 from	populations	 at	 risk	 for	PH	and	 are	based	on	echocardiographic	 data	 rather	 than	 from	 population-based	 studies	 with	 patients	undergoing	RHC.		
Group	1.	 In	Europe,	PAH	prevalence	and	incidence	are	 in	the	range	of	15–60	subjects	per	million	 population	 and	 5–10	 cases	 per	 million	 per	 year,	 respectively	 [21].	 In	 registries,	around	 50%	 of	 PAH	 patients	 have	 idiopathic,	 heritable	 or	 drug-induced	 PAH.	 In	 the	subgroup	 of	 associated	 conditions,	 the	 leading	 cause	 is	 connective	 tissue	 disease	 (CTD),	mainly	systemic	sclerosis	 (SSc)	 [22].	 Indeed,	SSc	accounts	 for	more	 than	70%	of	cases	of	CTD-related	PH	[23].	
PAH	affects	predominantly	females	of	childbearing	age	[24].	The	estimated	time	between	symptom	 onset	 and	 diagnosis	 is	 about	 2	 years	 and	 the	mean	 survival	 of	 untreated	 PAH	patients	is	2.8	years	[25].	Several	factors	for	the	development	of	PAH	have	been	identified.	They	 are	 defined	 as	 any	 factor	 or	 condition	 that	 is	 suspected	 to	 play	 a	 predisposing	 or	facilitating	 role	 in	 disease	 development.	 Risk	 factors	were	 classified	 as	 definite,	 likely	 or	possible,	based	on	the	strength	of	their	association	with	PH	and	their	probable	causal	role	[26].	 Definite	 risk	 factors	 for	 PAH	 are	 listed	 in	 the	 clinical	 classification	 table	 (Table	 2)	among	associated	PAH	conditions.	Different	drug	and	 toxins	with	 the	 corresponding	 risk	level	are	listed	in	Table	3.		
				
	 17	
Table	 3.	 Updated	 risk	 level	 of	 drugs	 and	 toxins	 known	 to	 induce	 pulmonary	 arterial	hypertension	
Definite Likely Possible 
• Aminorex 
• Fenfluramine 
• Dexfenfluramine 
• Toxic rapeseed oil 
• Benfluorex 
• Selective serotonin 
reuptake inhibitors 
• Amphetamines 
• Dasatinib 
• L-tryptophan 
• Methamphetamines  
• Cocaine 
• Phenylpropanolamine 
• St. John’s wort 
• Amphetamine-like drugs 
• Interferon α and β 
• Some chemotherapeutic 
agents such as alkylating 
agents. 
From:	Galiè	N.	et	al	2015	ESC/ERS	Guidelines	for	the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].		
Group	2.	 	 The	 prevalence	 of	 PH	 in	 patients	with	 chronic	 heart	 failure	 increases	with	 the	progression	 of	 functional	 class	 (FC)	 impairment.	 Up	 to	 60%	 of	 patients	with	 severe	 left	ventricular	 (LV)	 systolic	 dysfunction	 and	 up	 to	 70%	 of	 patients	 with	 heart	 failure	 with	preserved	 ejection	 fraction	 may	 present	 with	 PH.	 In	 left-sided	 valvular	 diseases,	 the	prevalence	of	PH	increases	with	the	severity	of	the	condition	and	related	symptoms.	When	present,	left	heart	disease	related-PH	results	in	more	severe	symptoms	and	worse	exercise	tolerance	 and	 exerts	 a	 negative	 impact	 on	 outcome	 [27-29].	 Compared	 with	 PAH,	 this	group	 of	 patients	 are	 often	 older,	 female,	 with	 a	 higher	 prevalence	 of	 cardiovascular	comorbidities	[30].		
Group	 3.	 The	 most	 common	 lung	 diseases	 associated	 with	 PH	 are	 chronic	 obstructive	pulmonary	disease	(COPD),	interstitial	lung	disease	and	combined	pulmonary	fibrosis	and	enphysema.	Mild	PH	is	common	in	both	severe	interstitial	lung	disease	and	severe	chronic	obstructive	lung	disease	[31],	while	severe	PH	is	uncommon	[32].	Severe	PH	can	be	seen	in	the	combined	emphysema/fibrosis	syndrome,	where	the	prevalence	of	PH	is	high	[33].	The	
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severity	of	PH	is	usually	poorly	associated	with	the	severity	of	the	underlying	lung	disese	[34-35].	 In	 any	 lung	 disease	 the	 appearance	 of	 PH	 is	 accompanied	 by	 a	 deterioration	 of	exercise	capacity	and	shorter	survival	[36-37].	
Group	4.			In	the	Spanish	PH	Registry,	CTEPH	prevalence	and	incidence	were	3.2	cases	per	million	and	0.9	cases	per	million	per	year,	respectively	[38].	Even	though	a	prevalence	of	CTEPH	of	3.8%	has	been	reported	in	survivors	of	acute	pulmonary	embolism	(PE),	the	true	incidence	of	CTEPH	after	acute	PE	is	lower,	in	the	range	of	0.5–2%	[39].	A	history	of	acute	PE	 was	 reported	 for	 74.8%	 of	 patients	 from	 the	 International	 CTEPH	 Registry	 [40].	Associated	 conditions	 included	 thrombophilic	 disorders	 (lupus	anticoagulant/antiphospholipid	antibodies,	protein	S	and	C	deficiency,	activated	protein	C	resistance	including	factor	V	Leiden	mutation,	prothrombin	gene	mu-	tation,	antithrombin	III	deficiency	and	elevated	factor	VIII)	in	31.9%	of	patients	and	splenectomy	in	3.4%.		
	
Pathology		
The	various	PH	groups	are	characterized	by	different	pathological	features	[41-42].	They	 present	 with	 either	 a	 predominance	 of	 pulmonary	 arterial	 remodeling	 or	 vein	remodeling	 or	 a	 variable	 contribution	 of	 both.	 Paradigmatic	 of	 the	 former	 is	 idiopathic	PAH,	 whereas	 pure	 PVOD	 and	 PH	 due	 to	 left	 heart	 dysfunction	 are	 characterized	predominantly	by	venous	remodeling	[43].		
Group	 1	 (PAH):	 pathological	 lesions	 affect	 the	 distal	 pulmonary	 arteries	 (<500	 um	 of	diameter)	 in	 particular.	 They	 are	 characterized	 by	 medial	 hypertrophy,	 intimal	proliferative	 and	 fibrotic	 changes	 (concentric,	 eccentric),	 adventitial	 thickening	 with	perivascular	 inflammatory	 infiltrates,	 complex	 lesions	 (plexiform,	 dilated	 lesions),	 and	thrombotic	 lesions	 (Figure	 3).	 Pulmonary	 veins	 are	 classically	 unaffected.	 The	 first	
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pathological	classification	is	attributable	to	Heath	and	Edwards	[44-45]	(Table	4).	
	Table	4.	Heath	and	Edwards	grading	scheme	for	vascular	pathology	in	pulmonary	arterial	hypertension	Grade	 Vascular	pathology	
1.	2.	3.	4.	5.		6.	
Distal	extension	of	muscle	and	medial	thickening	of	distal	arterioles	Medial	hypertrophy	with	neointima	in	small	muscular	arteries	Progressive	fibrotic	vascular	occlusion,	concentric	intimal	fibrosis	Progressive	arterial	dilation	with	plexiform	lesions	Chronic	dilatation	with	medial	and	intimal	fibrosis,	angiomatoid	lesions	and	hemosiderosis	Necrotizing	arteritis	From:	de	 Jesus	Perez	VA.	Molecular	pathogenesis	and	current	pathology	of	pulmonary	hypertension.	Heart	Fail	Rev	2016;	21(3):	239-57	[47].	
	
	Figure	 3.	 Pathological	 lesions	 of	 pulmonary	 arterial	 hypertension	 lungs	 characterized	 by	intima	and	media	remodeling	with	obstruction	of	arterioles,	perivascular	inflammation	and	aneurismatic	 lesions.	 Courtesy	 of	 Prof	 G.	 Thiene,	 Cardiovascular	 Pathology,	 Padua	University.	
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These	pathological	 lesions	are	distributed	through	the	entire	 lung.	The	exact	sequence	of	histological	 occurring	 in	 PAH	 remains	 to	 be	 clarified.	 The	 extent	 of	 intima	 and	 media	remodeling	 appears	 to	 progress	 independently	 because	 we	 could	 not	 find	 a	 close	correlation	between	both	forms	of	remodeling.	However,	media	remodeling	could	antedate	intima	remodeling	as	 suggested	by	 the	 few	human	studies	with	 sequential	 lung	biopsies.	Intima	 remodeling	 could	 be	 linked	 to	 alterations	 of	 pulmonary	 artery	 flow,	 imparted	 by	media	remodeling	and	vasoconstriction	or,	alternatively,	develop	as	an	independent	event	[	46].		
It	has	been	speculated	that	higher	grade	lesions	are	associated	with	worse	hemodynamic	parameters	 and	 right	 heart	 failure.	 However,	 lung	 tissue	 sections	 from	 PAH	 patients	demonstrate	a	wide	spectrum	of	lesion	severity	[47].	Moreover,	number,	distribution	and	severity	 of	 the	 lung	 lesions	 have	 been	 demonstrated	 to	 be	 similar	 among	 PAH	 patients	receiving	 or	 not	 long-term	 specific	 therapies	 [48].	 Anyway,	 authors	 admit	 that	 random	sampling	could	 serve	as	a	 source	of	bias	 that	needs	 to	be	considered	prior	 to	 reaching	a	definite	conclusion	[48].	
Group	 1’:	 includes	 mainly	 PVOD	 which	 involves	 septal	 veins	 and	 pre-septal	 venules	(constant	 involvement)	 with	 occlusive	 fibrotic	 lesions,	 venous	muscularization,	 frequent	capillary	 proliferation	 (patchy),	 pulmonary	 oedema,	 occult	 alveolar	 haemorrhage,	lymphatic	 dilatation	 and	 lymphnode	 enlargement	 (vascular	 transformation	of	 the	 sinus),	and	inflammatory	infiltrates.	Distal	pulmonary	arteries	are	affected	by	medial	hypertrophy,	intimal	fibrosis,	and	uncommon	complex	lesions.		
Group	2	(PH	due	to	left	heart	disease):	pathological	changes	in	this	group	are	characterized	by	 enlarged	 and	 thickened	 pulmonary	 veins,	 pulmonary	 capillary	 dilatation,	 interstitial	oedema,	alveolar	haemorrhage,	and	lymphatic	vessel	and	lymph	node	enlargement.	Distal	
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pulmonary	arteries	may	be	affected	by	medial	hypertrophy	and	intimal	fibrosis.		
Group	 3	 (PH	 due	 to	 lung	 diseases	 and/or	 hypoxia):	 pathological	 changes	 in	 these	 cases	include	medial	hypertrophy	and	 intimal	obstructive	proliferation	of	 the	distal	pulmonary	arteries.	A	variable	degree	of	destruction	of	the	vascular	bed	in	emphysematous	or	fibrotic	areas	may	also	be	present.		
Group	 4	 (CTEPH):	 pathological	 lesions	 are	 characterized	 by	 organized	 thrombi	 tightly	attached	to	the	pulmonary	arterial	medial	layer	in	the	elastic	pulmonary	arteries,	replacing	the	normal	 intima	(Figure	4).	These	may	completely	occlude	 the	 lumen	or	 form	different	grades	 of	 stenosis,	 webs,	 and	 bands	 [49].	 Interestingly,	 in	 the	 non-occluded	 areas,	 a	pulmonary	arteriopathy	 indistinguishable	 from	 that	of	PAH	 (including	plexiform	 lesions)	can	develop	 [50].	Collateral	vessels	 from	the	systemic	circulation	 (from	bronchial,	 costal,	diaphragmatic	 and	 coronary	 arteries)	 can	 grow	 to	 reperfuse	 at	 least	 partially	 the	 areas	distal	to	complete	obstructions.		
	
	
Figure	 4.	 Pathological	 lesions	 of	 chronic	 thromboembolic	 pulmonary	 hypertension	characterized	 by	 organized	 and	 recanalized	 endovascular	 thrombi.	 Courtesy	 of	 Prof	 G.	Thiene,	Cardiovascular	Pathology,	Padua	University.		
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Group	 5	 (PH	 with	 unclear	 and/or	 multifactorial	 mechanisms):	 this	 group	 includes	heterogeneous	 conditions	with	 different	 pathological	 pictures	 for	 which	 the	 aetiology	 is	unclear	or	multifactorial.		
	
Pathobiology	
Different	 pathobiological	 features	 [51-53]	 characterize	 the	 different	 clinical	 PH	groups.		
Group	1:	The	exact	process	responsible	for	the	initiation,	aggravation	or	acceleration	of	PH	remains	 to	 be	 defined.	 Mechanisms	 underlying	 PAH	 disease	 are	 vasoconstriction,	proliferative	 and	 obstructive	 remodeling	 of	 the	 pulmonary	 vessel,	 inflammation	 and	thrombosis.	Then,	the	pathogenesis	appeared	to	be	multifactorial	(Figure	5).	
	Figure	5.	Summary	of	mechanisms	involved	in	pathogenesis	of	PAH.	From:	de	Jesus	Perez	VA.	Molecular	pathogenesis	and	current	pathology	of	pulmonary	hypertension.	Heart	Fail	Rev	2016;	21(3):	239-57	[47].	
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The	 proposed	 theory	 is	 based	 on	 the	 action	 of	 multiple	 contributing	 factors	 on	 a	background	of	genetic	predisposition	[43]	(Figure	6).	
 Figure	 6.	 Proposed	 multifactorial	 factors	 influencing	 progression	 of	 pulmonary	hypertension.	From:	Tuder	RM	et	al.	JACC	2013;62(25	Suppl):D4-12	[43].		Vasoconstriction	has	been	related	 to	abnormal	 function	of	 the	smooth	muscle	cell	and	to	endothelial	 dysfunction,	 with	 impaired	 production	 of	 vasodilator	 and	 anti-proliferative	agents	and	overexpression	of	vasoconstrictor	and	proliferative	substances.	Many	of	these	abnormalities	 promote	 vascular	 remodeling,	 too.	 In	 addition,	 an	 increased	production	 of	extracellular	matrix	occurs	in	the	adventitia	layer.	Prothrombotic	abnormalities	have	been	demonstrated,	with	presence	of	thrombi	in	both	the	small	distal	and	proximal	pulmonary	arteries	[12].	
à	 Inflammation	 has	 been	 long	 recognized	 as	 an	 important	 pathogenetic	 element	 in	 PH	[54].	 In	addition	 to	 the	obliterative	changes	caused	by	 the	anomalous	growth	of	vascular	cells,	 there	 is	 also	 evidence	 that	 perivascular	 infiltration	 with	 inflammatory	 cells	 is	 a	
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common	finding	in	PAH	vascular	lesions.	These	infiltrates	are	predominantly	composed	of	macrophages,	dendritic	cells,	mast	cells	and	lymphocytes	that	can	appear	as	disorganized	cell	 clusters	 or	 form	highly	 organized	pulmonary	 tertiary	 lymphoid	 tissues	 [48].	 Beyond	these	 pathological	 findings,	 there	 is	 also	 evidence	 that	 circulating	 levels	 of	 certain	autoantibodies	and	inflammatory	cytokines	are	elevated,	which	reflect	activation	of	innate	and	 adaptive	 immunity	 pathways	 [55-56].	While	 it	 is	 unclear	whether	 inflammation	 is	 a	trigger	or	a	complication	of	the	vascular	pathology,	available	evidence	supports	its	role	as	a	major	 modifier	 of	 disease	 progression	 and	 has	 opened	 exciting	 opportunities	 for	 drug	development	 [47].	 Major	 unanswered	 questions	 still	 remain:	 i)	 the	 etiology	 of	 the	abnormal	host	response	to	inflammation	that	leads	to	the	initiation	and	progression	of	PH;	ii)	if	the	inflammatory	response	in	PAH	is	caused	by	autoimmunity	or	infection;	iii)	which	specific	features	of	the	inflammatory	response	can	be	enhanced	(if	protective)	or	blocked	(if	detrimental)	for	therapeutic	intervention	[43].	
Group	 2.	 Mechanisms	 involved	 in	 PH	 etiology	 are	 multiple	 and	 included	 the	 passive	backward	transmission	of	the	pressure	elevation.	This	is	the	case	of	the	so-called	“isolated	post-capillary	 PH”.	 Sometimes,	 the	 increase	 in	 pulmonary	 artery	 pressure	 (PAP)	 is	oversized	 respect	 to	 the	 increase	 of	 the	 PAWP,	 demonstrated	 by	 a	 DPG	 higher	 than	 7	mmHg.	This	is	the	“combined	form”	of	post-capillary	PH.	In	this	situation	the	elevation	of	PVR	is	due	to	an	increase	in	the	vasomotor	tone	of	the	pulmonary	arteries,	which	is	usually	reversible	 under	 acute	 pharmacological	 testing,	 and/or	 to	 fixed	 structural	 obstructive	remodelling	 of	 the	 pulmonary	 artery	 resistance	 vessels,	 not	 responding	 to	 acute	pharmacological	 challenge	 [57].	 Which	 factors	 lead	 to	 one	 or	 the	 other	 form	 is	 poorly	understood.	
Group	3.	 Pathobiological	 and	 pathophysiological	mechanisms	 involved	 in	 this	 setting	 are	multiple	 and	 include	 hypoxic	 vasoconstriction,	mechanical	 stress	 of	 hyperinflated	 lungs,	
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loss	of	capillaries,	inflammation,	and	toxic	effects	of	cigarette	smoke	[12].			
Group	4.	Non-resolution	of	 acute	 embolic	masses	which	 later	undergo	 fibrosis	 leading	 to	mechanical	 obstruction	 of	 pulmonary	 arteries	 is	 the	 most	 important	 pathobiological	process	 in	 CTEPH.	 Another	 mechanism	 is	 recurrent	 pulmonary	 thromboembolism	 or	 in	situ	thrombosis.	They	may	be	initiated	or	aggravated	by	abnormalities	in	either	the	clotting	cascade,	endothelial	cells,	or	platelets	[58].	Platelet	abnormalities	and	biochemical	features	of	a	procoagulant	environment	within	the	pulmonary	vasculature	support	a	potential	role	for	 local	 thrombosis	 in	 initiating	 the	 disease	 in	 some	 patients.	 In	most	 cases,	 it	 remains	unclear	whether	thrombosis	and	platelet	dysfunction	are	the	cause	or	the	consequence	of	the	 disease.	 Inflammatory	 infiltrates	 are	 commonly	 detected	 in	 the	 pulmonary	endarterectomy	 (PEA)	 specimens.	 Thrombophilia	 studies	 have	 shown	 that	 lupus	anticoagulant	 may	 be	 found	 in	 about	 10%	 of	 such	 patients,	 and	 20%	 carry	 anti-phospholipid	 antibodies,	 lupus	 anticoagulant,	 or	 both.	 A	 recent	 study	 has	 demonstrated	that	the	plasma	level	of	 factor	VIII,	a	protein	associated	with	both	primary	and	recurrent	venous	thromboembolism,	is	elevated	in	39%	of	patients	with	CTEPH.		
	
Genetic		
Group	1.	The	first	gene	discovered	to	be	linked	to	PAH	has	been	BMPR2.	This	gene	is	involved	in	the	regulation	of	the	bone	morphogenetic	protein	signaling	pathway,	that	plays	a	major	role	 in	regulating	normal	bone	development	and	deposition	of	calcium	in	tissues	[59-61].	Mutations	in	BMPR2	have	been	reported	in	approximately	75%	of	subjects	with	1	or	more	affected	relatives	(heritable	PAH)	and	approximately	20%	of	those	with	idiopathic	PAH	[62-64].	Mutations	in	several	other	genes	have	been	found,	including	mutations	in	the	activin	receptor-like	kinase-1	(ALK1)	gene	(65),	the	endoglin	(66),	the	SMAD9	e	(67),	the	
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Caveolin-1	 (68),	 and	 recently,	 the	KCNK3	 (69)	 genes.	Mutations	 in	 BMPR2	 or	ALK-1	 are	emerging	 as	 determinants	 of	 severity	 of	 PAH.	 Patients	with	 BMPR2	 or	 ALK-1	mutations	present	with	higher	pulmonary	vascular	resistance	(70).	There	is	also	evidence	that	these	patients	present	with	more	severe	disease	and	die	at	a	younger	age	compared	with	PAH	patients	 without	 mutations	 [71].	 Moreover,	 they	 are	 less	 likely	 to	 respond	 acutely	 to	vasodilators	 (72).	 Recent	 evidence	 suggests	 that	 the	 degree	 of	 pulmonary	 vascular	remodeling	 is	 greater	 in	 patients	 with	 BMPR2	 mutations	 compared	 with	 non-BMPR2–related	disease	at	the	time	of	transplantation	(73).		Clinical	studies	have	shown	that	not	all	carriers	of	BMPR2	mutations	acyually	develope	the	disease	as	the	estimated	penetrance	is	about	 20%,	 leading	 to	 the	 consideration	 of	 other	 genetic	 factors	 that	 could	 be	 acting	 as	modifiers	[47].			
Apart	 from	 major	 effects	 of	 rare	 sequence	 variants	 in	 heritable	 forms	 of	 PAH,	interindividual	 differences	 in	 response	 to	 the	 same	 stimulus	 are	 well	 documented	 in	subjects	 exposed	 to	 environmental	 hypoxia	 at	 high	 altitude	 or	 in	 the	 context	 of	 high	pulmonary	blood	flow	or	pulmonary	venous	hypertension.	This	variable	expressivity	most	certainly	 involves	 the	 impact	 of	 unknown	 genetic	 influences	 regulating	 the	 pulmonary	vascular	 response.	 Elegant	 studies	 demonstrated	 that	 this	 response	 is	 inherited	 (74),	though	the	identification	of	the	genetic	basis	of	PAH	is	the	subject	of	ongoing	research	(75).		
Group	1’.	Heritable	PVOD/PCH	has	been	recognized	in	consanguineous	families,	suggesting	recessive	transmission.	Whole	genome	sequencing	demonstrated	that	bi-allelic	mutations	in	 eukaryotic	 translation	 initiation	 factor	 2	 alpha	 kinase	 4	 were	 present	 in	 all	 familial	PVOD/PCH	 and	 in	 25%	 of	 histologically	 confirmed	 sporadic	 PVOD/PCH	 [76].	 This	 gene	encodes	 a	 serine-threonine	 kinase	 present	 in	 all	 eukaryotes	 that	 can	 induce	 changes	 in	gene	expression	in	response	to	amino	acid	deprivation.	
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Group	2.	No	specific	genetic	linkage	has	been	identified	[77].			
Group	3.	Gene	polymorphism	might	contribute	towards	determining	the	severity	of	PH	in	hypoxaemic	patients	with	COPD	[78].			
Group	4.	No	specific	genetic	mutations	have	been	linked	to	the	development	of	CTEPH.			
Group	5.	 	The	heterogeneity	of	this	group	prevents	an	appropriate	description	of	genetics,	epidemiology	and	risk	factors	in	these	guidelines.			
	
Genomics		 	 Besides	 investigation	of	 genetic	mutations,	molecular	 investigation	of	 lung	 tissues	or	 specific	 cell	 types	 can	 provide	 important	 information	 about	 the	 mechanisms	 of	 the	disease.	
Somatic	 genetic	 changes.	 Many	 evidences	 in	 the	 last	 decade	 permit	 to	 advance	 the	hypothesis	 that	 the	 pathogenesis	 of	 PAH	 is	 a	 neoplastic-like	 process	 [79-81].	Microdissection	of	plexiform	lesions	from	the	 lungs	of	 idiopathic	and	anorexigen-induced	PAH	cases	showed	that	endothelial	cells	have	a	monoclonal	pattern	of	X-inactivation	(80,	82).	 Many	 of	 the	 abnormal	 properties	 observed	 in	 pulmonary	 artery	 endothelial	 cells	(PAECs)	 and	 pulmonary	 artery	 smooth	 muscle	 cells	 (PASMCs)	 are	 analogous	 to	 cancer,	including	 increased	 proliferation,	 decreased	 apoptosis,	 activation	 of	 hypoxia-inducible	factor-	 1-alpha,	 mitochondrial	 abnormalities,	 and	 a	 shift	 from	 oxidative	 to	 glycolytic	metabolism	(83-89).		
	Epigenetic.	Regulation	 of	 gene	 expression	 is	 a	 finely	 tuned	 event	 that	 is	 coordinated	 by	various	mechanisms	that	work	in	tandem	to	ensure	that	a	given	gene	product	is	expressed	
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at	 target	 levels.	 Among	 these	 mechanisms,	 microRNAs	 (miRNAs)	 are	 responsible	 for	regulating	 the	 size	 of	 the	 pool	 of	 mRNA	 transcripts	 available	 for	 translation	 both	temporally	and	in	a	context-dependent	manner	[90].	Dysregulation	in	specific	miRNAs	has	been	observed	in	PAH	and	appears	to	contribute	to	the	abnormal	expression	of	candidate	genes	 associated	 with	 increased	 smooth	 muscle	 cell	 proliferation	 and	 survival,	 active	inflammation	and	development	of	PAH	in	various	animal	models	[90-91].		
Another	epigenetic	mechanism	involved	in	gene	regulation	is	DNA	methylation,	which	can	target	promoter	and	enhancer	regions	to	reduce	their	access	to	transcription	factors	[92].	Epigenetic	traits	are	stably	heritable	phenotypes	resulting	from	changes	in	a	chromosome	without	alterations	in	deoxyribonucleic	acid	sequence	(93).	Epigenetic	changes	are	thought	to	 lead	 to	cellular	 reprogramming,	 the	process	by	which	a	differentiated	cell	 type	can	be	induced	to	adopt	an	alternate	cell	fate.	This	idea	seems	to	be	consistent	with	observations	in	pulmonary	hypertension,	 in	which	PAECs,	PASMCs,	and	adventitial	 fibroblasts	have	all	been	 demonstrated	 to	 acquire	 significantly	 altered	 characteristics,	 including	 stable	increases	 in	 proliferation,	 resistance	 to	 apoptosis,	 metabolic	 switching,	 and	 pro-inflammatory	 gene	 expression.	 A	 candidate	 for	 epigenetic	 study	 is	 BMPR2,	 with	significantly	 down-regulated	 expression	 in	 many	 PAH	 lungs,	 even	 in	 the	 absence	 of	 a	germline	mutation	[94-95].		
	
Physiopathology	
Right	ventricular	remodeling	Patients	suffering	from	severe	forms	of	PAH	frequently	die	of	RV	failure	(RVF)	[96].	However,	 patients	 affected	 by	 PH	 differ	 substantially	 in	 tendency	 to	 develop	 RVF.	 This	leads	 to	a	variable	natural	history	with	some	subjects	 living	a	surprisingly	 long	 time	and	
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others	 dying	 more	 rapidly	 [97].	 RV	 remodeling	 in	 PAH	 represents	 a	 continuum.	Experimental	 studies	 often	 differentiate	 2	 patterns	 of	 RV	 remodeling	 on	 the	 basis	 of	morphometric	 and	 molecular	 characteristics:	 adaptive	 and	 maladaptive	 remodeling.	Adaptive	 remodeling	 is	 characterized	 by	 more	 concentric	 remodeling	 (Figure	 7)	 and	preserved	 systolic	 and	 diastolic	 function,	 whereas	maladaptive	 remodeling	 is	 associated	with	more	eccentric	hypertrophy	and	worse	systolic	and	diastolic	function	[98].	
A	clinical	definition	of	RVF	remains	a	work	in	progress;	it	could	be	defined	as	a	state	that	is	morphologically	and	functionally	distinct	from	compensated	RV	hyperthrophy	[96].	
	
	
Figure	 7.	 long-axis	 section	 of	 the	 right	 ventricle	 	 of	 a	 patients	 affected	 by	 pulmonary	arterial	hypertension;	 it	has	to	be	noticed	the	 	remarkable	hyperthrophy	of	 the	free	wall.	Courtesy	of	Prof	G.	Thiene,	Cardiovascular	Pathology,	Padua	University.			
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Urashima	 et	 al.	 studied	 the	 transcriptional	 differences	 between	 the	 RV	 and	 the	 LV	subjected	 to	 pressure	 overload	 in	 rodents	 and	demonstrated	 a	 differential	 expression	 of	genes	 between	 the	 pressure-overloaded	 RVs	 compared	 with	 the	 LV	 counterparts,	suggesting	 that	 the	RV	 and	 the	 LV	do	 not	 respond	 to	 pressure	 overload	 identically	 [99].	Some	 features	 have	 been	 recognized	 to	 characterize	 the	 myocardium	 in	 RVF	 patients.	Alterations	 of	 metabolism	 pathways	 have	 been	 demonstrated:	 decreased	 fatty	 acid	 and	glucose	 oxidation,	 increased	 glucose	 uptake	 and	 glycolysis,	 abnormal	 mitochodrial	ultrastructure	 and	 oxidative	 capacity	 [100].	 	 Another	 salient	 feature	 is	 the	 impaired	angiogenesis	 [101],	driven	by	a	 reduction	 in	vascular	endothelial	growth	 factor	 signaling	inhibition	 [102].	 However,	 whether	 decreased	 expression	 of	 	 the	 vascular	 endothelial	growth	factor	and	the	accompanying	reduction	in	capillaries	are	causes	or	consequences	of	RVF	 remain	 to	 be	 tested.	 Perhaps	 a	 direct	 consequence	 of	 capillary	 rarefaction	 in	 RVF	tissue	 would	 be	 cell	 death	 and	 replacement	 interstitial	 fibrosis,	 which	 have	 been	documented	 in	 RVF	 tissue	 [103-104].	Moreover,	 cardiomyocite	 apoptosis	 plays	 a	 role	 in	the	development	of	RV	dysfunction	[105].		
The	exact	mechanism	underlying	 the	 appearance	of	RV	 failure	 is	not	 clearly	understood.	Some	hypothesis	have	been	proposed	[96]:	
- one	contemplates	the	autophagy	as	a	model	explaining	transition	from	RV	adaptive	hyperthrophy	to	RVF.		Authors	postulate	that	RV	remains	compensated	by	inducing	adaptive	 autophagy	with	 an	 adequate	 turnover	 of	 damaged	proteins	 and	damaged	organelles.	Transitions	 to	RVF	happens	when	autophagy	becomes	maladaptive,	 the	damaged	 proteins	 and	 organelles	 that	 are	 not	 removed	 accumulate,	 and	 the	“congested”	cells	die.	In	short,	they	hypothesize	that	maladaptive	autophagy	causes	RVF.			- another	hypothesis	 is	based	on	 the	possibility	 that	 individuals	who	present	earlier	
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with	RVF	symptoms	are	genetically	prone	to	express	the	RVF	program.	- the	last	hypothesis	contemplate	that	phenotypically	altered	lung	vascular	cells	from	the	sick	lung	circulation	contribute	to	the	progression	from	adaptive	to	maladaptive	RV	hyperthrophy.	 In	an	 intricate	model	of	cardiopulmonary	 interaction,	circulating	cells	 and	 cell	 fragment,	 free-DNA	and	miRNAs	 from	 the	 sick	 lung	 circulation	 come	into	 contact	 with	 the	 myocardial	 microcirculation.	 It	 has	 been	 demonstrated	 that	circulating	 free	DNA	can	be	cytotoxic	[106],	and	miRNA	can	reprogram	endothelial	cell	genes.	
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Diagnosis	
The	diagnosis	of	PH	is	based	on	clinical	suspicion,	driven	by	symptoms	and	physical	examination,	 followed	by	 serial	 instrumental	 exams	 carried	out	 to	 confirm	 the	 suspicion	and	to	define	aetiology	and	severity	of	the	disease	[2].	The	approved	diagnostic	algorithm,	taken	from	the	current	guidelines	[2],	has	shown	in	8.	
	Figure	 8.	 Diagnostic	 algorithm.	 From:	 Galiè	 N.	 et	 al	 2015	 ESC/ERS	 Guidelines	 for	 the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].	CHD	 =	 congenital	 heart	 diseases;	 CT	 =	 computed	 tomography;	 CTD	 =	 connective	 tissue	 disease;	 CTEPH	 =	chronic	 thromboembolic	 pulmonary	 hypertension;	 DLCO=	 carbon	 monosside	 diffusing	 capacity;	ECG=electrocardiogram;	 HIV=human	 immunodeficiency	 virus;	 HR_CT=high	 resolution	 CT;	 mPAP=mean	pulmonary	artery	pressure;	PA	=	pulmonary	angiography;	PAH	=	pulmonary	arterial	hypertension;	PAWP	=	pulmonary	 artery	 wedge	 pressure;	 PFT	 =	 pulmonary	 function	 tests;	PH	 =	 pulmonary	 hypertension;	PVOD/PCH	 =	 pulmonary	 veno-occlusive	 disease	 or	 pulmonary	 capillary	 hemangiomathosis;	 PVR	 =	pulmonary	 vascular	 resistance;	 RHC	 =	 right	 heart	 catheterisation;	 RV	 =	 right	 ventricular;	 V/Q	 =	ventilation/perfusion.	aCT	 pulmonary	 angiography	 alone	 may	 miss	 diagnosis	 of	 chronic	 thromboembolic	pulmonary	hypertension.		
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Clinical	presentation	
Symptoms	are	non	specific	and	mainly	related	to	RV	dysfunction	and/or	related	to	the	 disease	 that	 causes	 or	 is	 associated	with	PH.	 Typical	 symptoms	 include	 shortness	 of	breath,	fatigue,	weakness,	angina	and	syncope.	At	the	beginning	they	are	tipically	triggered	by	exertion;	while	in	advanced	cases	they	occur	at	rest,	too.	Other	rare	symptoms	could	be	related	to	mechanical	complications	or	abnormal	distribution	of	blood	flow	in	pulmonary	vascular	 bed:	 haemoptysis;	 hoarseness	 or	 angina	 caused	 by	 a	 dilated	 pulmonary	 artery	compressing	 the	 left	 recurrent	 laryngeal	 nerve	 or	 the	 left	 main	 coronary	 artery,	respectively;	cardiac	tamponade	due	to	rupture	or	dissection	of	a	dilated	pulmonary	artery.	
Typical	 signs	 include:	 left	 parasternal	 lift,	 an	 accentuated	 pulmonary	 component	 of	 the	second	 heart	 sound,	 an	 RV	 third	 heart	 sound,	 a	 pansystolic	 murmur	 of	 tricuspid	regurgitation	 (TR)	 and	 a	 diastolic	murmur	 of	 pulmonary	 regurgitation.	 Elevated	 jugular	venous	 pressure,	 hepatomegaly,	 ascites,	 peripheral	 oedema	 and	 cool	 extremities	characterize	patients	with	advanced	disease.		
Electrocardiogram.	 An	 electrocardiogram	may	 provide	 supportive	 evidence	 of	 PH,	 but	 if	normal	it	does	not	exclude	the	diagnosis.	It	is	more	likely	abnormal	in	severe	rather	than	in	mild	PH.	Abnormalities	may	include	P	pulmonale,	right	axis	deviation,	RV	hypertrophy,	RV	strain,	 right	 bundle	 branch	 block,	 and	 QTc	 prolongation.	 While	 RV	 hypertrophy	 has	insufficient	sensitivity	(55%)	and	specificity	(70%)	to	be	a	screening	tool,	RV	strain	is	more	sensitive	[107].		
Chest	 radiograph.	 It	 is	 abnormal	 in	 90%	 of	 patients	 with	 idiopathic	 PAH	 at	 the	 time	 of	diagnosis.	 It	may	 assist	 in	differential	 diagnosis	 by	 showing	 signs	 suggesting	 lung	or	 left	heart	diseases.	However,	the	severity	of	PH	does	not	correlate	with	abnormalities	at	chest	Rx	and	a	normal	one	does	not	exclude	PH.		
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Echocardiogram.	 As	 shown	 in	 Figure	 8,	 in	 presence	 of	 a	 clinical	 suspicion	 of	 PH	 the	echocardiogram	is	the	first	exam	to	be	performed.	It	allows	to	estimate	systolic	PAP	and	to	confirm	 or	 reject	 the	 suspicion	 of	 PH.	 Echocardiographic	 estimation	 of	 sPAP	 has	 been	validated	by	Berger	et	al	and	Currie	et	al	in	1985	[108-109].		Then,	 several	 studies	 have	 shown	 modest	 to	 good	 correlations	 between	 estimated	 RV	systolic	 pressure	 and	 invasively	 measured	 pressures	 (R	 =	 0.57–0.93),	 suggesting	 that	technical	and	biological	variability	are	not	negligible	[110].	A	few	aspects	must	be	kept	in	mind	 to	 ensure	 accurate	 estimates	 of	 systolic	 PAP.	 Because	 velocity	 measurements	 are	angle	dependent,	TR	Doppler	velocity	should	be	taken	from	multiple	views	(and	off	axis	if	necessary),	searching	for	the	best	envelope	and	maximal	velocity.	In	case	of	a	suboptimal	continuous-wave	 Doppler	 spectrum,	 the	 injection	 of	 contrast	 agents	 (agitated	 saline,	sonicated	albumin,	air-blood-saline	mixture)	may	be	required	to	achieve	clear	delineation	of	 the	 jet	 envelope	 [111-112].	 Potential	 overestimation	 of	 Doppler	 velocities	 should	 be	taken	 into	 account	 because	 of	 contrast	 artifacts.	 Furthermore,	 in	 severe	 TR	with	 a	 large	color	 flow	 regurgitant	 jet,	 the	 peak	 velocity	 may	 not	 reflect	 the	 true	 RV–right	 atrial	pressure	gradient	because	of	early	equalization	of	RV	pressure	and	RAP.		
Other	echocardiographic	features,	aside	systolic	PAP,	might	raise	and	support	the	suspicion	of	PH.	These	parameters	describe	the	RV	size	and	pressure	overload,	the	pattern	of	blood	flow	velocity	out	of	the	RV,	the	diameter	of	the	pulmonary	artery	and	an	estimate	of	right	atrial	pressure	[113-115]	(Table	5).	
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Table	5.	Echocardiographic	signs	suggesting	pulmonary	hypertension.	
A.	The	ventricles	 B:	Pulmonary	artery	 C.	Inferior	vena	cava	and	
right	atrium	
Right	ventricle/left	ventricle	basal	diamater	ratio	>	1.0	
Right	ventricular	outflow	Doppler	acceleration	time	<	105	msec	and/or	midsystolic	notching	
Inferior	cava	diameter	>	21	mm	with	decreased	inspiratory	collapse	(<50%	with	a	sniff	or	<20%	with	quiet	inspiration)	Flattening	of	the	interventricular	septum	(left	ventricular	eccentricity	index	>	1.1	in	systole	and/or	diastole)	
Early	diastolic	pulmonary	regurgitation	velocity	>	2.2	m/sec	 Right	atrial	area	/end-systole)	>	18	cm2		 PA	diameter	>	25	mm	 	From:	Galiè	N.	et	al	2015	ESC/ERS	Guidelines	for	the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119.	PA=	pulmonary	artery	[2].		
Taking	together,	all	these	informations	permit	to	assign	a	level	of	probability	of	PH	(Table	6):	 high,	 intermediate	 and	 low.	 When	 interpreted	 in	 a	 clinical	 context,	 the	echocardiographic	result	is	required	to	decide	the	need	for	right	cardiac	catheterization	in	individual	patients.		
	Table	6.	Echocardiographic	probability	of	pulmonary	hypertension	Peak	tricuspid	regurgitation	velocity	(m/s)	 Presence	of	other	echo	“PH	sign”	 Echocardiographic	probability	of	pulmonary	hypertension	≤	2.8	or	not	measurable	 No	 Low	≤	2.8	or	not	measurable	 Yes	 Intermediate	2.9-3.4	 No	2.9-3.4	 Yes	 High	>	3.4	 Not	required	From:	Galiè	N.	et	al	2015	ESC/ERS	Guidelines	for	the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119.	PH=pulmonary	hypertension	[2].		
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The	 recommended	 plan	 for	 further	 patient	 investigation	 based	 on	 echocardiographic	probability	of	PH	is	shown	in	Table	7	for	symptomatic	patients.	
	
Table	7.	Diagnostic	management	suggested	according	to	echocardiographic	probability	of	pulmonary	 hypertension	 in	 patients	 with	 symptoms	 compatible	 with	 pulmonary	hypertension.	
Echocardiographic	
probability	of	PH	
W/o	risk	factors	
or	associated	
condition	for	PAH	
or	CTEPH	
Class/	
Level	
With	risk	factors	or	
associated	
conditions	for	PAH	
or	CTEPH	
Class/	
Level	
Low	 Alternative	diagnosis	should	be	considered	 IIa/C		 Echo	f-up	should	be	considered	 IIa/C	
Intermediate	
Alternative	diagnosis,	echo	f-up	should	be	considered	
IIa/C	 Further	assessment	of	PH	including	RHC	should	be	considered	 IIa/B	
Further	investigation	of	PH	may	be	considered	 IIb/C	
High	 Further	investigation	of	PH	(including	RHC)	is	recommended	
I/C	 Further	investigation	of	PH	including	RHC	is	racommended	 I/C	
From:	Galiè	N.	 et	 al	2015	ESC/ERS	Guidelines	 for	 the	diagnosis	 and	 treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].	CTEPH=chronic	 thromboembolic	 pulmonary	 hypertension;	 PAH=pulmonary	 arterial	 hypertension;	PH=pulmonary	hypertension;	RHC=right	heart	catheterization			
Table	 8	 shows	 the	 recommended	 investigation	 plan	 based	 on	 PH	 probability	 by	echocardiogram,	for	asymptomatic	patients.			
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Table	8.	Diagnostic	management	suggested	according	to	echocardiographic	probability	of	pulmonary	hypertension	in	asymptomatic	patients.	
Echocardiographic	
probability	of	PH	
W/o	risk	factors	or	
associated	
condition	for	PAH	
or	CTEPH	
Class/	
Level	
With	risk	factors	or	
associated	
conditions	for	PAH	
or	CTEPH	
Class/	
Level	
Low	 No	work	up	for	PAH	required	 III/C	 Echo	f-up	may	be	considered	 IIb/C	
Intermediate	 Echo	f-up	should	be	considered		 IIa/C		
Echo	f-up	is	recommended	 I/B	Is	associated	scleroderma,	RHC	should	be	considered	 IIa/B	High	 RHC	should	be	considered	 IIa/C	 RHC	is	recommended	 I/C	From:	Galiè	N.	 et	 al	2015	ESC/ERS	Guidelines	 for	 the	diagnosis	 and	 treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].	CTEPH=chronic	 thromboembolic	 pulmonary	 hypertension;	 PAH=pulmonary	 arterial	 hypertension;	PH=pulmonary	hypertension;	RHC=right	heart	catheterization		
Moreover,	 echocardiography	 can	 be	 helpful	 in	 detecting	 the	 cause	 of	 suspected	 or	confirmed	PH,	such	as	congenital	heart	disease	(CHD)	or	LV	heart	disease.	
If	 the	 echocardiographic	 probability	 of	 PH	 appears	 to	 be	 high	 or	 intermediate,	 the	diagnostic	algorithm	contemplates	tests	targeted	to	the	identification	of	the	more	common	clinical	groups	of	PH	(2	and	3).	
Pulmonary	 function	 tests	 and	 arterial	 blood	 gases.	 Pulmonary	 function	 tests	 and	 arterial	blood	 gases	 identify	 the	 contribution	 of	 underlying	 airway	 or	 parenchymal	 lung	disease.	Patients	 with	 PAH	 have	 usually	 mild	 to	 moderate	 reduction	 of	 lung	 volumes	 related	 to	disease	 severity.	 Although	 diffusion	 capacity	 can	 be	 normal	 in	 PAH,	 most	 patients	 have	decreased	 lung	 diffusion	 capacity	 for	 carbon	monoxide	 (DLCO).	 An	 abnormal	 low	DLCO,	defined	 as	 <45%	 of	 predicted,	 is	 associated	 with	 a	 poor	 outcome	 [116-117].	 The	
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differential	 diagnosis	 of	 a	 low	 DLCO	 in	 PAH	 includes	 PVOD,	 PAH	 associated	 with	scleroderma	and	parenchymal	lung	disease.	COPD	as	a	cause	of	hypoxic	PH	is	diagnosed	on	the	evidence	of	 irreversible	airflow	obstruction	together	with	increased	residual	volumes	and	 reduced	DLCO	 [118].	 Arterial	 blood	 gases	 of	 COPD	patients	 show	 a	 decreased	PaO2	with	 normal	 or	 increased	 PaCO2	 [119].	 A	 decrease	 in	 lung	 volume	 combined	 with	decreased	 diffusion	 capacity	 for	 carbon	monoxide	may	 indicate	 interstitial	 lung	 disease.	The	prevalence	of	nocturnal	hypoxaemia	and	central	sleep	apnoeas	are	high	 in	PAH	(70–80%)	 [120-121].	 Overnight	 oximetry	 or	 polysomnography	 should	 be	 performed	 where	obstructive	sleep	apnoea	syndrome	or	hypoventilation	are	considered.	
High-resolution	 computed	 tomography.	 Computed	 tomography	 (CT)	 imaging	 can	 provide	important	information	on	vascular,	cardiac,	parenchymal	and	mediastinal	abnormalities.	It	may	 raise	 the	 suspicion	 of	 PH	 by	 showing	 an	 increased	 pulmonary	 artery	 diameter	 and	pulmonary:ascending	aorta	diameter	ratio	≥	1.	Moreover,	CT	contribute	to	identify	causes	of	 PH	 such	 as	 CTEPH	 or	 lung	 disease,	 or	 provide	 clues	 as	 to	 the	 form	 of	 PAH	 (e.g.	oesophageal	 dilation	 in	 SSc	 or	 congenital	 cardiac	 defects).	 Finally,	 CT	 may	 provide	prognostic	 information	 [122].	 High-resolution	 CT	 provides	 detailed	 views	 of	 the	 lung	parenchyma	and	facilitates	the	diagnosis	of	interstitial	lung	disease	and	emphysema.	High-resolution	CT	may	also	be	very	helpful	where	there	is	a	clinical	suspicion	of	PVOD	[123].		
If	Group	2	or	3	PH	have	been	excluded,	presence	of	group	4-PH	has	to	be	investigated.		
Ventilation/perfusion	lung	scan.	The	ventilation/perfusion	scan	is	the	screening	method	of	choice	 for	 CTEPH	 because	 of	 its	 higher	 sensitivity	 compared	 with	 CT	 pulmonary	angiogram,	 especially	 in	 inexperienced	 centres	 [124].	 A	 normal-	 or	 low-probability	ventilation/perfusion	scan	effectively	excludes	CTEPH	with	a	sensitivity	of	90–100%	and	a	specificity	 of	 94–100%.	 However,	 many	 ventilation/perfusion	 scans	 are	 not	 diagnostic.	
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While	 a	 perfusion	 scan	 is	 still	 recommended	 as	 the	 screening	 test	 of	 choice,	 ventilation	scans	are	often	replaced	with	either	a	recent	chest	radiograph	or	a	recent	high-resolution	CT	 of	 the	 lungs,	 but	 such	 practices	 are	 not	 really	 evidence-based.	 If	 the	ventilation/perfusion	 scan	 shows	 multiple	 segmental	 perfusion	 defects,	 a	 diagnosis	 of	group	 4	 (CTEPH)	 PH	 should	 be	 suspected	 [125].	 The	 final	 diagnosis	 of	 CTEPH	 (and	 the	assessment	of	suitability	for	pulmonary	endarterectomy	(PEA))	will	require	CT	pulmonary	angiography,	RHC	and/or	selective	pulmonary	angiography	(Figure	9).		
	
	Figure	9.	Diagnostic	algorithm	for	chronic	thromboembolic	pulmonary	hypertension.	From:	Galiè	N.	et	al	2015	ESC/ERS	Guidelines	for	the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].	CT	=	computed	thomography;	CTEPH	=	chronic	thromboembolic	pulmonary	hypertension;	PAH	=	pulmonary	arterial	hypertension;	PH	=	pulmonary	hypertension;	V/Q	=	ventilation/perfusion.		aCT	pulmonary	angiography	alone	may	miss	diagnosis	of	chronic	thromboembolic	pulmonary	hypertension.		
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Contrast-enhanced	computed	tomography	.	Contrast	CT	angiography	of	the	PA	is	helpful	in	determining	whether	there	is	evidence	of	surgically	accessible	CTEPH.	It	can	delineate	the	typical	angiographic	findings	in	CTEPH,	such	as	complete	obstruction,	bands	and	webs	and	intimal	 irregularities,	 as	 accurately	 and	 reliably	 as	 digital	 subtraction	 angiography	 [126-127].	 It	 	 has	 become	 an	 established	 imaging	 modality	 for	 confirming	 CTEPH	 [128];	however,	this	investigation	alone	cannot	exclude	the	disease	[129].	
Pulmonary	angiography.	Traditional	pulmonary	angiography	 is	 required	 in	most	patients	for	 the	workup	of	CTEPH	 to	 confirm	diagnosis	 and	 identify	 those	who	may	benefit	 from	PEA	or	balloon	pulmonary	angioplasty	[130-131].	The	final	step	in	the	diagnostic	pathway	is	 selective	 pulmonary	 angiography	 in	 the	 anterior–posterior	 and	 lateral	 projections	illustrating	ring-like	stenosis,	webs	(‘slits’),	pouches,	wall	irregularities,	complete	vascular	obstructions	 as	 well	 as	 bronchial	 collaterals,	 and	 supports	 the	 technical	 assessment	 of	operability.		
Angiography	can	be	performed	safely	by	experienced	staff	in	patients	with	severe	PH	using	modern	contrast	media	and	selective	injections.		
	
Once	 excluded	 PH	 from	 group	 2,	 3	 and	 4;	 the	 attention	 has	 to	 be	 focused	 on	make	 the	diagnosis	of	group	1	and	5.	
Right	 heart	 catheterization	 and	 vasoreactivity.	 RHC	 should	 be	 performed	 after	 the	completion	of	other	investigations	so	that	 it	can	answer	specific	questions	that	may	arise	from	 these	 investigations	 and	 avoid	 an	 unnecessary	 procedure	 where	 an	 alternative	diagnosis	 is	 revealed.	 RHC	 is	 required	 to	 confirm	 the	 diagnosis	 of	 PAH	 and	 CTEPH,	 to	assess	the	severity	of	haemodynamic	 impairment	and	to	undertake	vasoreactivity	testing	
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of	the	pulmonary	circulation	in	selected	patients.	When	performed	at	expert	centres,	these	procedures	 have	 low	 morbidity	 (1.1%)	 and	 mortality	 (0.055%)	 rates	 [132].	 Left	 heart	catheterization	has	to	be	performed	in	patients	with	clinical	risk	factors	for	coronary	artery	disease	 or	 heart	 failure	 with	 preserved	 ejection	 fraction,	 as	 well	 as	 in	 patients	 with	echocardiographic	 signs	 of	 systolic	 and/or	 diastolic	 LV	 dysfunction.	 Measurement	 of	 LV	end-diastolic	 pressure	 is	 also	 important	 to	 avoid	 misclassification	 of	 patients	 with	 an	elevated	PAWP	when	this	is	unexpected	and	may	be	inaccurate.	Pulmonary	vasoreactivity	testing	 for	 identification	of	patients	suitable	 for	high-dose	calcium	channel	blocker	(CCB)	treatment	 is	recommended	only	 for	patients	with	 idiopathic-PAH,	heritable-PAH	or	drug-induced	PAH.	Inhaled	nitric	oxide	(NO)	at	10–20	parts	per	million	(ppm)	is	the	standard	of	care	for	vasoreactivity	testing,	but	i.v.	epoprostenol,	 i.v.	adenosine	or	inhaled	iloprost	can	be	used	as	alternatives.	A	positive	acute	response	is	defined	as	a	reduction	of	the	mean	PAP	≥10	 mmHg	 to	 reach	 an	 absolute	 value	 of	 mean	 PAP	 ≤40	 mmHg,	 with	 an	 increased	 or	unchanged	cardiac	output.	Only	about	10%	of	patients	with	idiopathic-PAH	will	meet	these	criteria.	 Interpretation	of	 the	PAWP	at	a	 single	point	 in	 time	needs	 to	be	performed	 in	a	clinical	 context.	 In	many	 patients	with	 left	 heart	 disease,	 PAWP	may	 be	 reduced	 to	 <15	mmHg	with	diuretics	[133-135].	For	this	reason,	the	effect	of	an	acute	volume	challenge	on	left	heart	filling	pressures	has	been	considered	[136].			
Cardiac	magnetic	resonance.	Cardiac	magnetic	 resonance	 (CMR)	 imaging	 could	have	high	predictive	value	for	the	identification	of	PH;	however,	it	cannot	exclude	PH	[137-139].	It	is	accurate	 and	 reproducible	 in	 the	 assessment	 of	 RV	 size,	 morphology	 and	 function	 and	allows	 non-invasive	 assessment	 of	 blood	 flow,	 including	 stroke	 volume,	 cardiac	 output,	pulmonary	arterial	distensibility	and	RV	mass.	In	patients	with	PH,	CMR	may	also	be	useful	in	 cases	 of	 suspected	 CHD	 if	 echocardiography	 is	 not	 conclusive.	 CMR	 provides	 useful	prognostic	information	in	patients	with	PAH	both	at	baseline	and	at	follow-up	[140-142].		
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Blood	test	and	immunology.	Blood	tests	are	required	to	identify	the	aetiology	of	some	forms	of	PH,	as	well	as	end-organ	damage.	Serological	 testing	are	required	to	detect	underlying	CTD,	 hepatitis	 and	HIV.	 Liver	 function	may	be	 abnormal	 because	 of	 high	 hepatic	 venous	pressure,	 liver	 disease	 and/or	 endothelin	 receptor	 antagonist	 therapy.	 Patients	 with	CTEPH	should	undergo	thrombophilia	screening.	N-terminal	pro-brain	natriuretic	peptide	may	be	elevated	in	patients	with	PH	and	is	an	independent	prognostic	factor.	
Abdominal	ultrasound	scan.	Similar	to	blood	tests,	abdominal	ultrasound	may	be	useful	for	identification	of	 some	of	 the	 clinical	 entities	 associated	with	PAH.	Abdominal	ultrasound	may	confirm	but	not	formally	exclude	portal	hypertension.		
Genetic	 testing.	 Patients	 with	 sporadic	 or	 familial	 PAH	 or	 PVOD/PCH	 should	 be	 advised	about	 the	 availability	 of	 genetic	 testing	 and	 counselling	because	of	 the	 strong	possibility	that	they	carry	a	disease-causing	mutation.	Trained	professionals	should	offer	counselling.		
	
	
Follow-up	The	attention	will	be	focused	mainly	on	PAH	patients.	Their	regular	assessment	 in	expert	 PH	 centres	 is	 recommended,	 with	 a	 follow-up	 visit	 every	 3-6	 months	 for	 stable	patients.	There	is	no	single	variable	that	provides	sufficient	prognostic	informations.	Then,	a	multidimensional	approach	is	needed,	as	shown	in	Table	9.	
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Table	9.	Risk	assessment	in	pulmonary	arterial	hypertension.	
Determinants	
of	prognosis	 Low	risk	<	5%	
Intermediate	
risk	5-10%	
High	risk	>	
10%	Clinical	signs	of	right	heart	failure	 Absent	 Absent	 Present	Progression	of	symptoms	 No	 Slow	 Rapid	Syncope	 No	 Occasional	syncope	 Repeated	syncope	WHO	functional	class	 I,	II	 III	 IV	6	MWD	 >	440	m	 165-440	m	 <	165	m	
Cardiopulmonary	exercise	testing	 Peak	VO2	>	15	ml/min/Kg	(>65%	pred)	VE/VCO2	slope<36	
Peak	VO2	11-15	ml/min/kg	(35-65%	pred)	VE/VCO2	slope	36-44.9	
Peak	VO2	<11	ml/min/kg	(<35%	pred)	VE/VCO2	slope	≥45	
NT-proBNP	plasma	levels	 BNP	<	50	ng/l				NT-proBNP	<300	ng/ml	 BNP	50-300	ng/l				NT-proBNP	300-1400	ng/ml	 BNP	>300	ng/l				NT-proBNP	>1400	ng/ml	Imaging	(echo,	CMR)	 RA	area	<	18	cm2			No	pericardial	effusion	 RA	area	18-26	cm2	No	or	minimal	pericardial	effusion	 RA	area	>	26	cm2	pericardial	effusion	
Haemodynamics	 RAP<8	mmHg	CI≥2.5	l/min/m2	SvO2>65%	 RAP	8-14	mmHg		CI	2-2.4	l/min/m2	SvO2	60-65%	 RAP>14	mmHg		CI<2	l/min/m2	SvO2<60%	From:	Galiè	N.	et	al	2015	ESC/ERS	Guidelines	for	the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].	BNP=brain	natriuretic	 peptide;	 CI=cardiac	 index;	 CMR=cardiac	magnetic	 resonance;	MWD=minute	wlaking	distance;	 RA=right	 atrium;	 RAP=right	 atrial	 pressure;	 SvO2=mixed	 venous	 oxygen	 saturation;	 VE/VCO2=	minute	ventilation	–	carbon	dioxide	production	relationship;	WHO=world	health	organization	
 
Not	all	 these	parameters	must	be	assessed	at	each	visit,	but	at	 least	 functional	class	plus	one	 measurement	 of	 exercise	 capacity	 and	 RV	 function	 have	 to	 be	 re-checked.	 Not	 all	variables	 may	 be	 in	 the	 same	 risk	 group;	 the	 comprehensive	 assessment	 of	 individual	patients	 guide	 treatment	 decisions.	 An	 adequate	 treatment	 response	 is	 considered	 in	presence	of	the	achievement	and/or	maintenance	of	a	low-risk	profile.		
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The	most	important	questions	to	be	addressed	at	each	visit	are:	
• is	there	any	evidence	of	clinical	deterioration	since	the	last	assessment?	
• if	 so,	 is	 clinical	 deterioration	 caused	 by	 progression	 of	 PH	 or	 by	 a	 concomitant	illness?	
• is	RV	function	stable	and	sufficient?	
• is	the	current	status	compatible	with	a	good	long-term	prognosis	(does	the	patient	meet	the	low-risk	criteria)?		
Clinical	 assessment	 remains	 a	 key	 part	 of	 the	 evaluation	 of	 patients	 with	 PH.	 WHO	 FC	remains	one	of	the	most	powerful	predictors	of	survival	[143-145].		The	 6-minute	 walking	 test,	 a	 submaximal	 exercise	 test,	 remains	 the	 most	 widely	 used	exercise	test.	The	test	is	easy	to	perform,	inexpensive	and	familiar	to	patients	and	centres.	However,	 it	 is	 influenced	by	several	 factors	 (sex,	 age,	height,	weight,	 comorbidities,	need	for	 O2,	 learning	 curve	 and	 motivation)	 that	 must	 be	 taken	 into	 account	 for	 the	interpretation	 of	 the	 result.	 Test	 results	 are	 usually	 given	 in	 absolute	 numbers	 because	only	 absolute	 values,	 but	 not	 changes	 in	 6-minute	 wlaking	 distance,	 provide	 prognostic	information.	Anyway,	 there	 is	no	 single	 threshold	 that	 is	 applicable	 for	 all	 patients	 [143,	146-148].	It	is	recommended	to	use	the	Borg	score	at	the	end	of	the	6-minute	walking	test	to	determine	the	level	of	effort.	In	addition,	some	studies	suggest	that	adding	peripheral	O2	measurements	and	heart	 rate	 response	may	 improve	 the	prognostic	 relevance,	but	 these	findings	 await	 independent	 confirmation	 [149-150].	 Cardiopulmonary	 exercise	 testing	 is	usually	 performed	 as	 a	 maximal	 exercise	 test	 and	 provides	 important	 information	 on	exercise	capacity	as	well	as	on	gas	exchange,	ventilator	efficacy	and	cardiac	function	during	exercise.	 Several	 variables	 determined	 by	 cardiopulmonary	 exercise	 test	 provide	prognostic	 information,	 although	peak	VO2	 is	most	widely	 used	 for	 therapeutic	 decision	
	 45	
making	[151-152].		
A	 wide	 variety	 of	 biomarkers	 have	 been	 explored	 as	 prognostic	 tools,	 but	 so	 far	 brain	natriuretic	peptide	and	NT-pro	brain	natriuretic	peptide	remain	the	only	biomarkers	that	are	widely	used	in	the	routine	practice	of	PH	centres	as	well	as	in	clinical	trials	[153].		
RV	 function	 is	 a	key	determinant	of	 outcome	 in	patients	with	PH	 [140,	154-160].	 In	 this	scenario	 non-invasive	 imaging	 techniques,	 such	 as	 echocardiography	 and	 CMR,	 cover	 a	major	 role	 [161].	 A	 number	 of	 CMR	 prognostic	 markers	 have	 been	 identified,	 including	increased	RV	volume,	reduced	LV	volume,	reduced	RV	ejection	fraction	and	reduced	stroke	volume.	There	 is	some	evidence	that	 follow-up	CMR	studies	may	have	utility	 in	 the	 long-term	management	of	PAH	by	identifying	RVF	prior	to	the	development	of	clinical	features	[140,	142,	162-163].	
Echocardiographic	evaluation	of	 the	RV	will	be	discussed	more	extensively	 further	 in	 the	text.	
Haemodynamics	assessed	by	RHC	provide	important	prognostic	information:	RA	pressure,	cardiac	 index	 and	mixed	 venous	 oxygen	 saturation	 are	 the	most	 robust	 indicators	 of	RV	function	and	prognosis.	There	are	still	uncertainties	around	the	optimal	timing	of	follow-up	RHC.	Strategies	vary	between	centres,	 from	regular	 invasive	haemodynamic	assessments	to	a	predominantly	non-invasive	follow-up	strategy.	There	is	no	evidence	that	an	approach	involving	 regular	 RHC	 is	 associated	 with	 better	 outcomes	 than	 a	 predominantly	 non-invasive	 follow-up	strategy.	However,	 there	 is	consensus	among	experts	 that	RHC	should	be	performed	whenever	therapeutic	decisions	can	be	expected	from	the	results,	which	may	include	changes	in	medications	and/or	decisions	regarding	listing	for	transplantation.		
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Therapy	Similar	to	what	we	did	about	the	follow-up	chapter,	the	therapy	section	will	mainly		focus	the	attention	on	PAH	patient	with	a	little	part	on	CTEPH	patients.	The	 current	 treatment	 strategy	 for	 PAH	 patients	 include:	 general	 measures,	 supportive	therapy,	specific	drug	therapy	[164].	General	 measures	 include	 avoidance	 of	 pregnancy.	 Although	 outcome	 of	 pregnancies	 in	PAH	 has	 improved	 [165],	 it	 is	 still	 associated	 with	 a	 significant	 mortality	 rate.	Immunization	of	patients	against	 influenza	and	pneumococcal	 infection	 is	 recommended.	Pneumonia	has	been	reported	to	be	cause	of	death	in	7%	of	cases	of	PAH	patients	[25].	In	addition,	a	psychosocial	support	is	recommended	because	PH	is	a	disease	with	a	significant	psychological,	 social	 and	 emotional	 impact	 on	 patients	 and	 their	 families	 [166].	 A	supervised	 exercise	 training	 for	 physically	 deconditioned	 patients	 is	 recommended.	However,	before	starting	physical	activity,	patients	should	be	optimally	pharmacologically	treated	and	in	stable	condition.	More	than	one	randomized	trials	demonstrated	the	efficacy	of	 exercise	 training	 in	 improving	 functional	 capacity	 and	 quality	 of	 life	 [167-171].	Nevertheless,	the	optimal	method	of	exercise	and	the	intensity	and	duration	of	the	training	remain	to	be	defined.	In	case	of	elective	surgery,	epidural	rather	than	general	anaesthesia	has	to	be	preferred,	because	probably	better	tolerated	[172-174].		
Supportive	 therapy	 include	administration	of	diuretics,	 in	patients	with	signs	of	RVF	and	fluid	retention,	and	continuous	long-term	O2	therapy,	when	arterial	blood	O2	pressure	is	less	than	60	mmHg.	Routine	oral	anticoagulant	treatment	is	not	recommended,	since	data	from	registry	and	randomized	clinical	trials	appear	heterogeneous	and	inconclusive	[175-177].	
Specific	drug	therapy	must	be	administered	according	to	the	therapeutic	algorithm	showed	
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in	the	current	guidelines	(Figure	10).		
	
	Figure	10.	Therapeutic	algorithm	for	pulmonary	hypertension	patients.		From:	Galiè	N.	et	al	2015	ESC/ERS	Guidelines	for	the	diagnosis	and	treatment	of	pulmonary	hypertension.	Eur	Heart	J	2016;37(1):67-119	[2].	CCB=calcium	channel	blockers;	DPAH=drug-induced	PAH;	FC=functional	class;	HPAH=heritable	PAH;	IPAH=idiopathic	PAH;	PAH=pulmonary	arterial	hypertension;		PCA=;	prostacyclin	analogues;	WHO=world	health	organization			
Disease	 specific	 treatment	 includes	 the	 administration	 of	 high	 doses	 of	 calcium	 channel	blockers	 (CCBs),	 only	 in	 patients	 affected	 by	 idiopathic-PAH,	 heritable-PAH	 and	 drug-induced	 PAH	 with	 a	 positive	 response	 at	 vasodilator	 test.	 However,	 it	 has	 been	
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demonstrated	that	only	a	small	number	of	patients	with	a	positive	vasodilator	test	do	well	with	 CCBs	 [178-179].	 The	 CCBs	 predominantly	 used	 are	 nifedipine,	 diltiazem	 and	amlodipine,	with	particular	emphasis	on	nifedipine	and	diltiazem	[178-179].	Patients	who	are	treated	with	CCBs	should	be	followed	closely	to	check	both	safety	and	efficacy,	with	a	complete	 reassessment,	 including	 RHC,	 after	 3-4	months	 of	 therapy.	 Continuation	 of	 the	CCBs	 therapy	 is	 recommended	 in	 presence	 of	 an	 adequate	 clinical	 and	 haemodynamic	response,	 defined	 by	 a	 functional	 WHO	 class	 I	 or	 II	 and	 a	 marked	 haemodynamic	improvement	 (see	 Table	 9).	 If	 patients	 do	 not	 responde	 to	 CCBs	 theapy,	 specific	 PAH	therapy	 is	 required.	 Vasodilator	 responsiveness	 does	 not	 appear	 to	 predict	 a	 favourable	long-term	response	to	CCB	therapy	in	patients	with	PAH	in	the	setting	of	CTD,	HIV,	porto-pulmonary	hypertension	and	PVOD	[180-181].		
Specific	 therapy	 includes	 three	 class	 of	 drugs:	 endothelin	 receptor	 antagonists;	phosphodiesterase	 type	 5	 inhibitors	 and	 guanylate	 cyclase	 stimulators;	 prostanoid	(prostacyclin	analogues	and	prostacyclin	receptor	agonists).	The	administration	of	the	first	class	 is	 driven	 by	 the	 demonstration	 of	 the	 endothelin	 system	 activation	 in	 both	 plasma	and	 lung	 tissue	 of	 PAH	 patients	 [182],	 along	 with	 the	 prominent	 role	 of	 the	 endothelin	system	 activation	 in	 the	 pathogenesis	 of	 PAH	 [183].	 	 This	 class	 of	 drugs	 include	ambrisentan,	 bosentan	 and	 the	 recently	 introduced	 macitentan.	 The	 administration	 of	phosphodiesterase	 type	 5	 inhibitors	 and	 guanylate	 cyclase	 stimulators	 is	 based	 on	 the	evidence	 that	 the	 pulmonary	 vasculature	 contains	 a	 substantial	 amount	 of	phosphodiesterase	type	5.	This	class	of	drugs	acts	through	a		vasodilator	effect,	obtained	by	the	 NO/cGMP	 pathway	 modulation,	 and	 an	 anti-proliferative	 effect	 [184-185].	Prostacyclins	 are	 endogeneously	 produced	 predominantly	 by	 endothelial	 cells.	 They	induce	 vasodilation	 of	 all	 vascular	 bed	 and	 inhibition	 of	 platelet	 aggregation;	 moreover	they	have	both	cytoprotective	and	antiproliferative	activities	[186].	The	administration	of	
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prostanoid	 is	 driven	 by	 the	 evidence	 that	 in	 PAH	 patients	 a	 disregulation	 of	 the	prostacyclin	pathways	is	present	[187].		
Both	 endothelin	 receptor	 antagonists	 and	 phosphodiesterase	 type	 5	 inhibitors	 are	administered	 either	 to	 patients	 responders	 to	 vasodilator	 tests	 but	without	 an	 adequate	response	 to	 CCBs	 therapy	 or	 to	 patients	 non-responders	 to	 vasoreactive	 test.	 This	 latter	cathegory	of	patients	can	be	treated	with	either	initial	monotherapy	or	initial	combination	therapy.	 If	 the	 non-vasoreactive	 patient	 is	 at	 high	 risk,	 initial	 combination	 therapy	(including	intravenous	prostanoid)	should	be	considered.	An	adequate	treatment	response	is	defined	by	the	achievement	or	maintenance	of	a	low-risk	profile	(see	section	on	Follow-up).	 In	 case	 of	 inadequate	 response	 to	 initial	mono-	 or	 combination	 therapy,	 sequential	double	or	triple	therapy	is	recommended.		
It	 seems	 reasonable	 to	 consider	 eligibility	 for	 lung	 transplantation	 after	 an	 inadequate	clinical	response	to	the	initial	monotherapy	or	initial	combination	therapy	and	to	refer	the	patient	for	lung	transplantation	soon	after	the	inadequate	clinical	response	is	confirmed	on	maximal	combination	therapy.		
Patients	 included	 in	 other	 PAH	 groups	 can	 benefit	 of	 specific	 management	 therapies,	tailored	on	the	single	case.	 In	patients	with	PAH	associated	with	congenital	heart	disease	the	possibility	of	undergo	to	the	defect	correction	has	to	be	considered.	It	is	feasible	only	in	patient	 with	 prevalent	 systemic-to-pulmonary	 shunt	 with	 low	 PVR,	 while	 is	controindicated	in	patients	with	high	PVR	values,	in	patients	with	Eisenmenger	syndrome	and	 is	 useless	 in	 patients	 with	 small/coincidental	 defects.	 In	 patients	 with	 CTEPH	 the	treatment	 of	 choice	 is	 pulmonary	 endoarterectomy.	 The	majority	 of	 patients	 experience	relief	 of	 symptoms	 and	 near	 normalization	 of	 haemodynamics	 [188-190].	 Operability	 of	patients	with	CTEPH	is	determined	by	multiple	factors:	patient	acceptance,	expertise	of	the	
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surgical	team	and	available	resources.	General	criteria	include	preoperative	WHO-FC	II–IV	and	surgical	accessibility	of	 thrombi	 in	 the	main,	 lobar	or	 segmental	pulmonary	arteries.	Advanced	age,	per	se,	 is	not	a	contraindication	 for	surgery.	There	 is	no	PVR	threshold	or	measure	 of	 RV	 dysfunction	 that	 can	 be	 considered	 to	 preclude	 pulmonary	endoarterectomy.	 Riociguat	 is	 recommended	 in	 symptomatic	 patients	 who	 have	 been	classified	as	having	persistent/recurrent	CTEPH	after	surgical	treatment	or	inoperable.	
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The	right	ventricle		A	 proper	 knowledge	 of	 RV	 anatomy	 and	 physiology	 is	 mandatory	 before	 trying	 to	understand	the	pathological	aspects	of	RV	function. The	 RV	 shows	 a	 complex	 shape.	 In	 contrast	 to	 the	 ellipsoidal	 shape	 of	 the	 LV,	 the	 RV	appears	triangular	when	viewed	from	the	side	and	crescent	shaped	when	viewed	in	cross	section	 [191].	 It	 can	 be	 divided	 in	 three	main	 parts:	 the	 inlet,	 the	 outlet,	 and	 the	 apical,	trabeculated	 part	 (Figure	 11).	 The	 RV	 free	 wall	 myocardium	 is	 composed	 mainly	 by	circumferential	fibers	in	the	superficial	layer	and	longitudinal	fibers	in	the	subendocardial	layer	[192].	Usually,	the	circumferential	fiber	layer	is	less	developed	than	the	longitudinal	one.	This	myocardial	fiber	architecture	explains	why,	in	healthy	subjects,	RV	pump	function	is	determined	mainly	by	longitudinal	shortening,	rather	than	by	transversal	displacement	(TD)	[193-194].		
 Figure	 11.	 Opened	 right	 ventricle:	 anterior	 view.	 From:	 Netter	 FH.	 Atlas	 of	 Human	Anatomy,	6th	edition.	
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The	physiological	RV	contraction	follows	a	peristaltic	pattern	that	starts	from	the	inlet	part	and	ends	to	the	outlet	one	25–50	msec	later	[195-196].	Several	distinct	events	contribute	to	overall	RV	pump	function:	(i)	 inward	movement	of	the	RV	free	wall,	which	produces	a	bellows	effect;	(ii)	contraction	of	the	longitudinal	fibers,	which	draws	the	tricuspid	annulus	toward	 the	RV	 apex;	 (iii)	 infundibular	 contraction;	 and	 (iv)	 contraction	 of	 the	 LV,	which	assists	 RV	 contraction	 via	 mechanical	 transduction	 across	 the	 shared	 interventricular	septum,	as	well	as	via	circumferentially	oriented	superficial	myofibers	that	are	contiguous	between	 the	 two	 ventricles.	 Therefore,	 the	 RV	 presents	 regional	 contraction	 differences	that	contribute	in	distinct	magnitude	and	timing	to	its	global	systolic	function	[197-198].			
In	 patients	 with	 RV	 pressure	 overload,	 with	 consequent	 RV	 hypertrophy,	 the	hypertrophied	fibers	change	their	spatial	orientation	and	become	more	circumferential.	As	a	 consequence,	 in	 PH	 patients,	 circumferential	 and	 radial	 shortening	 increase	 their	contribution	to	the	RV	pump	function	compared	to	normal	subjects	[199-200].		
Under	normal	conditions,	 the	RV	 is	coupled	with	a	 low-impedance	and	highly	distensible	pulmonary	vascular	system	with	a	right-sided	pressures	 that	are	significantly	 lower	than	comparable	left-sided	pressures	[201].	As	for	the	LV,	determinants	of	RV	systolic	function	are	 pre-load,	 contractility	 and	 afterload.	 The	 latter	 represents	 the	 load	 that	 RV	 has	 to	overcome	 during	 ejection.	 It	 has	 been	 demonstrated	 that,	 compared	 to	 the	 LV,	 the	 RV	demonstrates	an	increased	sensitivity	to	afterload	change	[202-203].		
Right	 and	 LV	 filling	 and	 emptying	 are	 tightly	 coupled.	 This	 phenomenon	 named	“ventricular	interdependence”	refers	to	the	fact	that	the	size,	the	shape	and	the	compliance	of	 one	 ventricle	 affects	 the	 size,	 the	 shape	 and	 the	 pressure-volume	 relationship	 of	 the	other	ventricle	through	direct	mechanical	interactions	[204].	Ventricular	interdependence	is	more	 apparent	with	 changes	 in	 loading	 conditions	 and	 plays	 an	 important	 role	 in	 the	
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pathophysiology	 of	 RV	 dysfunction.	 We	 can	 distinguish	 diastolic	 and	 systolic	interdependence.	 The	 first	 depends	 mainly	 from	 the	 pericardium,	 while	 the	 latter	 is	mediated	 mainly	 through	 the	 interventricular	 septum.	 Experimental	 animal	 studies	showed	 that	 20%	 to	 40%	 of	 RV	 systolic	 pressure	 and	 volume	 outflow	 results	 from	 LV	contraction	 [204].	 Moreover,	 in	 presence	 of	 scarring	 of	 the	 RV	 the	 septum	 is	 able	 to	maintain	circulatory	stability	as	long	as	the	RV	is	not	dilated	[205].			
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The	right	ventricular	failure	
	
RVF	is	a	complex	clinical	syndrome	that	can	result	from	any	structural	or	functional	cardiovascular	disorder	that	impairs	the	ability	of	the	RV	to	fill	or	to	eject	blood	[206].		
In	the	past	the	predominant	view	was	that,	 in	presence	of	PH,	the	RV	fails	because	of	the	afterload	mismatcht,	 and	 although	 patients	 died	 of	 RVF,	 the	 treatment	 of	 PH	 should	 be	directed	towards	the	pulmonary	vasculature	rather	than	the	RV.	A	number	of	papers	have	suggested	 that	 this	may	not	be	 the	whole	story.	First	of	all,	 a	Dutch	group	 [142]	showed	that	 RV	 dysfunction	 can	 progress	 even	 in	 patients	 who	 appear	 to	 have	 responded	 to	vasodilator	 therapy	 by	 reducing	 pulmonary	 vascular	 resistance.	 Moreover,	 RV	 failure	impacts	 on	 survival	 in	 any	 type	 of	 PH	 but	 with	 variable	 burden,	 depending	 on	 causal	disease	 and	 comorbidities	 [207].	 Indeed,	 patients	 with	 Eisenmenger	 syndrome	 show	 a	better	survival	and	develop	RV	failure	only	at	a	late	stage	of	the	disease	[208].	This	makes	the	point	that	RV	function	is	more	complex	than	simply	a	function	of	pulmonary	vascular	narrowing.	The	most	 important	 factors	appear	 to	be	 the	 type	and	severity	of	myocardial	injury	or	stress,	the	time	course	of	the	disease	(acute	or	chronic),	and	the	time	of	onset	of	the	disease	process	(newborn,	pediatric,	or	adult	years)	[206].	The	mechanisms	underlying	the	 occurrence	 of	 RVF	 are	 still	 not	 well	 understood;	 current	 hypotheses	 have	 been	previously	 described	 in	 the	 pathophysiology	 section.	 Ruiter	 et	 al	 [209]	 recently	demonstrated	 that	 the	 cellular	 alterations	 characterizing	 the	 failing	 RV	 in	 PH	 are	represented	in	the	free-wall	but	not	in	the	interventricular	septum.	
Few	data	are	available	in	literature	about	the	progression	of	the	RV	function	decline	in	PH	patients.	Mauritz	et	al.	[210]	showed,	using	CMR,	that	the	progression	of	RV	dysfunction	is	mainly	related	to	the	loss	of	RV	TD,	showing	also	a	good	correlation	between	prognosis	and	
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extent	 of	 residual	 TD.	Moreover,	 they	 showed	 that	 the	 decline	 in	 TD	 is	mostly	 due	 to	 a	progressive	leftward	displacement	of	interventricular	septum	(IVS)	rather	than	to	a	further	decrease	of	RV	free	wall	(RVFW)	TD	[210].	They	hypothesized	that	RV	dysfunction	in	PH	patients	may	start	with	a	 reduction	of	 tricuspid	anulus	plane	systolic	escursion	 (TAPSE),	that	continues	to	decrease	until	a	lower	limit	is	reached.	Progression	of	the	disease	induces	a	further	deterioration	of	the	RV	function	through	a	loss	of	transversal	shortening.	As	for	longitudinal	 shortening,	 a	 lower	 limit	 also	 is	 reached	 for	 the	 RVFW	 TD;	 thus,	 increased	leftward	 septal	 bowing	 is	 the	 main	 explanation	 for	 a	 further	 decline	 in	 RV	 transverse	shortening	 in	progressive	PH	 [210].	 	Differently	 from	 the	pattern	 showed	 in	presence	of	acute	pulmonary	embolism,	RV		apex	involvement	is	a	constant	feature	of	RV	dysfunction	in	chronic	PH	[211],	as	demonstrated	by	2D-STE	[212-213].		Particularly,	Unlu	S	et	al	[214]	showed	 that	 the	 visually	 assessed	 RV	 apical	 traction,	 a	 motion	 pattern	 caused	 by	 the	traction	of	the	RV	apex	from	the	LV,	occur	in	a	sizable	number	of	PH	patients	with	reduced	EF	and	represents	a	prognostic	factor	in	this	group	of	patients.	
Consequences	of	RVF	are	summarized	in	the	following	Figure	12.		
	
 Figure	12.	Pathophysiology	of	right	ventricular	failure.	From:	Haddad	F	et	al.	Circulation	2008;	117:	1717-31	[206].	
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RVF	 is	mainly	 characterized	 by	 a	 low	 cardiac	 output	 state.	 As	 stated	 before,	 ventricular	interdependence	plays	an	 important	role	 in	the	pathophysiology	of	RVF,	especially	 in	the	acute	setting.	RV	dilatation	and/or	pressure	overload	cause	a	leftward	shift	of	the	septum,	changing	 LV	 geometry;	 RV	 dilatation	 also	 may	 increase	 the	 constraining	 effect	 of	 the	pericardium.	These	 changes	 contribute	 to	 the	 low	 cardiac	 output	 state	 by	 decreasing	 LV	distensibility	 and	 preload.	 RV	 diastolic	 dysfunction	 impairs	 RV	 filling	 and	 increases	diastolic	 RV	 pressures	 and	 right	 atrial	 pressures.	 This	 may	 lead	 to	 fluid	 retention	 and	congestive	hepatopathy,	as	well	as	cardiac	cirrhosis	in	more	advanced	cases.	RVF	may	also	lead	to	significant	TR	
,	which	may	further	aggravate	RV	volume	overload	and	decrease	cardiac	output	[206].		
Then,	the	cardinal	clinical	manifestations	are:	fluid	retention;	decreased	systolic	reserve	or	low	cardiac	output;	atrial	or	ventricular	arrhytmias.	
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Echocardiographic	evaluation	of	the	right	ventricular	
function	
	 Many	 factors	 contribute	 to	 the	 challenges	 posed	 by	 the	 echocardiographic	 RV	assessment.	These	 include:	 the	 complex	geometry	of	 the	RV;	 the	 limited	definition	of	RV	endocardial	surface	caused	by	heavily	trabeculated	myocardium;	the	retrostenal	position,	which	 can	 limit	 echocardiographic	 windows;	 respiratory	 variability	 RV	 filling	 and	 the	marked	load	dependence	of	indices	of	RV	function	[192].	Multiple	standardized	2DE	views	should	be	obtained	 for	a	 comprehensive	assessment	of	 the	different	 segments	of	 the	RV,	including	 the	 apical	 four-chamber,	 RV-focused	 apical	 four-chamber	 and	 modified	 apical	four-chamber	views,	 left	parasternal	 long-	and	short-axis,	 left	parasternal	RV	 inflow,	and	subcostal	 views	 [114].	 Additional	 non-standard	 views	 may	 be	 required	 for	 an	 accurate	evaluation	of	specific	regions	of	interest.		
Conventional	echocardiography	provides	several	parameters	to	measure	RV	function,	such	as	RV	 fractional	 area	 change,	 TAPSE,	 lateral	wall	 S	wave	 velocity	 by	Tissue	Doppler	 and	myocardial	 performance	 index	 (Figure	 13).	 Among	 them	 only	 TAPSE	 has	 shown	 to	 be	 a	strong	 predictor	 of	 survival	 in	 PH	 patients	 [215].	 However,	 all	 of	 them	 value	 the	 RV	function	 only	 in	 one	 section,	 without	 taking	 into	 account	 neither	 the	 three-dimensional	shape	of	the	chamber	nor	its	whole	spatial	motion.	Then,	conventional	echocardiographic	measurements	 of	 RV	 function	 do	 not	 always	 reflect	 true	 RV	 pump	 function	 due	 to	 the	complex	geometry	of	the	RV	and	its	extreme	dependence	on	loading	conditions	[216].	New	echocardiographic	techniques,	such	as	2D	speckle	tracking	echocardiography	(STE)	and	3D	echocardiography	 (3DE),	 have	 been	 employed	 to	 provide	 a	 more	 comprehensive	assessment	of	RV	function.	Indeed,	these	new	echocardiographic	techniques	overcome	the	
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main	 limitations	 of	 both	 two-dimensional	 echo	 (geometric	 assumptions	 about	 RV	geometry)	 and	 M-mode	 and	 Doppler	 related	 techniques	 (external	 reference,	 angle-dependency)	and	provide	a	more	comprehensive	assessment	of	RV	function,	which	is	not	limited	to	the	assessment	of	the	longitudinal	excursion	anymore	[161].		
	Figure	13.	Echocardiographic	conventional	parameters	for	right	ventricular	function	evaluation.	TAPSE=tricuspide	anulus	plane	systolic	excursion;	TDI=tissue	dopplr	imaging	
	
Two-dimensional	Speckle	Tracking	Echocardiography	
Deformation	 imaging	 by	 2D-STE	 has	 been	 introduced	 to	 assess	 LV	 myocardial	function	 and	 recently	 applied	 to	 detect	 RV	 myocardial	 function	 in	 several	 pathological	conditions	 [217-225].	 Compared	 to	 Tissue	 Doppler	 Imaging,	 2D-STE	 is	 an	 angle-indipendent	 technique	 based	 on	 internal	 reference,	 thus,	 avoiding	 limitations	 related	 to	translational	 cardiac	motion.	 Preliminary	 researches	 showed	 good	 correlations	with	 the	
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other	 standard	 echo	 parameters	 of	 RV	 function,	 in	 particular	with	 TAPSE	 [226].	 Among	non-volumetric	 echo	 parameters,	 RV	 free-wall	 strain	 by	 STE	 demonstrated	 the	 closest	correlation	with	RV-ejection	fraction	(RVEF)	measured	by	CMR	[227].	
A	 recent,	 by	 date	 the	 largest	 study	 of	 healthy	 subjects	 showed	 different	 methods	 to	measure	RV	 longitudinal	 strain	 (LS),	both	global	 (RVGLS)	and	 free-wall	 (RVFWLS)	 [228].	Authors	provided	reference	values	(lower	 limits	of	normality)	 for	2D-STE	derived	RV	LS:	for	6-segment	RVGLS	-24.7	±	2.6%	(-20.0%)	for	men	and	-26.7	±	3.1%	(-20.3%)	and	for	3-segment	RVFWLS	-29.3	±	3.4%	(-22.5%)	 for	men	and	-31.6	 	±	4.0%	(-23.3%)	 for	women	[229].	 In	 the	 most	 up-to-date	 version	 of	 the	 chamber	 quantification	 guidelines	 an	abnormality	threshold	for	the	RVFWLS	was	set	at	-20%	[114].	
To	date	there	is	no	agreement	on	what	is	the	correct	method	to	evaluate	the	RV	function	by		2D-STE,	if	including	or	not	the	IVS.	While	some	research	groups	analyze	only	the	RV	FWLS	[222,	229]	others	 include	 the	 IVS	 in	 the	assessment	of	RV	 function	 	 [226,	230].	Recently,	Focardi	et	al	 [231]	demonstrated	 that	both	RVGLS	and	RVFWLS	strongly	correlated	with	CMR-derived	RVEF	 in	a	heterogeneous	group	of	 cardiac	patients.	However,	 among	 them,	RVFWLS	demonstrated	the	strongest	correlation	[231].	Despite	 clear	 rules	 on	 RV	 Ls	 measurements	 have	 not	 yet	 been	 defined,	 several	 studies	applying	RV	LS	are	available.	RV	LS	was	reported	to	be	significantly	 impaired	 in	patients	with	 PH	 and	 inversely	 correlated	 with	 systolic	 PAP	 and	 RV	 dimensions	[216,221,226,232,233].	RVGLS	correlated	strongly	with	RVEF	assessed	by	CMR	(Pearson’s	r	 =	 0.69)	 	 [234-235].	 RVFWLS	 ≥	 -18%	detected	 hemodynamic	 signs	 of	 RVF	 (Right	 atrial	pressure	>15	mmHg,	cardiac	index	<2	L/min	per	m2)	as	well	as	3DE	derived	RVEF	<	39%	(AUC	0.88	vs	AUC	0.89)		[211].	
RV	Ls	values	demonstrated	a	 significant	prognostic	 role	 in	PH	which	was	 incremental	 to	
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clinical	status,	overcoming	 the	other	echocardiographic	parameters	 [225,236,237].	RV	LS	has	been	reported	to	be	a	predictor	of	cardiovascular	events	[211,236],	all-cause	mortality	and	complications	[237].	Moreover,	Fine	et	al.	[237]	demonstrated	that	abnormal	RV	LS	is	predictive	of	reduced	survival,	stratifying	patients	prognosis.		
RV	function	is	heavily	load	dependent	and	myocardial	deformation	is	influenced	by	loading	conditions,	 too.	Accordingly,	 it	 has	been	demonstrated	 that	 in	patients	with	RV	pressure	overload,	 both	with	 and	without	 loss	 of	myocardial	 contractility,	RV	LS	was	 significantly	lower	 than	 in	 normal	 subjects	 [238].	 These	 data	 show	 that	 RV	 LS	 can	 be	 decreased	 in	presence	of	both	increased	afterload	and	normal	contractility,	and	in	presence	of	increased	afterload	 and	myocardial	 damage	with	 decreased	 contractility	 [238],	 underlying	 the	 fact	that	 the	 diagnostic	 significance	 of	 RV	 LS	 values	 must	 always	 be	 related	 to	 RV	 loading	conditions	 [239-240].	However,	 the	main	determinant	 of	RV	LS	 impairment	 seems	 to	be	myocardial	 contractility.	 Indeed	 PH	 patients	 with	 RV	 dysfunction	 showed	 lower	 RV	 	 LS	values	 in	 comparison	 to	 PH	 patients	 with	 preserved	 RV	 function	 [238].	 Not	 only	 the	absolute	 value	 of	 RV	 LS	 is	 predictive	 of	 prognosis	 in	 PH	 patients,	 but	 also	 its	 variation	during	follow-up	demonstrated	a	prognostic	role.	Patients	with	an	improvement	>5%	of	RV	LS	during	follow-up	demonstrated	better	survival	respect	to	patients	without	[241].		
Another	 2D-STE	 RV	 LS	 parameter	 is	 RV	 intraventricular	 dyssynchrony	 index	 (RV	 IVDI),	recently	described	[242-245].	It	is	calculated	as	the	standard	deviation	of	the	time	to	peak-systolic	strain	for	RVFW	and	IVS	segments,	adjusted	to	heart	rate.	Impairment	of	RV	IVDI	derives	 mainly	 from	 delayed	 contraction	 of	 RVFW	 [243].	 It	 occurs	 frequently	 in	 PAH	patients	 [246]	 and	 demonstrated	 to	 be	 an	 independent	 predictor	 of	 clinical	 worsening,	with	 possibility	 of	 normalization	 during	 effective	 treatments	 accompanied	 by	 a	 large	reduction	 of	 PVR	 [246].	 Determinants	 of	 RV	 RVDI	 have	 to	 be	 defined.	 Badagliacca	 et	 al	showed	 the	 presence	 of	 a	 correlation	 among	 RV	 IVDI	 and	 RV	 dilation	 and	 eccentric	
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hyperthrophy	 pattern,	 suggesting	 a	 role	 of	 segmental	 wall	 stress	 heterogeneity	 as	 the	major	 determinant	 of	 mechanical	 delay	 [247].	 To	 date,	 larger	 studies	 are	 required	 to	determine	its	clinical	significance	and	its	role	in	clinical	routine.	
	
Three-dimensional	echocardiography	
3DE	 is	 a	 recently	 introduced	 echocardiographic	 technique.	 It	 demonstrated	 to	 be	feasible,	accurate	and	reproducible	in	measuring	RV	volumes	and	ejection	fraction	in	adults	[248-256],	as	well	as	in	children	[257-258].	Nevertheless,	the	feasibility	of	obtaining	a	good	quality	full	volume	3D	data	set	acquisition	which	includes	the	RV	anterior	and	apical	lateral	segments	as	well	as	 the	RV	outflow	tract,	 in	patients	with	poor	 imaging	windows	and/or	dilated	RV,	remains	the	main	limitation	of	the	technique.	Accuracy	tends	to	decrease	with	increasing	RV	size,	limiting	its	application	in	patients	with	more	dilated	RV	[259].		
Recent	studies	showed	a	close	correlation	between	3DE	and	CMR	in	measuring	RV	volumes	and	ejection	fraction	[256,260-261]	(Table	10).		
Table	10.	Differences	between	right	ventricular	volumes	assessed	by	thre-dimensional	echocardiography	and	cardiac	magnetic	resonance	
Author	 Three-dimensional	echocardiography	End-Diastolic	Volume	(ml)	 End-systolic	Volume	(ml)	 Ejection	Fraction	(%)	Grapsa	et	al	 -4	(-11,	4)	 0	(-6,	6)	 -1	(-3,	0)	Sugeng	et	al	[269]	 -14	(-28,	0)	 -9	(-19,	1)	 -2	(-4,	0)	Van	der	Zwaan	et	al	 -34	(-43,	-25)	 -11	(-19,	3)	 -4	(-6,	-2)	Leibundgut	et	al	[260]	 -10	(-15,	-6)	 -5	(-8,	-1)	 0	(-2,	1)	Shimada	et	al	[261]	 -14	(-18,	-10)	 -6	(-8,	-3)	 -1	(-2,	0)	Modified	from:	Badano	et	al.	J	Cardiovasc	Ultras	2012;	20(1):	1-22	[256].	
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Although	 3DE	 appeared	 to	 underestimate	RV	 volumes	 in	 comparison	 to	 CMR	 [261],	 this	underestimation	showed	to	be	systematic	[253],	confirming	the	good	agreement	between	the	two	techniques	and	the	accuracy	of	3DE.	As	well	as	 in	healthy	subjects,	Li	et	al	 [262]	demonstrated	a	close	correlation	among	RVEF	measured	by	3DE	and	CMR	in	PH	patients.		
Normative	data	for	3DE	RV	volumes	including	age-,	body	size-,	and	sex-specific	reference	values	based	on	 large	cohort	studies	of	healthy	volunteers	has	recently	become	available	[253,263].	 The	 current	 guidelines	 on	 echocardiographic	 chamber	 quantification	 for	 the	first	 time	 included	 recommendations	 for	 3DE	 RV	 analysis	 specifying	 upper	 limits	 of	 RV	end-diastolic	 volume	 (87	 ml/m2	 in	 men	 and	 74	 ml/m2	 in	 women)	 and	 RV	 end-systolic	volume	(44	ml/m2	in	men	and	36	ml/m2	in	women)		[114].	
Applying	 3DE,	 Maffesanti	 et	 al	 [253]	 was	 able	 to	 confirm	 the	 correlation	 between	 RV	volumes	 and	 anthropometric	 variables	 (such	 as	 gender,	 age,	 and	 body size),	 previously	demonstrated	by	CMR	[264]	.	
Using	3DE,	it	has	been	confirmed	that	in	normal	people	the	three	compartments	of	the	RV	provides	a	different	contribution	 in	RV	systolic	contraction,	both	 in	 timing	as	 in	strength	[265-266].	Inflow	and	outflow	tracts	are	the	most	active	RV	compartments	contributing	to	its	 pump	 function,	whereas	 the	 apex	 contributes	 less,	 following	 a	 chronological	 order	 in	contraction,	that	reflects	the	peristaltic	pump	function	of	the	RV	[265].	In	pts	with	PH,	the	relative	 contribution	 of	 the	 three	 compartments	 to	 RV	 pump	 function	 seems	 to	 remain	unchanged,	 with	 the	 loss	 of	 the	 timing	 differences.	 The	 three	 compartments	 contract	simultaneously	 loosing	 the	 peristaltic	 function	 and	 making	 the	 RV	 behave	 as	 a	 single	chamber.	 This	 change	 is	 coupled	 by	 changes	 of	 the	 RV	 shape,	 from	 a	 triangular	 to	 a	cilindrical	one	[265].	In	particular,	a	new	methodology	which	allows	to	assess	3DE-derived	global	 and	 regional	 RV	 shape	 indices	 based	 on	 analysis	 of	 the	 RV	 curvature	 has	 been	
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recently	developed	and	tested	in	normal	subjects	and	in	patients	with	pulmonary	arterial	hypertension	 [267].	 It	 allows	 to	demonstrate	 that	 in	patients	with	pressure	overload	 the	RVOT	is	more	round,	both	body	and	apical	portions	of	the	septum	are	more	convex	bulging	into	the	LV	at	both	end-diastole	and	end-systole,	with	a	more	flattened	apical	free	wall.	The	curvature	 of	 the	 RV	 inflow	 tract	 was	 a	 more	 robust	 predictor	 of	 death	 than	 RVEF,	 RV	volumes,	or	other	regional	curvature	indices	[267].		
3DE	allows	 to	calculate	RVEF	 from	end-diastolic	and	end-systolic	volume	measurements,	providing	 an	 adequate	 assessment	 of	 true	 global	 RV	 pump	 function.	 Recent	 studies	confirmed	that	3DE	measurement	of	the	RVEF	is	accurate,	reproducible	and	correlate	well	with	CMR	both	in	adults	and	children	[255,257,268,269].	In	the	most	recent	meta-analysis	aimed	 to	 explore	 the	 accuracy	 of	 different	 imaging	 modalities	 (2DE,	 3DE,	 radionuclide	ventriculography,	 CT,	 gated	 single-photon	 emission	 CT,	 and	 invasive	 cardiac	cineventriculography)	for	RVEF,	using	CMR	as	reference	method,	3DE	has	proven	to	be	the	most	reliable	technique,	overestimating	the	RVEF	only	by	1.16%	with	the	lowest	limits	of	agreement	 (from	 -0.59	 to	 2.92%)	 [270].	 The	 reference	 values	 of	 3DE	 RVEF	 have	 been	recently	 obtained	 on	 a	 large	 cohorts	 of	 healthy	 volunteers	 [253,263].	 According	 to	 the	current	 guidelines	 on	 echocardiographic	 chamber	 quantification,	 3DE-derived	 RVEF	should	 be	 considered	 a	 method	 of	 choice	 for	 quantifying	 RV	 systolic	 function,	 with	 the	abnormality	threshold	<45%	[114].	
In	PH,	RVEF	measured	by	CMR	[142]	demonstrated	prognostic	power.	3DE	demonstrated	to	 be	 superior	 in	 comparison	 to	 conventional	 echocardiography	 in	 identifying	 RV	dysfunction	in	patients	with	PH	[271].	Recently,	Vitarelli	et	al	[211]	demonstrated	that	3DE	RVEF	 is	 accurate	 in	 predicting	 RVF,	 defined	 by	 haemodynamic	 parameters,	 and	 is	 an	independent	predictor	of	mortality	at	multivariate	analysis.	
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Aim	of	the	study		The	aim	of	the	study	was	the	characterization	of	RV	mechanics,	 in	term	of	relative	contribution	 of	 longitudinal	 and	 radial	 motion,	 in	 patients	 with	 PH.	 In	 order	 to	 better	understand	 the	 RV	 mechanics	 in	 patients	 with	 PH,	 we	 first	 assessed	 the	 normal	 RV	mechanics	 in	 healthy	 subjects	 and	 in	 its	 changes	 in	 a	 population	 at	 risk	 of	 PH,	 such	 as	systemic	 sclerosis	 patients.	 Then,	 we	 investigated	 the	 RV	 anatomical	 and	 functional	remodeling	 that	 occurs	 in	 the	 determination	 of	 the	 progressive	 RV	 dysfunction	characterizing	the	clinical	hystory	of	PH.																			
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Material	and	Methods	
	
Study	population	Three	populations	have	been	enrolled:	healthy	subjects;	patients	affected	by	SSc,	as	a	group	at	risk	of	PH;	and	patients	affected	by	PH.	Healthy	 subjects	 were	 prospectively	 recruited	 from	 October	 2011	 to	 July	 2013	 among	hospital	employees,	fellows	in	training,	their	relatives,	and	people	screened	for	driving	or	working	licenses.	Criteria	of	recruitment	included:	age	≥18	years,	no	history	or	symptoms	of	cardiovascular	or	lung	disease,	normal	physical	examination,	and	ECG.	Exclusion	criteria	were	 as	 follows:	 smoking,	 systolic	 blood	 pressure	 >140	mmHg,	 diastolic	 blood	 pressure	>80	mmHg,	history	of	drug-treated	hypertension,	diagnosis	of	diabetes	mellitus,	impaired	fasting	 glucose	 >100	 mg/dL,	 body	 mass	 index	 >30	 kg/m2,	 creatinine	 >1.3	 mg/	 dL,	estimated	 glomerular	 filtration	 rate	 <	 60	 mL/min	 per	 1.73	 m2,	 history	 of	 dyslipidemia	(total	cholesterol	>240	mg/dL,	low-density	lipoprotein	cholesterol	>130	mg/dL,	and	total	triglycerides	 >150	 mg/dL),	 poor	 apical	 acoustic	 window,	 unknown	 silent	 pathology	detected	by	echocardiography	(wall	motion	abnormalities;	valvular	stenoses	of	any	degree;	more	 than	 mild	 valvular	 regurgitation	 by	 multiparametric	 quantitative	 assessment),	professional	 sport	 activity,	 pregnancy,	 frequent	 extrasystoles	 precluding	echocardiographic	 protocol	 acquisitions.	 Among	 the	 healthy	 subjects	 a	 subgroup	 was	selected	in	order	to	be	age	and	gender-matched	with	the	SSc	and	PH	populations.	Written	informed	 consent	was	 obtained	 from	 all	 volunteers,	 and	 the	 study	was	 approved	 by	 the	local	Ethics	Committee	(protocol	2380P	approved	on	06/10/2011).		
Patients	 with	 SSc	 have	 been	 randomly	 enrolled	 between	 October	 2012	 and	 May	 2014.	Diagnosis	 of	 SSc	 was	 in	 agreement	 with	 the	 ACR/EULAR	 classification	 criteria	 [272].	
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Exclusion	criteria	were	the	presence	of	known	cardiovascular	disease	and	the	confirmed	or	suspected	PH,	measured	by	echocardiography	according	to	the	current	PH	guidelines	[2].	Particularly,	patients	with	maximum	velocity	of	TR	>	2.8	m/sec	have	been	considered	with	possible	 or	 probable	 PH	 and	 then	 have	 been	 excluded.	 Written	 informed	 consent	 was	obtained	from	all	patients,	and	the	study	was	approved	by	the	local	Ethics	Committee.		
Between	 October	 2010	 and	 January	 2016,	 patients	 affected	 by	 PH	 have	 been	 enrolled.	Inclusion	criteria	was	 th	definite	diagnosis	of	PH	obtained	at	RHC.	Exclusion	criteria	was	PH	secondary	to	left	heart	disease,	group	2	of	the	current	PH	classification	[2].		
	
Echocardiographic	acquisition	
A	 complete	 standard	M-mode,	 2D,	 and	 Doppler	 examination	 was	 performed,	 and	additional	 dedicated	 2DE	 and	 3DE	 acquisitions	 were	 obtained	 according	 to	 the	 study	protocol.	All	echocardiographic	studies	were	performed	by	experienced	researchers	using	a	Vivid	E9	scanner	(GE	Vingmed,	Horten,	Norway)	equipped	with	M5S	and	4V	probes.	The	2DE	 acquisition	 protocol	 included	 dedicated	 apical	 4-chamber	 RV-focused	 views.	 Image	depth	and	sector	size	were	adjusted	to	ensure	an	adequate	temporal	resolution	(50–80	fps)	for	 2D-STE-derived	 strain	 quantitation.	 Three	 consecutive	 cardiac	 cycles	were	 recorded.	For	3DE	analysis,	4-	and	6-beat	full-volume	RV	data	sets	were	acquired	during	breath-hold	from	the	apical	approach,	taking	care	to	avoid	any	artifacts	and	include	the	entire	structure	in	the	acquisition.		
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Echocardiographic	analysis	
Systolic	 PAP	was	 estimated	 based	 on	 the	 TR	 peak	 velocity	 and	mean	 right	 atrial	pressure	 (estimated	 from	 inferior	 vena	 cava	 size	 and	 respiratory	 excursion)	 [113].	 PVR	was	 calculated	 with	 the	 equation:	 TR	 Velocity/TVI-RVOT	 ×	 10	+	 0.16,	 demonstrated	 to	provide	a	good	noninvasive	estimation	of	invasive	PVR	by	Abbas	et	al	[273].	
Analysis	of	RV	3DE	datasets	allowed	the	evaluation	of	RV	volumes	and	RVEF.	Particularly,	they	 have	 been	 assessed	 offline	 using	 4D	 RV	 Function	 2.0	 software	 package	 (TomTec	Imaging	Systems,	Unterschleissheim,	Germany),	applied	on	dedicated	3D	data	sets,	and	a	software	platform	 for	data	management	 (Research	Arena.	TomTec	 Imaging	Systems).	RV	volumes	 were	 indexed	 for	 body	 surface	 area	 according	 to	 DuBois	 and	 DuBois	 formula	[274].	The	work	 flow	of	 the	RV	analysis	 software	 is	 as	 follows:	 Step	1,	 view	adjustment:	within	 the	3DE	data	 set	2	orthogonal	 cut	planes	of	LV,	 showing	apical	4-chamber	and	2-chamber,	 are	automatically	 selected	and	have	 to	be	correctly	alligned;	 then	2	orthogonal	cut	 planes	 of	 RV	 have	 to	 be	 adjusted.	 From	 these	 adjustments	 an	 orthogonal	 LV	 plane	passing	through	the	aortic	valve	will	be	obtained;	landmarks	have	to	be	positioned	at	the	hinge	points	of	the	aortic	valve	cusps.	Then	a	transversal	plane	of	the	RV	will	obtained,	in	which	a	transversal	line	has	to	be	positioned	joining	the	endocardial	surface	of	the	septum	to	the	RV	free-wall	one	(Figure	14).	Step	2,	tracking	revision:	on	the	basis	of	the	initial	view	adjustment	and	the	 landmarks,	 the	program	automatically	provides	4-chamber	and	three	coronal	 views	 of	 the	 right	 ventricle	 at	 end-diastole.	 The	 contours	 are	 automatically	identified.	Before	to	start	with	the	contours	adjustment,	the	hinge	point	of	tricuspid	leaflets	and	pulmonary	valve	cusps	can	be	checked	and	eventually	replaced	in	order	to	ameliorate	the	 definition	 of	 the	 inlet	 and	 outlet	 RV	 regions.	 Then,	 the	 observer	 can	 modify	 the	contours	 using	 dedicated	 tools.	 The	 same	 process	will	 be	 performed	 at	 the	 end-systolic	
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frame	(Figure	15	A	and	B).	End-diastolic	and	end-systolic	frames	are	automatically	selected	by	 the	 software.	 Step	 3,	 RV	 analysis:	 finally,	 the	 RV	 analysis	 display	 offers	 the	 dynamic	model,	a	time-volume	curve	and	values	of	RV	volumes	and	function	(Figure	16).	
	
	
	Figure	14.	Step	1	of	the	work-flow	of	3DE	RV	volumes	measurement.	View	adjustment.							
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	Figure	15.	Step	2	of	the	work-flow	of	3DE	RV	volumes	measurement.	Tracking	revision	of	the	end-diastolic	(A)	and	end-systolic	RV	contours	
		Figure	16.	Step	3	of	the	work-flow	of	3DE	RV	volumes	measurement.	RV	analysis	with	final	results.	
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From	 the	3D	analysis	we	obtained	 the	RV	beutel,	 on	which	a	 custom-made	 software	has	been	applied.	It	is	able	to	investigate	separately	longitudinal	and	radial	displacement,	deny	one	 of	 them.	 It	 permits	 to	 quantitate	 separately	 longitudinal	 and	 radial	 contribution	 to	RVEF	(Figure	17).	From	the	ratio	among	radial	or	longitudinal	EF	and	total	RVEF,	obtained	from	the	3D	analysis,	 it	was	possible	 to	estimate	 the	relative	contribution	of	 longitudinal	and	radial	displacement	to	the	global	RV	pump	function,	respectively	the	Radial	EF/RVEF	(RadEF/RVFE)	and	Longitudinal	EF/RVEF	(LongEF/RVEF).	
	
	Figure	17.	Time-volume	curves	of	right	ventricular	 total	(blue	dotted	curve),	 longitudinal	(red	 dotted	 curve)	 and	 radial	 (yellow	 dotted	 curve)	 deformation	 in	 an	 healthy	 subjects,	evaluated	by	a	custom-made	software,	showing	a	similar	contribution	of	 longitudinal	and	radial	 to	 right	 ventricular	 global	 pump	 function.	 Courtesy	 of	 Dr	 A	 Kovacs,	 Semmelweiss	University	Heart	and	Vascular	Center,	Budapest.		
Conversely,	RV	2D-STE	analysis	allowed	the	evaluation	of	RV	myocardial	deformation.	This	analysis	was	done	using	Q-analysis	software	package	(EchoPAC	BT	13;	GE	Vingmed).	After	manual	 tracing	 the	 end-systolic	 RV	 endocardial	 border,	 a	 region	 of	 interest	 (ROI)	 was	
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automatically	 generated;	 its	 width	 and	 position	 were	 manually	 adjusted	 to	 include	 the	entire	 myocardial	 wall	 and	 to	 exclude	 the	 pericardium.	 Pulmonary	 valve	 closure	 was	identified	 on	 the	 pulse-wave	 Doppler	 tracing	 of	 the	 RV	 outflow	 tract.	 The	 software	automatically	 divides	 the	 RVFW	 and	 the	 IVS	 in	 3	 segments	 (basal,	 mid,	 and	 apical),	resulting	in	a	6-segment	model.	The	quality	of	the	tracking	was	automatically	validated	by	software	and	confirmed	visually	 from	the	2D	 images.	Subjects	 in	whom	>2	segments	per	RV	 showed	persistent	 inadequate	 tracking	 despite	 attempts	 to	 readjust	 the	ROI	 position	and	width	were	excluded	from	analysis.	The	global	RVLS	was	automatically	calculated	by	the	software	and	corresponded	to	the	average	of	the	6	segments	systolic	peak	strain	values	(Figure	18).	The	RVFWLS	was	calculated	averaging	the	systolic	peak	strain	values	of	the	3	free-wall	 segments,	 as	 described	 elsewhere	 [228].	 A	 dedicated	 tool	 available	 in	 the	 Q-analysis	software	package	EchoPAC	BT	12	permits	to	obtain	the	TD	of	the	RV	myocardium.	Particularly,	 6	 curves	 will	 be	 obtained:	 3	 positive	 curves	 (corresponding	 to	 the	displacement	of	RV	free	wall	(RVFW)	segments)	and	3	negative	ones	(corresponding	to	the	displacement	of	the	IVS	segments)	(Figure	19).	The	RVFW	global	TD	was	obtained	as	the	arithmetic	mean	of	the	systolic	peak	values	of	the	3	lateral	segments;	IVS	TD	was	obtained	as	the	arithmetic	mean	of	the	systolic	peak	of	the	3	IVS	segments.	Global	TD	was	obtained	averaging	the	absolute	values	of	RV	FW	and	IVS	TD.	
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										Figure	18.	Longitudinal	strain	evaluation	of	the	right	ventricle	by	two-dimensional	speckle	tracking	echocardiography.	
	
	Figure	19.	Transversal	displacement	evaluation	of	 the	right	ventricle	by	two-dimensional	speckle	tracking	echocardiography.	Positive	curves	display	RV	Free	Wall	displacement,	the	negative	ones	display	the	interventricular	septum	displacement.	
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Statistical	analysis	
Normal	 distribution	 of	 variables	 was	 assessed	 by	 Kolmogorov–Smirnov	 test.	Accordingly,	 continuous	 variables	 are	 summarized	 as	 mean±SD,	 if	 normally	 distributed,	and	as	median	(25th	and	75th	percentiles)	otherwise.	Categorical	variables	were	reported	as	percentages.	In	all	analyses,	RVLS	parameters	and	RV	IVS	TD	were	considered	negative	(lower	 values	 indicating	 better	 deformation).	 Lower/upper	 limits	 of	 normality	 were	identified	as	the	mean	minus/plus	2	SD.		In	order	to	investigate	differences	among	normal,	patients	 at	 risk	of	PH	and	patients	with	PH,	 the	 selected	healthy	population,	 SSc	 and	PH	populations	were	compared.	In	order	to	 investigate	the	modifications	of	RV	mechanics	 in	PH	 pathology,	 PH	 population	 has	 been	 divided	 in	 two	 groups:	 patients	 at	 risk	 of	 RV	dysfunction	and	patients	with	definite	RV	dysfuntion.	The	parameter	chosen	to	define	the	absence	 or	 presence	 of	 RV	 dysfunction	 was	 the	 3DE	 RVEF.	 Particularly,	 the	 RVEF	 45%	value	 has	 been	 used	 as	 cut-off	 value,	 according	 to	 the	 current	 chamber	 quantification	guidelines	[114].	Differences	among	mean±SD	were	tested	with	T-test	and	ANOVA	test,	in	case	 of	 normal	 distribution.	 Otherwise,	 non	 parametric	 test	 (U-Mann	 Whitney)	 was	performed.	
	Regression	 analysis	 was	 performed	 to	 investigate	 correlations	 among	 RVEF	 and	longitudinal	EF,	 radial	EF,	PVR	and	 systolic	PAP	 (Pearson	and	Spearman	 tests).	All	 these	variables,	 statistically	significant	at	univariate	analysis,	were	 included	 in	 the	multivariate	analysis,	performed	by	binary	logistic	regression	analysis.		
All	 analyses	 were	 performed	 using	 SPSS	 13.0	 (SPSS	 Inc,	 Chicago,	 IL).	 P<0.05	 were	considered	significant.	
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Results	
	
Healthy	subjects	A	 total	 of	 270	 subjects	 fulfilled	 the	 inclusion	 criteria.	 Anthropometric	 and	echocardiographic	characteristics	are	summarized	in	Table	11.	The	age	ranged	from	18	to	76	years	and	distribution	per	decade	is	quite	homogeneous.		Women	were	more	prevalent	than	men	(56%).	Men	showed	larger	body	size	and	higher	values	of	systolic	and	diastolic	artery	 pressure.	 Moreover,	 men	 showed	 larger	 LV	 and	 right	 atrial	 size.	 Systolic	 PAP	appeared	higher	in	women,	while	PVR	were	similar	in	men	and	women.	Men	showed	larger	RV	 size,	 even	 after	 indexation	 for	 BSA,	 and	 lower	 RV	 pump	 function.	 TAPSE	 and	 S’	appeared	 similar	 between	 men	 and	 women.	 2D-STE	 LS	 demonstrated	 that	 RVGLS	 and	RVFWLS	 were	 significantly	 different,	 with	 higher	 values	 for	 RVFWLS;	 moreover,	 their	values	 differ	 among	 gender	 with	 values	 significantly	 higher	 in	 women.	 Lower	 limits	 of	normality	were	 -20%	and	 -22%	 for	RVGLS	 and	RVFWLS	 respectively.	RVFW	TD	 showed	positive	values,	while	 IVS	TD	showed	negative	values.	Global	TD	showed	positive	values.	No	 differences	 among	 gender	 has	 been	 shown.	 Lower	 limits	 of	 normality	 for	 RVFW	 and	global	TD	were	1.4	and	2.1,	respectively.	Upper	limit	of	normality	for	IVS	TD	was	-1.9.									
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Table	11.	Healthy	subjects.	Clinical	and	echocardiographic	characterisctics		 All		
(270)	
Men		
(119)	
Women	
(151)	
p	
Anthropometric	variables	Age,	ys	 44	±	14	 44	±	14	 44	±	14	 0.91	Height,	cm	 170	±	9	 177	±	7	 165	±	7	 <0.0001	Weight,	Kg	 67	±	11	 76	±	9	 61	±	8	 <0.0001	BSA,	m2	 1.78	±	0.2	 1.9	±	0.12	 1.7	±	0.1	 <0.0001	Heart	rate,	bpm	 67	±	10	 66	±	10	 67	±	10	 0.31	SAP,	mmHg	 122	±	14	 128	±	13	 117	±	14	 <0.0001	DAP,	mmHg	 74	±	8	 77	±	8	 71	±	8	 <0.0001	
Echocardiographic	characteristics	LV	EDV,	ml/m2	 54	±	10	 59	±	10	 50	±	8	 <0.0001	LV	EF,	%	 64	±	4	 63	±	4	 66	±	4	 <0.0001	2D	RA	MaxVol,	ml/m2	 22	(18-27)	 25	(21-30)	 20	(16-24)	 <0.0001	sPAP,	mmHg	 21	±	6	 20	±	7	 22	±	6	 0.02	PVR,	WU	 1.4	(1.1-1.6)	 1.3	(1-1.6)	 1.4	(1.2-1.6)	 0.24	RV	EDA,	cm2/m2	 10.3	±	1.9	 11	±	1.8	 9.8	±	1.7	 <0.0001	RV	ESA,	cm2/m2	 5.2	±	1.1	 5.7	±	1.2	 4.8	±	1	 <0.0001	RV	FAC,	%	 50	±	6	 48	±	7	 51	±	6	 0.003	3D	RV	EDV,	ml/m2	 56		±	12	 61	±	12	 52		±	10	 <0.0001	3D	RV	ESV,	ml/m2	 23		±	6	 26		±	6	 21		±	5	 <0.0001	3D	RV	EF,	%	 59		±	6	 58		±		6		 60		±	6	 0.007	TAPSE,	mm	 25	(23-27)	 24	(23-27)	 25	(24-27)	 0.3	S’,	cm/sec	 14	(13-16)	 15	(14-16)	 14	(13-16)	 0.98	RVGLS,	%	 -26		±	3§	 -25		±	3	 -27		±	3	 <0.0001	RVFWLS,	%	 -31		±	4§	 -29		±	4	 -32		±		4	 <0.0001	RV	FW	TD,		mm	 4.4		±	1.5	 4.4		±	1.1	 4.4		±	1.5	 0.67	IVS	TD,	mm	 -4.5		±	1.3	 -4.6		±	1.2	 -4.5		±	1.1	 0.31	Global	RV	TD,	mm	 4.5		±	1.2	 4.5		±	1.2	 4.5		±	1.1	 0.82	BSA=body	surface	area;	DAP=diastolic	artery	pressure;	EDA=end-diastolic	area;	EDV=end-diastolic	volume;	EF=ejection	 fraction;	 ESA=end-systolic	 area;	 ESV=end-systolic	 volume;	 FAC=fractional	 area	 change;	IVS=interventricular	 septum;	 LV=left	 ventricular;	 PVR=pulmonary	 vascular	 resistance;	 RA=right	 atrial;	RV=right	 ventricular;	 RVFWLS=RV	 free	 wall	 longirtudinal	 strain;	 RVGLS=RV	 global	 longitudinal	 strain;	SAP=systolic	 artery	 pressure;	 sPAP=systolic	 pulmonary	 artery	 pressure;	 TAPSE=tricuspid	 annulus	 plane	systolic	excursion;	TD=transversal	displacement;	WU=Wood	Unit.	
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We	obtained	normal	values	of	longitudinal	and	radial	RVEF,	and	their	relative	contribution	to	global	RVEF		only	in	the	cohort	of	healthy	subjects	who	were	age	and	gender	matched	with	 SSc	 and	 PH	 ones	 (Table	 12).	 Both	 longitudinal	 and	 radial	 components	 equally	contributed	to	global	RVEF.	In	addition,	the	extent	of	longitudinal	and	radial	components	to	global	 RVEF	 were	 similar	 between	 men	 and	 women.	 Lower	 limits	 of	 normality	 for	longitudinal	 and	 radial	 components	of	RVEF	were	19%	and	17%,	 respectively;	while	 the	ratios	 LongEF/RVEF	 and	 RadEF/RVEF	were	 similar	 (35%	 for	 both).	 In	 healthy	 subjects	both	longitudinal	and	radial	motion	showed	a	moderate	linear	correlation	with	3DE	RVEF	(r=0.51,	p=<0.0001;	r=0.61,	p<0.0001,	respectively).	
	Table	12.	Subgroup	of	healthy	subjects.	Echocardiographic	longitudinal	and	radial	parameters		 All	(57)	 Men	(12)	 Women	(45)	 P*	3D	LongEF,	%	 27	±	4°	 27	±	4	 27	±	4	 0.7	3D	RadEF,	%	 27	±	5°	 27	±	4	 27	±	6	 0.6	3D	LongEF/RVEF	 47	±	6ç	 48	±	5	 47	±	6	 0.93	3D	RadEF/RVEF	 47	±	6	ç	 47	±	7	 47	±	6	 0.87	*=men	vs	women;	°p=NS;	çp=NS	LongEF=longitudinal	 ejection	 fraction;	 RadEF=radial	 ejection	 fraction	 ;	 RVEF=	 right	 ventricular	 ejection	fraction		
	
Systemic	sclerosis	patients	75	 patients	 fulfilled	 the	 inclusion	 criteria	 for	 SSc.	 Mean	 age	 was	 56	 ±	 13	 years.	Women	were	more	prevalent	than	men	(87%).	Mean	disease	duration	were	14	±	9	years.	The	cutaneous	form	was	diffuse	in	41%	and	limited	in	59%	of	patients.	All	of	them	showed	positivity	 for	 antinucleus	 antibody	 with	 the	 following	 distribution:	 anti-centromere	 in	39%,	scl-70	in	40%	and	aspecific	in	21%.			
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Pulmonary	hypertension	patients	59	 patients	 fulfilled	 the	 inclusion	 criteria	 for	 PH.	 Some	 of	 them	 underwent	more	than	 one	 echocardiogram	 during	 their	 clinical	 follow-up,	 at	 different	 timing.	 Then,	 we	collected	 a	 total	 of	 81	 complete	 echocardiograohic	 studies.	 The	 mean	 age	 was	 59	 ±	 14	years.	Women	were	 prevalent	 (79%).	 Patients	 were	 affected	 from	 different	 form	 of	 PH,	with	the	following	distribution:	64%	of	type	1;	7%	of	type	3;	16%	of	type	4;	2%	of	type	5	and	 the	 remaining	 were	 undefined.	 According	 to	 protocol,	 no	 patients	 with	 type	 2	(secondary	to	 left	heart	disease)	was	included.	LV	2DE	end-diastolic	volume	was	85	±	26	ml	and	LV	2DE	EF	was	66	±	6%.	The	majotiry	of	patients	(82	%	of	them)	showed	a	normal	çV	 diastolic	 function	 or	 an	 abnormal	 relaxation	 pattern,	 while	 15%	 showed	 a	pseudonormal	pattern	and	3%	a	restrictive	pattern.	At	the	time	of	the	echocardiographic	study,	48%	patients	were	symptomatic	(NYHA	class	≥	II);	 15%	 of	 them	 showed	 right	 bundle	 branch	 block	 at	 electrocardiogram;	 55%	 of	 them	were	in	specific	therapy	for	PH	(4	patients	with	calcium	channel	blockers;	27	patients	with	endothelin	 inhibitors;	 20	 patients	 with	 phosphodiesterasis	 inhibitors;	 2	 patients	 with	prostanoid;	 3	 patients	with	 riociguat),	 of	whom	83%	 single	 therapy	 and	 17%	 combined	therapy.							
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Characterization	of	right	ventricular	function	and	mechanics	in	
Healthy	Subjects	-	Systemic	Sclerosis	–	Pulmonary	Hypertension	Comparative	 data	 among	 healthy	 subjects,	 systemic	 sclerosis	 patients	 and	 PH	patients	are	reported	in	Table	13.	The	three	groups	were	similar	for	age	and	gender.	SSc	patients	showed	to	have	a	lower	BSA	and	higher	heart	rate	and	systolic	artery	pressure	values.	Right	atrial	maximal	volume	was	similar	 among	 normals	 and	 SSc	 patients,	 but	 consistently	 larger	 in	 PH	 patients.	 Systolic	PAP	and	PVR	were	significantly	higher	in	PH	patients,	but	near	normal	in	SSc	patients.	RV	appeared	to	be	larger	in	PH	patients	with	no	differences	between	healthy	sunjects	and	SSc	patients.	RV	pump	function	was	significantly	 impaired	 in	PH	patients,	but	 in	SSc	patients	was	 similar	 to	 that	 of	 healthy	 subjects.	 The	 analysis	 of	 RV	 mechanics	 demonstrated	preserved	values	of	longitudinal	and	radial	function	in	SSc	patients,	both	as	absolute	than	relative	values.	Conversely,	in	PH	patients	longitudinal	and	radial	function	absolute	values	were	 reduced,	 while	 the	 relative	 contribution	 of	 longitudinal	 motion	 was	 preserved,	whereas	 the	 radial	 contribution	 demonstrated	 to	 be	 impaired,	 near	 the	 lower	 limit	 of	normality	(Figure	20).	TAPSE	and	S’	wave	were	lower	in	SSc	and	mainly	in	PH,	but	without	reaching	pathological	values.	Myocardial	deformation	analysis	by	2D-STE	showed	that	both	RVGLS	 and	 RVFWLS	 were	 preserved	 in	 SSc	 patients,	 and	 impaired	 in	 PH	 patients.	 TD	analysis	 demonstrated	 normal	 values	 in	 SSc	 patients;	while	 PH	 patients	 demonstrated	 a	slight	 decrease	 of	 RVFW	TD,	 a	 significant	 reduction	 of	 the	 leftward	 septal	motion	 and	 a	decresed	global	RV	TD.						
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Table	13.	Comparative	analysis	between	healthy	subjects,	systemic	sclerosis	patients	and	pulmonary	hypertension	patients.			 Healthy	(57)	 SSc	pts	(75)	 PH	pts	(81)	 p	
Anthropometric	variables	Age,	ys	 56	±	10	 56	±	13	 59	±	14	 0.15	Female,	%	 81	 87	 79	 0.43	Height,	cm	 165	±	8	 164	±	8	 163	±	9	 0.30	Weight,	Kg	 66	±	10	 62	±	10	 66	±	11	 0.03	BSA,	m2	 1.72	±	0.15	 1.67	±	0.16	 1.72	±	0.17	 0.05	Heart	rate,	bpm	 66	±	7	 77	±	11	 73	±	13	 <0.0001	SAP,	mmHg	 126	±	17	 133	±	22	 124	±	20	 0.05	DAP,	mmHg	 74	±	8	 77	±	8	 73	±	11	 0.10	
Echocardiographic	characteristics	2D	RA	MaxVol,	ml/m2	 22	(18-26)	 25	(21-33)	 44	(32-57)	 <0.0001	sPAP,	mmHg	 23	±	5	 27	±	5	 59	±	22	 <0.0001	PVR,	WU	 1.4	(1.3-1.6)	 1.6	(1.5-1.9)	 3	(2.3-4)	 <0.0001	RV	EDA,	cm2/m2	 10	±	2*	 11.6	±	2.4*	 18	±	5.5*	 <0.0001	RV	FAC,	%	 52	±	5*	 47	±	7*	 31	±	10*	 <0.0001	3D	RV	EDV,	ml/m2	 67		±	14	 64	±	16	 106	±	39*	 <0.0001	3D	RV	ESV,	ml/m2	 28	±	7	 27	±	10	 65	±	33*	 <0.0001	3D	RVEF,	%	 58	±	4	 58		±		6		 41	±	11*	 <0.0001	3D	LongEF,	%	 27	±	4	 28	±	6	 18	±	7*	ç	 <0.0001	3D	RadEF,	%	 27	±	5	 25	±	6	 15	±	7*	ç	 <0.0001	3D	LongEF/RVEF	 47	±	6	 49	±	9	 47	±	9	 0.10	3D	RadEF/RVEF	 47	±	6	 44	±	8	 36	±	11*	 <0.0001	TAPSE,	mm	 26	±	2	 22	±	4	 18	±	5	 <0.0001	S’,	cm/sec	 15	±	3	 13	±	2	 11	±	3	 <0.0001	RVGLS,	%	 -25	±	3	 -24	±	3	 -17	±	6*	 <0.0001	RVFW	LS,	%	 -31	±	4	 -29		±	5	 -20	±	7*	 <0.0001	RVFW	TD,		mm	 5.3	±	2	 4.9	±	2	 4	±	2.4*	 0.011	IVS	TD,	mm	 -4.8	±	1.3	 -4	±	1.7*	 -1.9	±	3*	 <0.0001	Global	RV	TD,	mm	 5	±	1.4	 4.5	±	1.6	 2.9	±	2.3*	 <0.0001	+p=significant.	BSA=body	surface	area;	DAP=diastolic	artery	pressure;	EDA=end-diastolic	area;	EDV=end-diastolic	volume;	 ESA=end-systolic	 area;	 ESV=end-systolic	 volume;	 FAC=fractional	 area	 change;	 IVS=interventricular	septum;	LongEF=longitudinal	ejection	fraction;	LV=left	ventricular;	PVR=pulmonary	vascular	resistance;	RA=right	atrial;	RadEF=radial	ejection	fraction;	RV=right	ventricular;	RVFWLS=RV	free	wall	longirtudinal	strain;	RVGLS=RV	global	 longitudinal	 strain;	 SAP=systolic	 artery	 pressure;	 sPAP=systolic	 pulmonary	 artery	 pressure;	TAPSE=tricuspid	annulus	plane	systolic	excursion;	TD=transversal	displacement;	WU=Wood	Unit.	
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	Figure	 20.	 Time-volume	 curves	 of	 right	 ventricular	 total	 (light	 blue	 dotted	 curve),	longitudinal	 (orange	 dotted	 curve)	 and	 radial	 (dark	 blue	 dotted	 curve)	 deformation	 in	 a	pulmonary	 hypertension	 patient,	 evaluated	 by	 a	 custom-made	 software,	 showing	 a	reduced	 radial	 component	 contribution	 to	 the	 global	 right	 ventricular	 pump	 function.	Courtesy	of	Dr	A	Kovacs,	Semmelweiss	University	Heart	and	Vascular	Center,	Budapest.	
	
	
Characterization	of	Right	Ventricular	 function	and	mechanics	 in	Healthy	
Subjects	–	Pulmonary	Hypertension	at	risk	of	RV	dysfunction	–	Pulmonary	
Hypertension	with	RV	dysfunction	Comparative	 data	 among	 healthy	 subjects,	 PH	 patients	 at	 risk	 of	 and	 with	 RV	dysfunction	are	reported	in	Table	14.	Patients	 with	 and	 without	 RV	 dysfunction	 were	 similar	 in	 age,	 gender	 distribution	 and	anthropometric	 characteristics.	 PH	 patients	 with	 RV	 dysfunction	 showed	 a	 higher	 heart	rate,	 compared	 with	 the	 other	 two	 groups,	 with	 similar	 arterial	 pressure	 values.	 Right	atrial	size	was	progressively	larger	in	PH	patients;	and	systolic	PAP	and	PVR	progressively	higher	in	the	two	PH	groups.	Patients	 with	 PH	 at	 risk	 of	 RV	 dysfunction	 demonstrated	 enlarged	 RV	 volumes	 with	reduced	RV	pump	function,	although	without	reaching	pathological	values.	Conversely	PH	
	 81	
patients	with	RV	dysfunction	showed	the	largest	RV	volumes	with	a	significantly	impaired	RV	global	pump	 function.	The	analysis	of	RV	mechanics	 showed	 that	 in	PH	patients	with	preserved	RVEF,	both	longitudinal	and	radial	functions	were	reduced	compared	to	healthy	subjects,	 but	 still	within	 the	normal	 range,	with	normal	values	of	 longitudinal	 and	 radial	relative	contribution	(Figure	21-A).	Conversely,	absolute	values	of	 longitudinal	and	radial	components	 of	 RVEF	 were	 consistently	 reduced	 in	 presence	 of	 a	 reduced	 RVEF.	Nevertheless,	 the	 relative	 contribution	 of	 the	 longitudinal	 component	 still	 remains	preserved	 in	 PH	 population	 despite	 the	 reduced	 RV	 pump	 function,	 whereas	 the	 radial	component	was	significantly	reduced	(Figure	21-B).	TAPSE	and	S’	were	pathological	only	in	the	PH	group	with	RV	dysfunction.	Deformation	analysis	showed	that	RVGLS	and	RVFWLS	were	slighlty	decreased	in	PH	population	with	preserved	RVEF	but	significantly	reduced	in	presence	 of	 RV	 dysfunction.	 RVFW	 TD	 appeared	 preserved	 in	 the	 first	 population	 and	slighlty	 decrease	 in	 the	 latter.	 IVS	 TD	 demonstrated	 that	 the	 leftward	 septal	 motion	progressively	 decrease	 with	 reducing	 RVEF.	 Then,	 the	 global	 TD	 is	 mildly	 reduced	 in	presence	of	preserved	RVEF	and	significantly	impaired	in	presence	of	RV	dysfunction.													
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Table	 14.	 Comparative	 analysis	 between	 healthy	 subjects,	 patients	 with	 PH	 at	 risk	 of	 right	ventricular	dysfunction	and	patients	with	PH	with	right	ventricular	dysfunction.		 Healthy	(57)	 PH	with	
RVEF≥45%	(33)	
PH	with	
RVEF<45%	(47)	
p	
Anthropometric	variables	Age,	ys	 56	±	10	 60	±	13	 59	±	15	 0.23	Female,	%	 81	 82	 77	 0.82	Height,	cm	 165	±	8	 164	±	10	 162	±	8	 0.23	Weight,	Kg	 66	±	10	 66	±	12	 65	±	10	 0.85	BSA,	m2	 1.72	±	0.15	 1.74	±	0.2	 1.71	±	0.15	 0.72	Heart	rate,	bpm	 66	±	7	 68	±	14	 76	±	15	 <0.0001	SAP,	mmHg	 126	±	17	 129	±	20	 125	±	17	 0.12	DAP,	mmHg	 74	±	8	 74	±	11	 72	±	11	 0.81	
Echocardiographic	characteristics	2D	RA	MaxVol,	ml/m2	 22	(18-26)	 33	(27-43)	 64	(42-82)	 <0.0001	sPAP,	mmHg	 23	±	5	 48	±	17	 67	±	22	 <0.0001	PVR,	WU	 1.4	(1.3-1.6)	 2.7	(2.1-3)	 3.9	(2.9-4.7)	 <0.0001	RV	EDA,	cm2/m2	 10	±	2*	 14	±	3*	 21	±	5*	 <0.0001	RV	FAC,	%	 52	±	5*	 39	±	7*	 25	±	7*	 <0.0001	3D	RV	EDV,	ml/m2	 67	±	14*	 80	±	21*	 126	±	38*	 <0.0001	3D	RV	ESV,	ml/m2	 28	±	7*	 39	±	12*	 83	±	31*	 <0.0001	3D	RVEF,	%	 58	±	4*	 52	±	4*		 34	±	7*	 <0.0001	3D	LongEF,	%	 27	±	4*	 23	±	4*	 15	±	5*		 <0.0001	3D	RadEF,	%	 27	±	5*	 22	±	5*	 10	±	4*		 <0.0001	3D	LongEF/EF	 47	±	6	 46	±	8	 47	±	10	 0.10	3D	RadEF/EF	 47	±	6	 42	±	9	 32	±	10*	 <0.0001	TAPSE,	mm	 26	±	2	 22	±	5	 16	±	4	 <0.0001	S’,	cm/sec	 15	±	2	 13	±	3	 10	±	3	 <0.0001	RV	Global	LS,	%	 -25	±	3*	 -21	±	3*	 -13	±	4*	 <0.0001	RVFW	LS,	%	 -31	±	4*	 -26		±	4*	 -17	±	6*	 <0.0001	FW	RV	TD,		mm	 5.3	±	2	 4.8	±	2	 3.5	±	2*	 0.011	IVS	RV	TD,	mm	 -4.8	±	1.3*	 -2.9	±	2.5*	 -1.1	±	3.2*	 <0.0001	Global	RV	TD,	mm	 5	±	1.4*	 3.8	±	1.9*	 2.3	±	2.4*	 <0.0001	*p=significant.	BSA=body	surface	area;	DAP=diastolic	artery	pressure;	EDA=end-diastolic	area;	EDV=end-diastolic	volume;	 EF=ejection	 fraction;	 ESA=end-systolic	 area;	 ESV=end-systolic	 volume;	 FAC=fractional	 area	 change;	IVS=interventricular	septum;	LongEF=longitudinal	ejection	fraction;	LV=left	ventricular;	PVR=pulmonary	vascular	resistance;	 RA=right	 atrial;	 Rad/EF=radial	 ejection	 fraction;	 RV=right	 ventricular;	 RVFWLS=RV	 free	 wall	longirtudinal	strain;	RVGLS=RV	global	longitudinal	strain;	SAP=systolic	artery	pressure;	sPAP=systolic	pulmonary	artery	pressure;	TAPSE=tricuspid	annulus	plane	systolic	excursion;	TD=transversal	displacement;	WU=Wood	Unit.	
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	Figure	21.	A	 -	 Pulmonary	Hypertension	patient	with	preserved	 right	 ventricular	 ejection	fraction,	showing	preserved	and	similar	values	of	 longitudinal	 (orange	dotted	curve)	and	radial	 (dark	blue	dotted	curve)	 contribution	 to	global	 systolic	 function	 (light	blue	dotted	curve).	 B	 -	 Pulmonary	 Hypertension	 patient	 with	 impaired	 right	 ventricular	 ejection	fraction,	showing	preserved	 longitudinal	(orange	dotted	curve)	contribution	and	reduced	radial	 (dark	blue	dotted	curve)	 contribution	 to	global	 systolic	 function	 (light	blue	dotted	curve).	 Courtesy	 of	 Dr	 A	 Kovacs,	 Semmelweiss	 University	 Heart	 and	 Vascular	 Center,	Budapest.		
	
Different	patterns	of	interventricular	septum	transversal	displacement	in	
Pulmonary	Hypertension	patients	Data	 reported	 above	 showed	 a	 pathological	 involvement	 of	 the	 IVS	 TD	 even	 in	presence	 of	 preserved	RV	 global	 pump	 function,	 suggesting	 its	 early	 involvement	within	the	pathological	changes	of	RV	motion	due	to	a	pressure	overload.	By	the	evaluation	of	the	IVS	TD	of	each	PH	patient,	we	demonstrated	the	presence	of	four	different	patterns,	with	different	distribution	according	to	the	presence	or	absence	of	reduced	RVEF.	Particularly,	the	 four	patterns	 are:	 type	0,	 normal	motion	with	 a	 single	negative	 curve	 at	TD	analysis	(Figure	22-A);	type	1,	characterized	by	a	preliminary	negative	curve	followed	by	a	positive	deflession	 (Figure	 22-B);	 type	 2,	 characterized	 by	 a	 positive	 deflession	 followed	 by	 a	negative	one	(Figure	22-C);	type	3,	characterized	by	a	single	positive	curve	(Figure	22-D).	
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PH	patients	with	normal	RV	pump	function	showed	type	0	in	64%	of	cases,	type	1	in	11%	and	type	2	 in	 the	remaining	cases.	Otherwise,	PH	population	with	reduced	RVEF	showed	type	 0	 in	 37%	of	 cases,	 no	 type	 1,	 type	 2	 in	 56%	of	 patients	 and	 type	 3	 in	 7%	of	 cases	(p=0.005).	 Indeed,	 type	 0	 and	 1	 showed	 normal	 3DE	 RVEF	 (44±9	 and	 53±4%,	respectively),	 while	 type	 2	 and	 type	 3	 showed	 lower	 3DE	 RVEF	 (38±10	 and	 34±9,	respectively)	with	p=NS	 among	 type	0	 and	1	 and	 among	 type	2	 and	3	but	with	p=0.009	among	 type	 1	 and	 2.	 Instead	 of	 it,	 no	 significant	 differences	 among	 systolic	 PAP	 values	among	the	different	IVS	TD	patterns	have	been	found.	Particularly,	type	0	showed	systolic	PAP	58±20	mmHg,	while	it	was	78±34,	74±22	and	84±5	in	the	remaining	three	groups	with	statistical	significance	only	among	type	0-type	2	(p=0.005)	and	type	0-type	3	(p=0.04).			
	Figure	 22.	 	 Different	 patterns	 of	 interventricular	 septum	 transversal	 displacement	 in	pulmonary	hypertension	patients.	A:	Type	0,	normal	motion	with	a	single	negative	curve.	B:	Type	1,	a	negative	deflession	followed	by	a	positive	one.	C:	Type	2,	a	positive	deflession	followed	by	a	negative	one.	D:	type	3,	a	single	positive	deflession.	
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Determinants	 of	 right	 ventricular	 global	 pump	 function	 in	 Pulmonary	
Hypertension	patients	Univariate	 analysis	 showed	 strong	 linear	 correlations	 among	 3D	 RVEF	 and	longitudinal	function,	radial	function,	PVR	and	systolic	PAP.	Particularly,	it	showed	that	the	reduction	of	RVEF	is	correlated	with	a	reduction	of	longitudinal	and	radial	function	(Figure	23	A-B),	and	with	higher	PVR	and	systolic	PAP	values	(Figure	23	C-D).	The	 multivariate	 analysis	 demonstrated	 that	 only	 longitudinal	 and	 radial	 motion	 are	independent	predictors	of	reduced	3DE	RV	EF,	but	not	PVR	and	systolic	PAP	(Table	15).		
	Figura	 23.	 Linear	 correlations	 among	 3DE	 right	 ventricular	 ejection	 fraction	 (EF)	 and	longitudinal	 EF	 (A),	 radial	 EF	 (B),	 pulmonary	 vascular	 resistance	 (PVR)	 (C)	 and	 systolic	pulmonary	artery	pressure	(sPAP)	(D).				
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Table	15.	Multivariate	analysis.	Indipendent	predictors	of	impaired	right	ventricular	pump	function		 OR	 IC	 p	LongEF	 2.2	 1.2	-	3.9	 0.009	RadEF	 2.5	 1.3	-	4.6	 0.005	PVR	 --	 --	 NS	sPAP	 --	 --	 NS	LongEF=longitudinal	 ejection	 fraction;	PVR=pulmonary	vascular	 resistance;	RadEF=radial	 ejection	 fraction;	sPAP=systolic	pulmonary	artery	pressure	
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Discussion		 This	 is	 the	 first	 echocardiographic	 study	 investigating	 the	 RV	 mechanical	components,	 such	 as	 longitudinal	 and	 radial	 displacement,	 in	 healthy	 subjects	 and	 their	changes	 occurring	 in	 presence	 of	 various	 degrees	 of	 PH,	 a	 pathological	 condition	characterized	by	pressure	overload.	The	results	of	our	study	can	be	summarized	as	follows:	i)	 in	healthy	 subjects	 the	 radial	 and	 longitudinal	 components	of	RV	mechanics	appear	 to	participate	equally	to	the	global	RV	pump	function;	ii)	in	healthy	subjects	the	IVS	shows	a	lefward	septal	motion;	iii)	SSc	patients	without	PH,	classified	as	a	population	at	high	risk	of	PH,	show	normal	RV	size	and	function	with	unchanged	longitudinal	and	radial	contribution	and	unchanged	deformation	parameters	compared	to	healthy	subjects;	 iv)	 in	PH	patients	with	 preserved	 RV	 pump	 function	 the	 relative	 contribution	 of	 longitudinal	 and	 radial	displacement	is	unchanged	compared	to	healthy	subjects.	Conversely,	in	PH	patients	with	reduced	 RVEF	 there	 is	 a	 prevalent	 reduction	 of	 the	 relative	 contribution	 of	 radial	displacement,	 although	 a	 progressive	 decrease	 of	 both	 longitudinal	 and	 radial	 motion	occurs;	 v)	 in	 PH	 patients,	 the	 IVS	 changes	 progressively	 its	 motion	 pattern,	 showing	 a	correlation	with	a	progressive	RVEF	 impairment	but	not	with	 the	RV	 loading	conditions,	defined	by	systolic	PAP	values.		
RV	mechanics	in	healthy	subjects	Anathomical	evidences	demonstrated	that	the	RV	is	characterized	by	a	two-layered	structure	with	 the	 subepicardial	myofibres	 arranged	more	 or	 less	 circumferentially	 in	 a	direction	 that	 is	 parallel	 to	 the	 atrioventricular	 groove	 and	 encircle	 the	 subpulmonary	infundibulum,	 and	 the	 deep	 myofibres	 aligned	 longitudinally,	 apex	 to	 base.	 [192].	Differently,	 the	 LV	 has	 a	 three-layered	 structure	 with	 the	 epicardial	 cells	 oriented	
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obliquely,	the	mid-myocardial	cells	more	circumferentially,	and	the	endocardial	cells	again	obliquely,	 with	 a	 well-developed	 midwall	 circumferential	 layer	 responsible	 for	 the	predominance	of	circumferential	shortening	and	radial	thickening	of	the	LV	[275-276].	The	RV	 myocardial	 structure	 explains	 why	 RVEF	 seems	 to	 be	 determined	 mainly	 by	longitudinal	 shortening	 [193].	 Nevertheless,	 this	 statement	 does	 not	 have	 clear	demonstrations.	To	the	best	of	our	knowledge,	there	is	only	one	echocardiographic	study	in	which	RV	longitudinal	and	circumferential	shortening	have	been	investigated	[194]	which	showed	 that	 compared	 with	 the	 left	 ventricle,	 in	 the	 RV	 the	 longitudinal	 shortening	 is	dominant	over	short-axis	function	[194].	Nevertheless,	no	study	investigating	the	relative	contribution	of	the	two	components	are	available.		
The	 single	 observation	 of	 the	 presence	 of	 a	 well-developed	 longitudinal	 layer	 does	 not	exclude	automatically	the	possible	consistent	contribution	of	other	motion	components	in	the	genesis	of	RV	global	pump	function.	Haber	et	al	reported	that	RV	contributes	by	itself	mainly	to	its	long-axis	deformation,	whereas	the	tangential	component	of	its	displacement	was	 larger	 due	 to	 LV	 coupling	 [195].	 Our	 study	 is	 the	 first	 investigating	 the	 relative	contribution	of	 the	 two	components,	 over	 their	 absolute	 values,	 highlighting	 for	 the	 first	time	 that	 both	 longitudinal	 and	 radial	motion	 contribute	 equally	 to	 the	 RV	 global	 pump	function.	
Deformation	 analysis	 allowed	 us	 to	 demonstrate	 that	 in	 normal	 conditions	 the	interventricular	septum	shows	a	leftward	systolic	motion.	Indeed,	the	evaluation	of	the	RV	radial	 motion	 by	 2D-STE	 showed	 that	 the	 IVS	 moves	 away	 from	 the	 RV	 cavity	 during	systole,	 describing	 a	 negative	 curve.	 This	 finding	 is	 in	 agreement	 with	 previous	observations	showing	that,	under	normal	conditions,	the	IVS	has	a	right	convexity,	and	this	configuration	is	maintained	during	the	cardiac	cycle	[277].		
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RV	 mechanics	 in	 Systemic	 Sclerosis	 patients	 without	 Pulmonary	
Hypertension	
Our	results	demonstrated	 that	 the	RV	of	SSc	patients,	 in	absence	of	PH,	maintains	normal	 size	 and	 pump	 function.	 Moreover,	 they	 showed	 normal	 RV	 mechanics,	 both	 in	term	 of	 relative	 contribution	 of	 longitudinal	 and	 radial	 displacement	 as	 in	 term	 of	 RV	myocardial	deformation.		
Previous	 observations	 demonstrated	 that	 the	 RV	 impairment	 in	 SSc	 patients	 is	 mainly	related	to	the	appearance	of	PH	[278].	Nevertheless,	primary	RV	myocardial	 involvement	has	been	described	[279-281]	and	thought	to	be	the	consequence	of	a	general	vasospastic	mechanism	 [282].	The	 suspicion	of	 an	 intrinsic	RV	myocardial	 involvement	derives	 from	the	 observation	 that	 patients	 with	 SSc	 related-PH	 have	 a	 worse	 prognosis	 respect	 to	patients	 with	 idiopathic	 PH	 [2].	 Few	 and	 discordant	 data	 about	 the	 RV	 function	 in	 SSc	patients	 have	 been	 reported	 in	 studies	 which	 used	 2D-STE	 to	 assess	 RV	 myocardial	function.	In	a	previous	study	reported	by	Matias	et	al	[283],	the	RV	basal	free	wall	strain	of	SSc	patients	without	PH	was	not	different	from	controls.	Conversely,	Schattke	et	al.	[284]	reported	that	the	RV	basal	and	mid-free	wall	strain	values	of	SSc	patients	without	PH	was	lower	 than	 controls.	 Recently,	 Durmus	 et	 al	 [285]	 reported	 that	 patients	 with	 SSc	 in	absence	of	PH	showed	lower	values	of	RV	LS	respect	to	a	healthy	control	group.	The	only	data	about	RV	size	and	function	using	3DE	come	from	a	previous	paper	from	our	research	group	 [286].	 It	 showed	 that	 PH	 free-SSc	 patients	 have	 slightly	 larger	 RV	with	 lower	 RV	pump	 function	 (despite	 still	 within	 normal	 values)	 in	 presence	 of	 a	 normal	 myocardial	deformation	by	2D-STE.	The	differences	between	the	results	of	the	previous	study	and	the	actual	one	may	be	due	 to	 the	different	 sample	size	 (larger	 in	 the	 latter	analysis)	and	 the	
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application	of	a	new	and	more	powerful	version	of	 the	software	 for	 the	3DE	RV	analysis	[287].	
	
RV	mechanics	in	Pulmonary	Hypertension	patients	The	main	findings	of	our	study	are	the	changes	of	the	RV	mechanics	in	presence	of	PH.	Our	results	suggested	that	despite	the	fact	that	RV	pump	function	impairment	in	PH	patients	is	correlated	 to	 a	 progressive	 reduction	 of	 both	 longitudinal	 and	 radial	 displacement,	 the	radial	 component	 was	 more	 affected	 than	 the	 longitudinal	 one.	 Our	 conclusion	 are	 in	contrast	 with	 the	 data	 by	 Mauritz	 et	 al	 [210].	 They	 studied	 the	 longitudinal	 and	 radial	function	of	PAH	patients	by	cardiac	CMR	and	stated	that	the	progressive	RV	failure	in	PAH	is	associated	with	a	parallel	decline	in	longitudinal	and	transverse	shortening	until	a	floor	effect	is	reached	for	longitudinal	shortening,	with	a	further	reduction	of	RV	function	is	due	to	 progressive	 leftward	 IVS	 displacement.	 However,	 the	 two	 studies	 are	 not	 comparable	and	many	aspects	have	to	be	taken	into	account.	Particularly,	they	compared	CMR	studies	obtained	 at	 baseline	 and	 at	 1	 year,	 while	 we	 consider	 single	 echocardiographic	 exams	without	 a	 follow-up	 control.	 They	 divided	 patients	 according	 to	 a	 clinical	 parameter,	survival	rate,	while	we	classified	patients	according	to	an	instrumental	parameter,	the	3DE	RVEF.	Finally,	 they	studied	the	 longitudinal	and	transversal	motion,	but	not	their	relative	contribution	to	the	global	RV	function.	
In	agreement	with	the	findings	of	Mauritz	et	al,	Simon	et	al	[238]	demonstrated	a	reduction	of	 RVFW	 longitudinal	 shortening	 in	 compensated	 PH	 patients,	 that	 worsens	 in	decompensated	 ones,	 stating	 that	 RV	 FWLS	 reduction	 may	 be	 an	 earlier	 step	 in	 the	development	 of	RVF.	Accordingly,	 our	 compensated	PH	patients	 showed	 lower	 values	 of	RVGLS	and	RVFWLS	compared	to	normal	subjects,	but	without	reaching	abnormal	values.	It	 has	 to	 be	 underlined	 that	 strain	 analysis	 have	 been	 done	with	 different	methods,	 not	
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comparable	 to	 each	 other,	 and	 that	 the	 study	 from	 Simon	 et	 al	 merely	 evaluated	 the	longitudinal	 shortening.	 Indeed,	 deformation	 analysis	 by	 2D-STE	 obtained	 in	 our	 PH	population	showed	that	the	first	parameter	consistently	impaired	in	presence	of	preserved	RVEF	is	 the	IVS	TD	but	not	the	 longitudinal	RV	motion.	Our	conclusion	 is	 that	maybe	the	first	modification	in	presence	of	PH	condition	is	the	change	of	the	IVS	deformation.		
Moreover,	 our	 results	 demonstrated	 that	 the	 IVS	 progressively	 changes	 its	 transversal	motion	 showing	 several	 patterns,	 differently	 distributed	 according	 to	 the	 presence	 or	absence	of	RV	pump	dysfunction,	without	significant	correlations	with	systolic	PAP	values.	It	 is	well	 known	 that	 abnormal	 IVS	 curvature	has	been	associated	 to	 the	presence	of	PH	[113,	276].	However,	the	novel	finding	regards	the	dynamic	behaviour	of	the	IVS,	and	not	its	static	appearance.	Mori	S	et	al	[288],	applying	M-mode	echocardiography,	demonstrated	that	patients	with	PH	show	two	different	peculiar	transversal	motion	patterns	of	the	IVS,	with	 different	 clinical	 and	 haemodynamic	 significance.	 They	 distinguished	 an	 “early	systolic	anterior	motion”	(Type	A)	and	an	“early	diastolic	posterior	motion”	(Type	B)	with	the	 first	 showing	 a	 low	 cardiac	 index	 despite	 similar	 systolic	 PAP.	 These	 data	 are	 in	agreement	with	our	findings.	Type	A		septal	motion	from	Mori	et	al	can	be	assimilated	to	our	 type	 2	 and	 type	 3	 septal	 motion	 patterns,	 which	 were	 not	 associated	 to	 increased	systolic	PAP	values	but	to	significantly	lower	3DE	RVEF	values.	Conversely,	type	B	can	be	assimilated	to	our	Type	1	pattern.	Similarly	Sato	et	al	[289]	developed	a	“paradoxical	IVS	motion	 index”,	 evaluating	 the	 IVS	 motion	 by	 2D-STE	 in	 short-axis	 views.	 They	demonstrated	 that	 higher	 values	 of	 this	 index	 correlated	 with	 the	 amount	 of	 the	 late	gadolinium	 enhancement	 at	 ventricular	 insertion	 points.	 The	 concept	 coming	 from	 their	results	 is	 that,	 greater	 is	 the	 paradoxical	 septal	 motion,	 with	 a	 progressively	 more	pronounced	 early	 systolic	 motion	 toward	 the	 RV	 cavity,	 and	 more	 pronounced	 is	 the	amount	 of	 the	 late	 gadolinium	 enhancement	 at	 CMR.	 Late	 gadolinium	 enhancement	
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junctional	 pattern	 has	 been	 reported	 to	 be	 related	 to	worse	 outcome	 in	 terms	 of	 death,	need	of	 lung	 transplantation,	 initiation	of	prostacyclin	 therapy,	 and	decompensated	RVF,	stratifying	 prognosis	 [290]. All these results are in agreement and suggest that more 
pronounced is the rightward IVS TD in PH patients and worse is the clinical presentation of the 
patients. Larger studies are needed to confirm this observation and to demonstrate its clinical 
relevance. 
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Limitations	
	Some	limitations	of	our	study	have	to	be	taken	into	account.	This	is	a	single	center	study	with	a	limited	sample	size	of	PH	patients.	No	data	about	follow-up	of	the	patients	are	available;	then	the	prognostic	predictivity	of	the	echocardiographic	parameters,	in	term	of	clinical	outcome,	has	not	been	evaluated.																								
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Conclusions	
	In	 healthy	 subjects,	 RV	 pump	 function	 seems	 to	 be	 determined	 by	 an	 equally	contribution	of	longitudinal	and	radial	deformation.		In	presence	of	SSc,	without	PH,	the	RV	appeared	to	be	preserved,	both	in	term	of	global	function	and	of	relative	longitudinal	and	radial	displacement.	In	presence	of	PH,	a	pathological	condition	characterized	by	pressure	overload,	both	 these	 two	components	appeared	 to	be	reduced.	However,	 the	progressive	lowering	of	global	RV	pump	function	appeared	to	be	mainly	driven	by	the	 impairment	of	the	radial	function,	with	the	IVS	firstly	involved.																			
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ESPERIENZA	
LAVORATIVA		 	 Da	aprile	2016	a	oggi	Ospedale	dell’Angelo.	Mestre	Contratto	a	tempo	Determinato	per	Dirigente	Medico	di	Cardiologia		Da	marzo	a	Dicembre	2015	Istituto	Oncologico	Veneto	IRCCS,	servizio	di	Cardiologia	Contratto	libero-professionale	Ambulatorio	di	Cardiologia		Dal	02/05/2012	a	marzo	2015		 	 Cittadella	Socio	Sanitaria	di	Cavarzere	S.r.l.,	Cavarzere	(VE)		 	 Contratto	di	Prestazione	d’Opera	Intellettuale	con	attività	libero	professionale		 	 Ambulatorio	di	Cardiologia	con	esecuzione	di	esami	strumentali	(ecocardiografia)	
	
	 	 	 Dal	17/09/2012	al	31/12/2012		 	 Casa	di	Cura	Dott.	Pederzoli,	Peschiera	del	Garda	(Vr)		 	 Contratto	di	libero	professionista		 	 Turni	di	guardia	in	reparto	di	Cardiologia		
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ISTRUZIONE	E	
FORMAZIONE		 	 Da	Gennaio	2013	a	giugno	2016		 	 Università	degli	Studi	di	Padova		 	 Scuola	di	Dottorato	di	Ricerca	in	Scienze	Mediche,	Cliniche	e	Sperimentali,	indirizzo	Scienze	Cardiovascolari			 	 	Da	Marzo	2008	a	Marzo	2012		 	 Università	degli	Studi	di	Padova		 	 Scuola	di	specializzazione	in	Cardiologia,	ai	sensi	del	DLg	368/1999.			 	 Specializzazione	in	Cardiologia,	voto	70/70	e	Lode		 	 		 	 Da	Novembre	2007	a	Gennaio	2008		 	 Università	degli	Studi	di	Padova		 	 Tirocinio	professionalizzante		 	 Abilitazione	alla	Professione	Medica		 	 	Da	Settembre	2001	a	Luglio	2007		 	 Università	degli	Studi	di	Padova		 	 Facoltà	di	Medicina	e	Chirurgia		 	 Laurea	Specialistica	in	Medicina	e	Chirurgia,	voto	110/110	e	
Lode		 	 			 	 Da	Settembre	1991	a	Ottobre	2003		 			 	 Pianoforte;	solfeggio;	storia	della	musica;	armonia.		 	 Diploma	di	Pianoforte	
CAPACITÀ	E	COMPETENZE	
PERSONALI	MADRELINGUA																ALTRE	LINGUE	 	 ITALIANA	INGLESE						Capacità	di	scrittura:	buona	
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					Capacità	di	lettura:	buona						Capacità	di	espressione	orale:	discreta		
											ATTIVITÀ	SCIENTIFICHE	 	 -	Corsi/congressi:	• presentazione	di	comunicazioni	orali	a	4	congressi	nazionali;	
• presentazione	 di	 poster	 a	 7	 congressi,	 di	 cui	 2	 nazionali	 e	 5	internazionali;	
• relatrice	ad	un	congresso	nazionale;			
• partecipazione	come	uditore	a	19	congressi/seminari/corsi;	
• corso	ACLS	Provider	2011;	
• corso	 intensivo	 di	 Risonanza	 Magnetica	 Cardiaca	 presso	 il	Dipartimento	 di	 Scienze	 Cardiache,	 Toraciche	 e	 Vascolari	dell’Università	di	Padova.		-	Pubblicazioni:	
Paper	
• Napodano	M,	Ramondo	A,	Tarantini	G,	Peluso	D,	Compagno	S,	Fraccaro	C,	Frigo	AC,	Razzolini	R,	Iliceto	S.	"Predictors	and	time-related	impact	of	distal	embolization	during	primary	angioplasty”	Eur	Heart	J.	2009	Feb;30(3):305-13.	
• Napodano	M,	Tarantini	G,	Ramondo	A,	Cacciavillani	L,	Corbetti	F,	Marra	MP,	Fraccaro	C,	Peluso	D,	Razzolini	R,	Iliceto	S.	Myocardial	abnormalities	underlying	persistent	ST-segment	elevation	after	anterior	myocardial	infarction.	J	Cardiovasc	Med	2009	Jan;10(1):44-50	
• Pepe	M,	Napodano	M,	Tarantini	G,	Fraccaro	C,	Cutolo	A,	Peluso	
D,	Isabella	G,	Ramondo	A,	Iliceto	S.	“Percutaneous	coronary	intervention	for	unprotected	left	main	disease	in	very	high	risk	patients:	safety	of	drug-eluting	stents”	Heart	Vessel	2011;	26:	17-24.	
• Cresce	GD,	Peluso	D,	Panfili	M,		Favaro	A,	Cannarella	A,	Picichè	M,	Salvador	L.	Left	Atrial	Wall	Hematoma	as	a	Consequence	of	Percutaneous	Coronary	Angioplasty.	Ann	Thorac	Surg	2012;	93:	
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e57-9.	
• Badano	LP,	Boccalini	F,	Muraru	D,	Dal	Bianco	L,	Peluso	D,	Bellu	R,	Zoppellaro	G,	Iliceto	S.	Current	Clinical	Applications	of	Transthoracic	Three-Dimensional	Echocardiography.	J	
Cardiovasc	Ultras	2012;	20(1):	1-22	
• Muraru	D,	Cattarina	M,	Boccalini	F,	Dal	Lin	C,	Peluso	D,	Zoppellaro	G,	Bellu	R,	Sarais	C,	Xhyheri	B,	Iliceto	S,	Badano	LP.	Mitral	Valve	anatomy	and	function-new	insights	from	three	dimensional	echocardiography.	J	Cardiovasc	Med	2013	Feb;	14	(2):	91-9	
• Kocabay	G,	Peluso	D,	Badano	LP,	Iliceto	S.	Diastolic	Mitral	Regurgitation	in	2:1	Atrioventricular	Block:	Insight	of	the	Diastolic	Pressure.	Echocardiography	2012;	0:	1-3		
• Kocabay	G,	Muraru	D,	Peluso	D,	Iliceto	S,	Badano	LP.	Three-Dimensional	Transesophageal	Echocardiography	of	Aortic	Atherosclerosis.	Echocardiography	2012;0:1-3	
• Napodano	M,	Peluso	D,	Perazzolo	Marra	M,	Frigo	AC,	Tarantini	G,	Buja	P,	Gasparetto	V,	Fraccaro	C,	Isabella	G,	Razzolini	R,	Iliceto	S.	Time-dependent	Detrimental	Effects	of	Distal	Embolization	on	Myocardium	and	Microvasculature	during	Primary	Percutaneous	Coronary	Intervention.	JACC	Cardiov	Interv	2012;	5	(11):	1170-77	
• Muraru	D,	Boccalini	F,	Cattarina	M,	Peluso	D,	Dal	Bianco	L,	Zoppellaro	G,	Segafredo	B,	Nour	A,	Sarais	C,	Badano	LP.	Quantitation	of	cardiac	chamber	geometry	and	function	using	transthoracic	three-dimensional	echocardiography.	J	Cardiov	Echogr	2012;	22	(4):	146-158	
• Peluso	D,	Badano	L,	Denisa	M,	Dal	Bianco	L,	Cucchini	U,	Kocabay	G,	Kòvacs	A,	Casablanca	S,	Iliceto	S.	Right	atrial	size	and	function	assessed	with	three-dimensional	and	speckle	traking	echocardiography	in	200	healthy	volunteers.	Eur	Heart	J	Cardiov	Imag	2013;	14	(11):	1106-14.	
• Muraru	D,	Badano	LP,	Peluso	D,	Dal	Bianco	L,	Casablanca	S,	
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Kocabay	G,	Zoppellaro	G,	Iliceto	S.	Comprehensive	analysis	of	left	ventricular	geometry	and	function	by	three-dimensional	echocardiography	in	healthy	adults.	JASE	2013;	26	(6):	618-28	
• Muraru	D,	Maffesanti	F,	Kocabay	G,	Peluso	D,	Bianco	LD,	Piasentini	E,	Jose	SP,	Iliceto	S,	Badano	LP.	Ascending	Aorta	Diameters	Measured	by	Echocardiography	Using	Both	Leading	Edge-to-Leading	Edge	and	Inner	Edge-to-Inner	Edge	Conventions	in	Healthy	Volunteers.	Eur	Heart	J	CV	Imag2013;	15	(4):	415-22.	
• 	Kocabay	G,	Muraru	D,	Peluso	D,	Cucchini	U,	Mihaila	S,	Padayattil-Josè	S,	Gentian	D,	Iliceto	S,	Vinereanu	D,	Badano	LP.	Normal	Left	Ventricular	Mechanics	by	Two-dimensional	Speckle-tracking	Echocardiography.	Reference	Values	in	Healthy	Adults.	Rev	Esp	Cardiol	2014;	67	(8)	651-8.	
• Mihăilă	S,	Muraru	D,	Piasentini	E,	Miglioranza	MH,	Peluso	D,	Cucchini	U,	Iliceto	S,	Vinereanu	D,	Badano	LP.	Quantitative	Analysis	of	Mitral	Annular	Geometry	and	Function	in	Healthy	Volunteers	Using	Transthoracic	Three-Dimensional	Echocardiography.	JASE	2014;	27	(8):	846-57	
• Muraru	D,	Cucchini	U,	Mihăilă	S,	Miglioranza	MH,	Aruta	P,	Cavalli	G,	Cecchetto	A,Padayattil-Josè	S,	Peluso	D,	Iliceto	S,	Badano	LP.	Left	Ventricular	Myocardial	Strain	by	Three-Dimensional	Speckle-Tracking	Echocardiography	in	Healthy	Subjects:	Reference	Values	and	Analysis	of	Their	Physiologic	and	Technical	Determinants.	JASE	2014;	27	(8):	858-871.	
• Pigatto	E,		Peluso	D,	Zanatta	E,	Polito	P,	Miatton	P,	Bourji	K,	Badano	LP,	Punzi	L,	Cozzi	F.	Evaluation	of	right	ventricular	function	performed	by	3d-echocardiography	in	scleroderma	patients.	Reumatismo	2014;	66	(4):	259-63	
• Peluso	D,	Tona	F,	Muraru	D,	Romeo	G,	Cucchini	U,	PerazzoloMarra	M,	Iliceto	S	and	Badano	LP.	Right	Ventricular	Geometry	and	Function	in	Pulmonary	Hypertension:	Non-Invasive	Evaluation.	Diseases	2014,	2,	274-295	
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• Mihaila	S,	Muraru	D,	Haertel	Miglioranza	M,	Piasentini	E,	
Peluso	D,	Cucchini	U,	Iliceto	S,	Vinereanu	D,	Badano	LP.	Normal	mitral	annulus	dynamics	and	its	relationship	with	left	ventricular	and	left	atrial	function.	Int	J	Cardiovasc	Img	2015	;	31	(2):	279-290	
• The	EchoNoRMAL	(Echocardiographic	Normal	Ranges	Meta-Analysis	of	the	Left	Heart)	Collaboration.	Ethnic-Specific	Normative	Reference	Values	for	Echocardiographic	LA	and	LV	Size,	LV	Mass,	and	Systolic	Function	The	EchoNoRMAL	Study.	JACC	Cardiovasc	Imag	2015;	8	(6):	656-665	
• Peluso	D,	Bianchi	A,	Bonanno	L,	Banzato	A.	Unusual	echocardiographic	appearance	of	a	cardiac	metastasis	from	lung	carcinoma.	J	Cardiovasc	Ultras	2015	Dec	17.	doi:	10.1002/jcu.22325.	[Epub	ahead	of	print]	
• Muraru	D,	Onciul	S,	Peluso	D,	Soriani	N,	Cucchini	U,	Aruta	P,	Romeo	G,	Cavalli	G,	Iliceto	S,	and	Badano	LP.	Sex-	and	Method-Specific	Reference	Values	for	Right	Ventricular	Strain	by	Two-	Dimensional	Speckle-Tracking	Echocardiography.	Circulation	Cardiovasc	Imag	2016;	9:	e003866	
• Surkova	E,	Peluso	D,	Kasprzak	JD,	Badano	LP.	Use	of	novel	echocardiographic	techniques	to	assess	right	ventricular	geometry	and	function.	Kardiol	Pol	2016	Apr	4.	doi:	10.5603/KP.a2016.0041.	[Epub	ahead	of	print.	
Book	chapter:		The	Right	Atrium	chapter	of	the	II	edition	of	the	“Textbook	of	Real	-	Time	Three	Dimensional	Echocardiography”,	edited	by	Dr.	Badano,	Dr.	Lang,	Dr.	Mor-Avi	and	Dr.	Muraru.	In	press.	
Abstracts:	pubblicazione	di	103	abstracts	dal	2008	ad	oggi	di	cui:	20	come	primo	nome;	62	a	congressi	internazionali	e	41	a	congressi	nazionali;	
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• Docente	 del	 Master	 di	 “Ecocardiografia	 di	 base	 ed	 avanzata”	 del	Dipartimento	 di	 Scienze	 Cardiache,	 Toraciche	 e	 Vascolari	dell’Università	di	Padova.		
• Peer	 reviewer	 per	 le	 riviste:	 Journal	 of	 the	 American	 Heart	Association;	 Journal	 of	 Advances	 in	 Medical	 and	Pharmaceutical	Sciences	-	 Frequenza	 presso	 il	 Laboratorio	 di	 Ecocardiografia	 della	 Cl.	Cardiologica	 di	 Padova,	 responsabile	 Dr.	 L.P.	 Badano	 (aprile	2011	 ad	 oggi),	 dove	 ho	 sviluppato	 esperienza	 nell’ambito	 di:	ecocardiografia	 standard	 mono-	 e	 bidimensionale;	ecocardiografia	 tridimensionale	 transtoracica	 e	 transesofagea	utilizzando	 le	macchine	GE	Vivid	 E9	 e	 Philips	 IE33,	 entrambe	dotate	delle	rispettive	sonde	3D	transtoracica	e	transesofagea;	ecostress	farmacologico	con	dipiridamolo	e	dobutamina;	esame	della	riserva	coronarica;	gestione	digitale	delle	immagini	e	loro	post-processing,	acquisendo	esperienza	con	i	software	EchoPac	(GE	 Healthcare,	 Horten,	 N),	 TomTec	 4D	 LV,	 TomTec	 4D	 LA	 e	TomTec	 4D	 RV	 (TomTec	 Imaging	 Systems	 GmbH,	Unterschleissheim-D),	 Philips	 QLAB	 (Koninklijke	 Philips	Electronics).		 	 		
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Activities	during	PhD	period	
	Durante	il	periodo	di	dottorato	è	stata	svolta	la	seguente	attività	formativa:	-	Cicli	di	conferenze	clinico-patologiche	del	Dipartimento	di	Scienze	Cardiache,	Toraciche	e	Vascolari.	AA	2012/2013,	2013/2014,		2014/2015.		-	Summer	School.	23-27	settembre	2013	c/o	IOV	IRCCS,	Padova	-	Corso	Scientific	Writing.	3-6	giugno	2014	Padova	-	Autumn	School.	20	ottobre	2014	c/o	Palazzo	del	Bo,	Padova	-	Spring	School.	29-30	maggio	2015,	Bressanone	(BZ).		L’attività	di	ricerca	è	esitata	nella	pubblicazione	dei	seguenti	lavori	scientifici:	1. Muraru	D,	Cattarina	M,	Boccalini	F,	Dal	Lin	C,	Peluso	D,	Zoppellaro	G,	Bellu	R,	Sarais	C,	Xhyheri	B,	 Iliceto	S,	Badano	LP.	Mitral	Valve	anatomy	and	 function-new	 insights	from	three	dimensional	echocardiography.	J	Cardiovasc	Med	2013	Feb;	14	(2):	91-9		2. Kocabay	G,	Peluso	D,	Muraru	D,	Iliceto	S	,Badano	LP.	Diastolic	Mitral	Regurgitation	in	 2:1	 Atrioventricular	 Block:	 Insight	 of	 the	 Diastolic	 Pressure.	 Echocardiography	
2013;	30	(2):	E51-2.		3. Peluso	 D,	 Badano	 L,	 Denisa	 M,	 Dal	 Bianco	 L,	 Cucchini	 U,	 Kocabay	 G,	 Kòvacs	 A,	Casablanca	 S,	 Iliceto	 S.	 Right	 atrial	 size	 and	 functional	 assessed	 with	 three-dimensional	 and	 speckle	 traking	 echocardiography	 in	 200	 healthy	 volunteers.	Eur	
Heart	J	Cardiov	Imag	2013;	14	(11):	1106-14		4. Muraru	D,	Badano	LP,	Peluso	D,	Dal	Bianco	L,	Casablanca	S,	Kocabay	G,	Zoppellaro	G,	Iliceto	S.	Comprehensive	analysis	of	left	ventricular	geometry	and	function	by	three-dimensional	echocardiography	in	healthy	adults.	JASE	2013;	26	(6):	618-28	5. Muraru	D,	Maffesanti	F,	Kocabay	G,	Peluso	D,	Bianco	LD,	Piasentini	E,	Jose	SP,	Iliceto	S,	Badano	LP.	Ascending	Aorta	Diameters	Measured	by	Echocardiography	Using	Both	Leading	Edge-to-Leading	Edge	and	Inner	Edge-to-Inner	Edge	Conventions	in	Healthy	Volunteers.	Eur	Heart	J	CV	Imag	2013;	15	(4):	415-22.		6. Kocabay	G,	Muraru	D,	Peluso	D,	Cucchini	U,	Mihaila	S,	Padayattil-Josè	S,	Gentian	D,	Iliceto	 S,	 Vinereanu	 D,	 Badano	 LP.	 Normal	 Left	 Ventricular	 Mechanics	 by	 Two-dimensional	Speckle-tracking	Echocardiography.	Reference	Values	in	Healthy	Adults.	Rev	Esp	Cardiol	2014;	67	(8):	651-8	
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7. Mihăilă	 S,	Muraru	D,	 Piasentini	 E,	Miglioranza	MH,	Peluso	 D,	 Cucchini	U,	 Iliceto	 S,	Vinereanu	 D,	 Badano	 LP.	 Quantitative	 Analysis	 of	 Mitral	 Annular	 Geometry	 and	Function	 in	 Healthy	 Volunteers	 Using	 Transthoracic	 Three-Dimensional	Echocardiography.	JASE	2014;	27(8):	846-57.		8. Muraru	 D,	 Cucchini	 U,	 Mihăilă	 S,	 Miglioranza	MH,	 Aruta	 P,	 Cavalli	 G,	 Cecchetto	 A,	Padayattil-Josè	S,	Peluso	D,	 Iliceto	S,	Badano	LP.	Left	Ventricular	Myocardial	Strain	by	 Three-Dimensional	 Speckle-Tracking	 Echocardiography	 in	 Healthy	 Subjects:	Reference	 Values	 and	 Analysis	 of	 Their	 Physiologic	 and	 Technical	 Determinants.	JASE	2014;	27(8):	858-871.		9. Pigatto	 E,		Peluso	 D,	 Zanatta	 E,	 Polito	 P,	Miatton	 P,	 Bourji	 K,	 Badano	 LP,	 Punzi	 L,	Cozzi	 F.	 Valutazione	 della	 funzione	 ventricolare	 destra	 mediante	 ecocardiografia	tridimensionale	nei	pazienti	con	sclerosi	sistemica”.	Reumatismo	2014;	66	(4):	259-263		10. Peluso	D,	Tona	F,	Muraru	D,	Romeo	G,	Cucchini	U,	Perazzolo	Marra	M,	Iliceto	S	and	Badano	LP.	Right	Ventricular	Geometry	and	Function	 in	Pulmonary	Hypertension:	Non-Invasive	Evaluation.	Diseases	2014;	2:	274-295		11. Mihaila	 S,	 Muraru	 D,	 Haertel	 Miglioranza	 M,	 Piasentini	 E,	 Peluso	 D,	 Cucchini	 U,	Iliceto	 S,	 Vinereanu	 D,	 Badano	 LP.	 Normal	 mitral	 annulus	 dynamics	 and	 its	relationship	with	 left	ventricular	and	 left	atrial	 function.	 Int	 J	Cardiovasc	 Img	2014	Oct	16	DOI	10.1007/s10554-014-0547-0		12. The	 EchoNoRMAL	 (Echocardiographic	 Normal	 Ranges	 Meta-Analysis	 of	 the	 Left	Heart)	 Collaboration.	 Ethnic-Specific	 Normative	 Reference	 Values	 for	Echocardiographic	LA	and	LV	Size,	LV	Mass,	and	Systolic	Function	The	EchoNoRMAL	Study.	JACC	Cardiovasc	Imag	2015;	8	(6):	656-665.	13. Peluso	D,	Bianchi	A,	Bonanno	L,	Banzato	A.	Unusual	echocardiographic	appearance	of	a	 cardiac	metastasis	 from	 lung	carcinoma.	 J	Cardiovasc	Ultras	2015	Dec	17.	doi:	10.1002/jcu.22325.	[Epub	ahead	of	print]	14. Muraru	D,	 Onciul	 S,	 Peluso	 D,	 Soriani	 N,	 Cucchini	 U,	 Aruta	 P,	 Romeo	G,	 Cavalli	 G,	Iliceto	 S,	 and	 Badano	 LP.	 Gender-	 and	Method-Specific	 Reference	 Values	 for	 Right	Ventricular	 Strain	 by	 Two-	 Dimensional	 Speckle-Tracking	 Echocardiography.	Circulation	 Cardiovasc	 Imag	 2016	 Feb;9(2):e003866.	 doi:	10.1161/CIRCIMAGING.115.003866.	
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15. Surkova	 E,	 Peluso	 D,	 Kasprzak	 JD,	 Badano	 LP.	 Use	 of	 novel	 echocardiographic	techniques	to	assess	right	ventricular	geometry	and	function.	Kardiol	Pol	2016	Apr	4.	doi:	10.5603/KP.a2016.0041.	[Epub	ahead	of	print]			L’attività	di	ricerca	è	esitata	nella	stesura	dei	seguenti	abstracts:	
	
2013	
• 5th	World	Simposium	of	Pulmonary	Hypertension		1. Peluso	D,	Kovàcs	A,	Dal	Bianco	L,	Muraru	D,	Perazzolo	Marra	M,	Sarais	C,	Badano	LP,	 Iliceto	 S.	 “Impairment	 of	 right	 atrial	 mechanics	 and	 function	 in	 pulmonary	hypertension	 patients	 assessed	 by	 2D	 speckle	 tracking	 and	 three-dimensional	echocardiography”.	Poster.	2. Peluso	 D,	 Kovàcs	 A,	 Dal	 Bianco	 L,	 Muraru	 D,	 Cucchini	 U,	 Badano	 LP,	 Iliceto	 S.	“Characterization	 of	 right	 atrial	 mechanics	 by	 2D-speckle	 tracking	echocardiography	in	healthy	subjects”.	Poster		3. Peluso	D,	Kovàcs	A,	Dal	Bianco	L,	Muraru	D,	Padayattil	S,	Badano	LP,	Iliceto	S.	“RA	volumes	 and	 phasic	 function	 by	 3-dimensional	 echocardiography	 in	 healthy	subjects”.	Poster		4. Kovács	 A,	Peluso	 D,	 Muraru	 D,	 Perazzolo	Marra	M,	 Badano	 LP,	 Dal	 Bianco	 L,	 De	Lazzari	 M,		 Iliceto	 S.	 “Paradoxical	 septal	 motion	 index	 strongly	 correlates	 with	invasive	hemodynamic	parameters”.		Poster		5. Kovács	A,	Peluso	D,	Muraru	D,	Ermacora	D,	Badano	LP,	Dal	Bianco	L,	Zoppellaro	G,	Iliceto	 S.	 Characterization	 of	 a	 novel	 parameter	 of	 right	 ventricular	 function	 by	speckle	tracking	echocardiography	in	healthy	subjects”.	Poster		6. Kovács	 A,	 Peluso	 D,	 Muraru	 D,	 Perazzolo	 Marra	 M,	 Badano	 LP,	 Dal	 Bianco	 L,	Segafredo	 B,	 Iliceto	 S.	 ”Transverse	 displacement:	 a	 novel	 echocardiographic	parameter	describing	right	ventricular	function	in	pulmonary	hypertension”.	Poster	
• European	Congress	of	Rheumatology		7. Pigatto	 E,	Peluso	 D,	 Rizzo	M,	 Zanatta	 E,	Muraru	D,	 Favaro	M,	 Badano	 L,	 Punzi	 L,	Cozzi	F.	Right	ventricular	function	by	3D-echocardiography	and	2D-speckle	tracking	
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in	sclerodermia	patients	without	pulmonary	hypertension.	Ann	Rheum	Dis	2013;	72	(suppl	3):	509	
• American	College	of	Cardiology		8. Badano	LP,	Muraru	D,	Zoppellaro	G,	Cucchini	U,	Ermacora	D,	De	Lazzari	M,	Peluso	
D,	 Perazzolo-Marra	 M,	 Iliceto	 S.“Predictive	 value	 of	 2D	 and	 3D	 deformation	parameters	 and	 wall	 motion	 score	 to	 identify	 transmural	 myocardial	 necrosis	 in	stemi	 patients:	 a	 comparative	 study	 against	 CMR”.	 JACC	 2013;	 61	 (10	S)doi:10.1016/S0735-1097(13)61013	9. Badano	 LP,	 Peluso	 D,	 Muraru	 D,	 Dal	 Bianco	 L,	 Kovacs	 A,	 Iliceto	 S.“Right	 atrial	volumes	 and	 phasic	 functions	 by	 3D	 echocardiography	 in	 healthy	 subjects”	 JACC	2013;	61	(10S)	doi:10.1016/S0735-1097(13)61101-8	
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